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Bipolar disorder (BD) is a mental disorder with an unpredictable relapsing-remitting course 
with manic or depressive episodes. Overall prevalence of BD subtypes is approximately 4.4% 
of the general population (Merikangas et al., 2007). BD is one of the most debilitating illnesses 
worldwide (Wittchen et al., 2011) and its disturbance is associated with recurrent mood disorder 
episodes, as well as neurocognitive dysfunction and psychiatric comorbidities (Grande et al., 
2016; Malhi et al., 2007). Symptoms include changes in mood, energy, motor activity, sleep, 
appetite, thought, and cognition (AmericanPsychiatricAssociation, 2013). Cognitive symptoms 
are listed among the clinical symptoms in BD. Furthermore, neurocognitive impairment is a 
core dimension of BD, which persists throughout euthymic episodes (Bora, 2018). 
Accordingly, attention, memory, and executive function domains are the most commonly 
disturbed cognitive functions in BD.  
In Vivo Assessment of Cognition  
Large numbers of neurons are distributed in the specialized areas of the brain for sophisticated 
networks for perception and cognition in humans. Coordination of these networks by 
oscillations is suggested to be provided by low (theta, alpha) and high (beta, gamma) frequency 
oscillations via the representation of neural correlates of sensory or cognitive information 
(Varela et al., 2001). The brain networks are at different levels and each cognitive function is 
associated with distinct neural networks (Petersen and Sporns, 2015). Neuroimaging techniques 
allow for the examination of individual networks associated with cognitive functions. The 
application of non-invasive imaging technologies has advanced the investigation of the neural 
basis of cognition through the mechanistic studies of neurocognitive circuits. Among the 
currently available dynamic functional assessment technologies, functional magnetic resonance 
imaging (fMRI), functional near infrared spectroscopy (fNIRS), and electroencephalography 
(EEG) are the most commonly used methods. While fMRI is able to characterize the spatial 
distribution of the networks, EEG offers unique information about the synchronization 
capabilities of the neural networks with high temporal resolution. In other words, despite its 
poor spatial resolution, temporal resolution is the major advantage of the EEG. This advantage 
makes the EEG a unique method for task-based cognition studies.  
The scalp-EEG records the electrical activity of the brain, whereas the magnetic resonance 
imaging (MRI) is based on variations of magnetic vectors of water molecules. Radiofrequency 
pulses align and release molecular directions and the changes are captured and translated into 
images. The iron atoms add magnetic properties to the hemoglobin molecule and binding or 
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releasing oxygen may alter its magnetization. Furthermore, functionally active brain regions 
induce vasomotor changes and increase blood supply in response to activation, which is called 
hemodynamic response. The hemodynamic changes are captured by the fMRI and functionally 
active brain regions are detected. The functional near infrared spectroscopy (fNIRS) is also able 
to capture changes in the hemodynamic response (Herold et al., 2018). Alterations in the 
infrared light illumination of the superficial cortical tissues depend on changes in their oxy-
hemoglobin content. This change is sensed and measured by the fNIRS (Herold et al., 2018). 
In addition, the MRI can detect biomolecules, because their molecular configuration possesses 
biophysical properties. Glutamate and glutamine, N-acetylaspartate, choline, inositol, creatine 
or GABA can be detected by proton magnetic resonance spectroscopy (H-MRS), whereas 
phosphorous MRS (P-MRS) is able to measure bioenergetic molecules consisting of 
phosphorus atoms. Oxygen, carbon, lithium or fluorine MRS coils are also available for 
measuring specific molecules in vivo. However, the EEG signal is the direct response of the 
actively working neurons that contribute to the cognitive process. 
Coherent brain functions might be achieved by synchronizing dedicated neuron groups that 
account for integrative brain functions. Neurons are organized to perform a particular brain 
function and resonate at a frequency, called oscillation. The term oscillation designates a 
repeated variation of a parameter (current or voltage) between two extreme values with an 
optional requirement of the regularity of the variation. Brain oscillations are grouped according 
to their frequencies: delta (0.5–3.5 Hz), theta (4–8 Hz), alpha (8–13 Hz), beta (14–28 Hz) and 
gamma (30–70 Hz) rhythms (Başar, 1999).  Each frequency is associated with specific brain 
functions. Theories of functional significance for these brain rhythms are conclusive and 
supported by evidence. Oscillations may occur either spontaneously, or induced or evoked by 
a sensory stimulus, which might be event-related (Başar, 1998). A stimulus evokes a 
coordinated response in the neuron population and the brain transits from irregular neural 
activity to synchronous network-level work. Although complex connections establish 
sophisticated networks in the brain, dedicated networks are assigned for specific functions.  The 
type of the function determines the brain region and the neuronal assembly produces a specific 
oscillation at a particular frequency and phase. Synchronous firing of the neurons is provided 
by integrative brain functions to set up networks. Psychiatric disorders might be associated with 
pathologies that disrupt these integrative brain functions and might be expressed in the 
dysfunction of certain networks.  
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Cognitive function can be examined through studying the EEG evaluation and response 
processes instigated by specific tasks that artificially produce an environmental stimulus. The 
task may be designed to provoke either a cognitive (top-down operation) or an automatic 
(bottom-up) processing. Bottom-up (stimulus-driven) tasks (i.e. mismatch negativity [MMN], 
auditory steady-state response (ASSR) or dual-click paradigm [P50]) are independent of 
performance and available for all clinical populations. In contrast, top-down tasks rely on 
mental operations on sensory or cognitive information. Top-down tasks are associated with 
attention, decision making, and working memory and these functions are performed by complex 
networks consisting of prefrontal, parietal and temporal cortices (Wagner et al., 1998). Each 
stimulus of the cognitive tasks induces changes in specific brain waves, either in their 
magnitudes or phases. Moreover, maintenance of specific frequency bands across trials with 
respect to an event indicates consistent and quantifiable brain activity or response. In short, 
with its high temporal resolution, the EEG may facilitate assessment of cognitive networks by 
means of cognitive tasks (Kenemans and Kahkonen, 2011).    
Brain Oscillations in Bipolar Disorder 
The classical event-related potentials analysis revealed that the classical P300 magnitude might 
either be decreased (Fridberg et al., 2009; O'Donnell et al., 2004b; Salisbury et al., 1998) or 
remain unchanged in bipolar disorder compared to healthy controls (Hall et al., 2007a; Kaya et 
al., 2007; Schulze et al., 2008). On the other hand, P200 and N200 are diminished in BD 
compared to schizophrenia and healthy control groups (Ethridge et al., 2015; Hamm et al., 
2013; Mokhtari et al., 2016). Resting-state EEG may exhibit neurophysiological activity of the 
default mode network. Patients with the diagnosis of BD had increased magnitudes in delta, 
theta and alpha activity at rest (Narayanan et al., 2014). A high-resolution EEG source 
localization (LORETA) study reported that patients with BD either in manic or depressive states 
showed decreased theta and enhanced beta power in prefrontal and parietal cortices and 
temporal pole in resting state condition (Painold et al., 2014). On the other hand, the most 
consistent finding was the gamma band power reduction in euthymia (Oda et al., 2012; Parker 
et al., 2019; Rass et al., 2010) and mania (O'Donnell et al., 2004a) upon Auditory Steady State 
Response (ASSR) task. Gamma (Lee et al., 2010) and beta band (Parker et al., 2019) are also 
disturbed in BD. The ASSR and mismatch negativity (MMN) tasks enable the examination of 
the auditory cortices and their connected networks (Garrido et al., 2009; Sivarao, 2015). Thus, 
alterations in schizophrenia and BD may point to the pathology of the auditory cortices. 
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Psychosis was the most important clinical determinant of the EEG findings in patients with BD 
(Hamm et al., 2013; Lundin et al., 2018). However, almost all psychotropic medications alter 
the neurophysiology; therefore, EEG studies with medicated patients might be biased to a 
degree. Clinical EEG studies in patients with BD showed inconsistent results because of 
confounders, of which the most pronounced were cognitive and clinical heterogeneity in 
patients with BD (Bora et al., 2019) and psychotropic treatments (Atagun, 2016).  
In Vivo Assessment of Neurochemistry (magnetic resonance 
spectroscopy) in Bipolar Disorder 
Proton magnetic resonance imaging spectroscopy (H-MRS) is able to identify molecules with 
their physical configuration in a given volume. The point-resolved spectroscopy sequence 
(PRESS) provides quantitation of glutamate, N-acetylaspartate, choline, inositol and creatine, 
whereas Meshcher-Garwood point-resolved spectroscopy sequence (MEGAPRESS) is able to 
quantitate the GABA neurotransmitter (Mullins et al., 2014). The standard sizes of the voxels 
of the MRS are 8cc (2X2X2cm) in the PRESS sequence and 27cc (3X3X3cm) in the 
MEGAPRESS sequence.  
The MRS signal consists of different peaks and resonances. Each peak is related with a specific 
type of compound or combination of metabolites. Glutamate is one of the most abundant 
aminoacids in the brain. Because it lacks methyl groups and has methylene and methine groups, 
glutamate is measured in three different peaks by the proton-MRS (1H-MRS) (2.08, 2.34 and 
3.74ppm). These signals from glutamate are difficult to distinguish from the analogous peaks 
arising from glutamine at about 2.44, 2.12, and 3.75ppm (Maddock and Buonocore, 2012). 
Glutamine to glutamate ratio in concentration is 40/60 percent (Jensen et al. 2009) and signals 
of glutamine confound glutamate peaks unless optimized MRS methods are used. GABA and 
glutathione are also suspected to contribute to these signals. Therefore, this combined signal is 
abbreviated as glutamix (glx) and this resonance is considered an indicator of glutamatergic 
neurotransmission (Maddock and Buonocore, 2012). The N-acetylaspartate (NAA) resonance 
(at 2.02ppm) contains largely NAA and a small proportion is N-acetylaspartylglutamate 
(NAAG). Acetyl coenzyme A and aspartate are the components of NAA and it is synthesized 
in mitochondria (Moore and Galloway, 2002). Thus, NAA is an acetyl donor for acetyl 
coenzyme A. NAA is also known to cycle between neurons and oligodendrocytes, which 
contain the enzyme that catabolize NAA-aspartoacetylase. The cycle of the NAAG is similar 
to the NAA, but its catabolic enzyme (NAAG peptidase) is located on the cell membrane of 
 7 
IN
T
R
O
D
U
C
T
IO
N
 
1 
astrocytes (Baslow, 2000). Choline peak (3.23ppm) is composed of phosphorylcholine (PC) 
and glycerophosphorylcholine (GPC); therefore, it is thought to be a potential biomarker for 
membrane phospholipid metabolism (Moore and Galloway, 2002). Choline compounds 
embedded in the membranes are not measurable by the MRS, but free phosphatidylcholine is 
visible to it. The choline peak is higher in white matter, because it has a larger amount of choline 
related compounds. During the turnover of the membrane, the free proportion of the choline is 
measured; therefore, neurodegenerative diseases that increase phospholipid turn-over may 
amplify this peak. The myo-inositol (mI) peak (3.56ppm) consists of mI and minor 
contributions from glycine and inositol-1-phosphate (Moore and Galloway, 2002). The 
phosphoinositol messenger pathway, the metabolism of membrane phospholipids, and the 
regulation of neuronal osmolarity are physiological functions of mI. The creatine (Cr) peak 
(3.02 ppm) consists of phosphocreatine and creatine combined and these metabolites are high 
energy phosphate compounds that can easily diffuse through membranes (Maddock and 
Buonocore, 2012). Cr levels are related with the global health of brain cells and alterations may 
indicate impairment of their function or integrity.  
 
It has been consistently found in MRS studies that glutamatergic compound levels are increased 
in patients with bipolar disorder (Gigante et al., 2012; Yuksel and Ongur, 2010) and 
schizophrenia (Merritt et al., 2016). Levels of other metabolites including GABA are less 
consistent and variable across brain regions (Egerton et al., 2017; Yildiz-Yesiloglu and Ankerst, 
2006). Some studies reported decreased levels of metabolites, whereas some studies reported 
no change. In addition to clinical heterogeneity, most of the studies are cross-sectional and 
performed with small sample sizes, and voxels were located in different brain regions. 
However, studies have reported relationship between mismatch negativity amplitude and 
glutamatergic compound levels in the hippocampus (Chitty et al., 2015; Kaur et al., 2019). In 
addition, P300 amplitude was related to glutamatergic compound levels in the anterior 
ciungulate cortex in another study (Hall et al., 2015b). These findings indicate that 
glutamatergic compounds might be related with the disorder and its related mechanisms.  
The aim of this thesis is to present a neurophysiological and neurochemical outline to alterations 
in cognitive function in bipolar disorder. Auditory oddball paradigm and P50 sensory gating 
(SG) are based on auditory networks and sensory systems provide bases for cognitive function. 
The auditory cortices are vulnerability zones for psychosis (Vita et al., 2012) and bipolar 
disorder (Oribe et al., 2010). Therefore, my aim was to examine the neurophysiological 
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assessment of auditory task-based (oddball and P50 SG paradigms) EEG studies and 
neurochemistry of auditory cortices. 
Theta frequency oscillations are suggested to be involved with the integration of distant brain 
regions (von Stein and Sarnthein, 2000). Furthermore, cortical theta rhythm reflects dynamic 
interactions between the hippocampal system and the neocortex during cognitive tasks, 
particularly memory function (Bastiaansen and Hagoort, 2003). Thus, scalp-EEG theta 
oscillation provides relevant information about memory related processes in the networks 
associated with the hippocampal formation. Indeed, theta rhythmic activity may facilitate the 
formation of dynamic neural assemblies that constitute the neural processors of cognition. 
According to the networks approach, etiopathogenetic mechanism of BD is related with the 
disruption in the corticolimbic and fronto-temporal networks (Benes and Berretta, 2001; 
Blumberg et al., 2002; Phillips et al., 2003). These networks also serve cognitive and emotion 
regulation functions (Strakowski et al., 2005). Therefore, cognitive task-based theta oscillations 
might be influenced by the pathogenesis of BD and altered theta responses are likely to 
represent neurophysiologic correlates of cognitive deficits in BD (Sakowitz et al., 2000). In 
Chapter 2, alteration in event-related theta oscillations in medication-free patients with bipolar 
disorder is described (Atagun et al., 2013). The oddball paradigm was the cognitive task of the 
study. The oddball paradigm is a valid working memory task that is relevant for the assessment 
of neurophysiological correlates of cognitive dysfunction in BD.  
Delta waves in the frequency range of 1-4 Hz are usually observed during the slow-wave sleep, 
indicating hypersynchrony in the neuronal activities of the nuclei. Delta oscillations are 
suggested to be related with different frequency oscillations, rather than being a specific 
independent oscillation (IFSECN) (1974). On the other hand, interaction within thalamocortical 
networks yields a complex pattern whose reflection at the EEG level takes the shape of 
polymorphic waves, including delta oscillations (McCormick and Pape, 1990). Delta 
oscillations may also be generated by cortical neurons, probably with unique cellular 
mechanisms and they join the neurocognitive processes (Guntekin and Basar, 2016). However, 
event-related delta oscillations have been rarely studied in the general population or in 
psychiatric populations. On the other hand, delta frequency oscillations are believed to be the 
major component of the P300 amplitude and thus might be disturbed in BD. Chapter 3 describes 
the assessment of event-related delta oscillations in medication-free patients with BD (Atagun 
et al., 2014).    
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Because of their large spectral interval and functional difference, beta oscillations are 
classically divided into two sub-bands, B-1 in 14 to 20 Hz and B-2 in 20 to 30 Hz intervals in 
the EEG literature. A well-established functional role of beta oscillations is the programming 
of voluntary motor movements. Although a variety of beta-oscillations with different spatial 
distribution and reactivity exists, the majority of the beta-oscillations are outputs of pyramidal-
neurons of deep layers (layer V mostly). Interestingly, beta-oscillations may have a non-
synaptic origin, in which electrical coupling emerges by axonal excitation in the layer V of the 
cortex (Roopun et al., 2006). Beta-2 rhythm in this network is set by cholinergic currents, while 
NMDA receptor antagonist ketamine also increases the ability of the prefrontal cortex to 
generate beta oscillations. In addition, because benzodiazepines increase the power of beta 
oscillations and decrease their frequency, it is proposed that a cortical inter-neuronal network 
might be responsible for the generation of cortical beta rhythms (Roopun et al., 2006; Traub et 
al., 2004). Neuroplastic changes in the brain drives networks to oscillate at beta frequency 
instead of gamma frequency (Whittington et al., 2000). These changes indicate that 
pharmacological interventions may induce changes in beta oscillations (Yoshimura et al., 
2007). Because of its pharmacological actions and biophysical properties, lithium may cause 
alterations in neurophysiology. As lithium is the most prescribed mood stabilizer in BD and its 
mechanisms of action remain unclear, in Chapter 4, I investigated the effects of lithium on brain 
oscillations in patients with BD (Atagun et al., 2015a). Patients with bipolar disorder, both on 
and off lithium monotherapy were compared with a healthy control group.  
Sensory gating is the mechanism that provides filters to reduce the perceived environmental 
stimuli and the dual-click paradigm is a classical measure of sensory gating in EEG experiments 
(Baker et al., 1987). Two successive clicks are presented and their responses are compared. 
Response to the second click should be lower than the first click. The difference between the 
amplitudes is believed to be related with the cognitive process of sensory gating. Alteration in 
this early attentive information processing decreases brain’s ability to filter redundant inputs 
and overloads higher brain functions, leading to cognitive fragmentation and behavioral 
disturbances (Venables, 1964). Sensory gating has been widely assessed in both schizophrenia 
(Bramon et al., 2004; de Wilde et al., 2007b) and BD (Cheng et al., 2016). Furthermore, it has 
been documented with magnetoencephalography (Thoma et al., 2005; Wang et al., 2014a; 
Wang et al., 2014b) and MRI (Thoma et al., 2004) that P50 SG alterations are related with 
superior temporal lobes in bipolar disorder and schizophrenia. On the other hand, little is known 
about SG alterations in the different terms of the disorders and the effects of medications. 
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Chapter 5 presents the meta-analysis of P50 studies in bipolar disorder and schizophrenia 
(Atagun et al. Submitted). Clinical states and effects of medications are assessed in this meta-
analysis.  
In Vivo Neurochemistry of Superior Temporal Lobes in Patients with 
Bipolar Disorder 
The auditory cortices are located in the Heschl’s gyrus and planum temporale in superior 
temporal lobes. Primary auditory cortices are surrounded by the Wernicke’s Area and other 
association cortices are located around the belt between the temporal cortex and parietal cortex. 
These connected adjacent structures process auditory information and contact higher cognitive 
networks for further information processing. Since auditory cortices are shown to be 
functionally disturbed in the neuroimaging studies of BD and schizophrenia, they warrant 
further research. I aimed to assess the biochemistry of auditory cortices in schizophrenia and 
BD, by means of H-MRS. First, I investigated glutamate levels in patients with schizophrenia 
and type I BD in Chapter 6 (Atagun et al., 2015b) and type II in Chapter 7 (Atagun et al., 2017). 
Second, I investigated GABA levels in patients with schizophrenia and BD in Chapter 8 
(Atagun et al., 2018).  
The relationship between neurocognitive dysfunction and cortical alterations (in particular 
auditory cortices) in BD will be discussed. Clinical variations and potential confounders are 
going to be evaluated. Neurophysiology is a good way to evaluate cognitive function, since it 
provides the opportunity to assess dynamic changes through event-related experiments. Event-
related spectral perturbations and phase synchronization might be accurate only with neuronal 
integrity and pathologies may disturb these mechanisms. Disturbed neuronal integrity might be 
related with structural as well as functional abnormalities, including chemical alterations. In 
Chapter 9, a comprehensive discussion will be presented. 
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Abstract 
 
Background: Theta oscillations are related to cognitive functions and reflect functional 
integration of frontal and medial temporal structures into coherent neurocognitive 
networks. This study assessed event-related theta oscillations in medication-free, 
euthymic patients with bipolar disorder upon auditory oddball paradigm.  
 
Method: Twenty-two DSM-IV euthymic bipolar I (n =19) and II (n =3) patients and 
twenty-two healthy subjects were included. Patients were euthymic for at least 6 
months, and psychotropic-free for at least 2 weeks. EEG was recorded at 30 electrode 
sites. Auditory oddball paradigm and sensory stimuli were used. Event-related 
Oscillations were analyzed using adaptive filtering in two different theta frequency 
bands (4–6 Hz, 6–8 Hz). 
 
Results: In healthy subjects, slow theta (4–6 Hz) responses were significantly higher 
than those of euthymic patients upon target, non-target and sensory stimuli (p<0.05). 
Fast theta (6–8 Hz) responses of healthy subjects were significantly higher than those 
of euthymic patients upon target-only stimuli (p<0.05).  
 
Conclusion: Reduced theta oscillations during auditory processing provide strong 
quantitative evidence of activation deficits in related networks in bipolar disorder. Fast 
theta responses are related to cognitive functions, whereas slow theta responses are 
related to sensory processes more than cognitive processes.  
Keywords: Bipolar disorder, theta oscillations, medication-free, euthymia, cognitive 
dysfunction  
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1. Introduction 
Cognitive deficits and emotional dysregulation in euthymia are indicators of enduring 
pathology in bipolar disorder (BD). Disruptions of the connections between frontal cortex, 
amygdala, basal ganglia, thalamus, entorhinal cortex and hippocampus are suggested to 
participate in the underlying pathology of bipolar disorder (Dupont et al. 1995; Caligiuri et al. 
2004; Blumberg et al. 2002; Philips et al. 2003; Strakowski et al. 2005). These connections are 
also believed to serve in modulation of cognition and emotional consonance (Strakowski et al. 
2005).  
In contrast to the wealth of neuroimaging studies in BD, little is known about electrophysiologic 
correlates. Cognitive deficits in BD may indicate that EEG recorded under cognitive task 
conditions would be better suited to identify electrophysiological correlates of cognitive 
dysfunctions. Event-related potential studies of P300 peak amplitudes produced inconsistent 
results in BD; Some studies reported reduced P300 amplitudes (Muir et al. 1991; El-Badri et 
al. 2001; Salisbury et al. 1998; O’Donnell et al. 2003; O’Donnell et al. 2004b; Fridberg et al. 
2009), while some others reported no difference between healthy controls and patients with BD 
(Souza et al. 1995; Strik et al. 1998; Hall et al. 2007; Kaya et al. 2007; Schulze et al. 2007, 
2008).   
Dysfunction in sensory or cognitive processes cannot be explained only by a frequency 
response; however, connectivity deficits between involved brain sites may be reflected in a 
frequency response (Başar 2006). Over the last decade, oscillatory activity has increasingly 
been applied in various clinical pathologies, including bipolar disorder (see reviews Başar and 
Güntekin 2008; Başar 2010). The degree of resting state long-range synchrony was found to be 
significantly reduced in manic patients in comparison to healthy controls at all frequencies 
(Bhattacharya 2001). Medicated euthymic patients had increased delta and decreased beta 
synchronization in the frontal sites (Chen et al. 2009). Patients in manic or mixed state were 
found to have deficits in auditory EEG synchronization in beta and gamma range activity during 
click entrainment paradigm (O’Donnell et al. 2004a). Gamma band power reduction has also 
been found in euthymia (Lee et al. 2010). Auditory steady state response (ASSR) is thought to 
be generated by neural networks, including auditory cortices and thalamo-cortical circuits 
(Pantev et al. 1996; Rass et al. 2010). Deficits in generation and maintenance of ASSR in 
bipolar disorder may indicate disturbances in neural networks involved in auditory cortices 
(O’Donnell et al. 2004a, Rass et al. 2010). When comparing evoked neural oscillations in the 
 21 
D
E
C
R
E
A
S
E
 O
F
 T
H
E
T
A
 R
E
S
P
O
N
S
E
 IN
 E
U
T
H
Y
M
IC
 B
IP
O
L
A
R
 P
A
T
IE
N
T
S
 D
U
R
IN
G
 A
N
 O
D
D
B
A
L
L
 P
A
R
A
D
IG
M
 
2 
left hemisphere in response to speech sounds, patients with BD displayed larger evoked 
oscillations than both schizophrenics and healthy controls in an MEG study (Oribe et al. 2010). 
In almost all of these studies, patients were medicated. Yener et al. (2007) showed that theta 
oscillations were significantly greater in patients with mild AD on cholinomimetic medication 
compared with those of medication-free patients with AD.   
Previous studies by our group investigating oscillatory responses to visual oddball stimuli in 
medication-free bipolar patients found increased occipital beta activity in manic (Özerdem et 
al. 2008) and reduced long distance gamma coherence in manic (Özerdem et al. 2010) and 
euthymic states (Özerdem et al. 2011). Başar et al. (2012) recently showed that, in spontaneous 
EEG, bipolar patients had significantly reduced alpha activity in comparison to healthy 
controls.  
Theta oscillations have been proposed to provide integration and communication between 
different brain areas (Başar 2010; Başar-Eroğlu and Demiralp 2001; Başar et al. 2001; Kirk and 
Mackay 2003; Sarnthein et al. 1998). Theta rhythm has been considered to be the fingerprint of 
all limbic structures; it is most prominent in the hippocampal formation (Lopes da Silva 1990). 
Theta oscillations are related to memory, attention and cognitive control processes (e.g., see 
Başar et al. 2001, Başar 1998, 1999; Klimesch 1999; Kahana et al. 1999), thus they are of 
particular interest in cognitive paradigms. Numerous structures in frontal (e.g., Gevins et al. 
1997; Onton et al. 2005; Mitchell et al. 2008) and medial temporal regions (e.g., Başar-Eroglu 
et al. 1992; Kahana et al. 1999; Raghavachari et al. 2001; von Stein and Sarnthein 2000) 
generate cognition-related theta oscillations. Theta activity reflects functional integration of the 
abovementioned structures into coherent neurocognitive networks (see e.g. Başar et al. 2001; 
Başar 1998; Klimesch 1999; von Stein and Sarnthein 2000 for reviews). Thus, altered theta 
responses are likely to represent neurophysiologic correlates of cognitive deficits in BD 
(Sakowitz et al. 2000). 
To our knowledge, no studies to date have compared the theta band power of control and BD 
samples. Electrophysiological assessments of oscillations provide high temporal resolution and 
therefore assessments of oscillatory responses to sensory or cognitive events constitute a useful 
imaging modality. Assessment of brain responses in the absence of any potential symptom or 
medication-related confounding effects may provide a major advantage to understand the 
underlying pathophysiology of bipolar disorder. The aim of this study was to assess evoked and 
event-related oscillatory responses to auditory stimuli in medication-free euthymic bipolar 
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patients in comparison to healthy controls. Since verbal learning and verbal memory deficits 
are the most consistent cognitive dysfunctions in BD (Robinson et al. 2006; Bora et al. 2009), 
it can be hypothesized that theta responses to auditory oddball paradigm within the patient 
group may differ from healthy controls. 
2. Method 
2.1. Subjects 
Twenty-two euthymic, drug-free patients with euthymic bipolar I (n =19) or bipolar II (n =3) 
diagnoses (female/male=16/6; mean age± SD: 31.18 ± 6.34, range: 23–44 years), and sex 
(female/male: 16/6), age (mean age of healthy controls: 29.41±7.77, range=20–45) and 
education (mean years of education for bipolar patients=12.7±3.9 vs. healthy controls=14.1±1.7 
years) -matched healthy controls were enrolled into the study (Table 1). All subjects were 
interviewed with the Turkish version of the SCID-I (Structured Interview according to DSM-
IV)  (First et al. 1996). The local Ethical Committee of Bakırkoy Research and Training 
Hospital approved the study. Each participant provided written informed consent. Patients 
needed to be euthymic at least for 6 months, psychotropic-free for at least two weeks prior to 
study enrollment; to score 7 or less on the reliable and validated Turkish versions of the Young 
Mania Rating Scale (YMRS) (Young et al. 1978; Karadağ et al. 2002), Hamilton Depression 
Rating Scale (HAM-D 21) (Hamilton 1960; Aydemir and Deveci 2003); to have no co-morbid 
axis I diagnosis, and to be medically healthy, as confirmed by physical examination and routine 
laboratory tests. Exclusion criteria were: Pregnancy, lactation, consumption of alcohol or illicit 
substances within the previous 2 weeks, history of alcohol- or substance misuse, axis 1 
psychiatric comorbidity and neurological conditions such as neurodegenerative diseases, 
epilepsy, and brain surgery. Volunteers who proved to have no present or past psychiatric 
condition on SCID-I interview and to be medically healthy on physical examination were 
enrolled as the control group.  
2.2. Stimuli and Paradigms 
Participants were seated in a dimly-lit isolated room with eyes open. Two types of stimuli were 
presented: simple auditory stimuli for analyzing auditory evoked potentials (AEP), and auditory 
oddball paradigm for analyzing auditory event-related potentials (AERP). The auditory stimuli 
had 16 ms rising time, 50 ms falling time and 1000 ms duration, and were presented by two 
loudspeakers. 
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 The auditory simple stimuli were tones of 80 dB and 1500 Hz. The inter-stimulus 
intervals varied randomly between 3 and 7 seconds. The total number of stimuli was 60. 
 The classical auditory oddball paradigm that was used in the experiments consisted of 
two types of stimuli: task-relevant target and task- irrelevant non-target (standard). The 
total number of stimuli was 120 (40 target, 80 non-target). Target (80 dB, 1600-Hz 
tones) and non-target (1500-Hz tones) were presented in a random sequence. The 
interval between tones varied randomly between 3 and 7 seconds. The subjects were 
instructed to keep a mental count of the number of target (1600 Hz) tones.  
The evoked and event-related theta responses to the target, non-target and simple auditory 
stimulation stimuli were analyzed and compared.  
2.3. Electrophysiological Recording  
EEG was recorded with 30 Ag–AgCl electrodes mounted in an elastic cap (Easy-cap) according 
to the international 10-20 system. Additionally, two linked earlobe electrodes (A1 + A2) served 
as references. The EOG from the medial upper and lateral orbital rim of the right eye was also 
registered. For the reference electrodes and EOG recordings, Ag–AgCl electrodes were used. 
All electrode impedances were less than 10 kΩ. The EEG was amplified by means of a 
BrainAmp 32-channel DC device with band limits of 0.01– 250 Hz. The EEG was digitized on-
line at a sampling rate of 500 Hz. 
2.4. Evoked and Event-related Oscillatory Analysis by Means of 
Adaptive Filtering. 
Artifacts were eliminated by manual off-line selective averaging, taking into consideration the 
EOG recorded from the right eye. The sweep numbers were equalized randomly between the 
target, non-target and simple auditory stimulation conditions. The epochs (between 0 and 800 
ms) of each subject were averaged and then the digital FFT-based power spectrum analysis was 
performed. (10% Hanning windowing function was evaluated in order to calculate the theta 
frequency peak). Subject averages and grand averages were calculated for each electrode site 
and experimental condition. As seen in Figure 1, in the grand average of response power 
spectrum upon stimulation of target stimuli, two different peaks were detected in theta 
frequency in the healthy control group, both for slow theta (4–6 Hz) and fast theta (6–8 Hz). 
Adaptive filtering was applied in analyzing the data in both healthy and patient groups, due to 
the two different peaks observed in theta frequency range only in healthy controls. Adaptive 
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filtering of the response provides a major advantage that subsystems of the system might be 
selectively removed to obtain isolation. Separate isolation of the filters may allow the choice of 
amplitude and frequency characteristics of the filters. Ideal filters may be applied without phase 
shifts. Furthermore, this method also permits the definition of filters with exact characteristics 
their adequate regulation according to the amplitude characteristics of the system (for further 
information see Başar 2004). Accordingly, each subject’s averaged evoked and event-related 
potentials were digitally filtered in slow theta (4–6 Hz) and fast theta (6–8 Hz) frequency 
ranges. The maximum peak-to-peak amplitudes for each subject’s averaged slow theta (4–6 
Hz) and fast theta (6–8 Hz) responses were analyzed; that is, the largest peak-to-peak value in 
these frequency ranges in terms of μVs found in the time window between 0 and 500 ms.  
Figure 1. Power spectrum of auditory evoked and event related responses over left frontal (F3) 
location 
 
2.5. Statistical Analysis  
SPSS was used for statistical analysis. A repeated measure ANOVA was used to determine the 
statistical significance of differential theta responses over different conditions, locations, and 
between patients and controls. Two separate ANOVAs were used for the two different 
frequency theta ranges (4–6 Hz and 6–8 Hz). In the analysis of theta responses, repeated 
measures of ANOVA included the healthy controls and euthymic patients as the between-
subjects factor; stimulus types (target, non-target, simple auditory stimulation) at three levels, 
locations [frontal (F3–F4), central (C3–C4), temporal (T7–T8), temporo-parietal (TP7–TP8), 
Parietal (P3–P4), Occipital (O1–O2)] signals at six levels and hemispheres (right, left) at two 
levels were included as within-subject factors. Greenhouse–Geisser corrected p-values are 
reported. The t-test was used for post-hoc comparisons. In all analyses, the level of significance 
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was p<0.05 with 95 % confidence interval. In the analysis of behavioral data, due to extreme 
values, logarithmic transformation was applied to numbers of errors and Spearman’s correlation 
analysis was used for correlations. Spearman’s correlation test was used to obtain correlations 
between the clinical data and evoked and event-related theta oscillatory responses. Each 
subjects’ frontal, central, temporal, temporo-parietal, parietal and occipital values were 
obtained by calculating average values of left and right electrode values and these averages 
were used to obtain correlations between clinical variables.  
3. Results 
Clinical characteristics of the patients are given in Table 1. All patients were drug-free for at 
least two weeks and euthymic for at least 6 months; mean score for the 21-item HAM-D was 
2.55 (±2.3) and mean score for YMRS was 0.55 (±1.19).  
Table 1. Subjects’ characteristics 
 Patients with 
Bipolar Disorder 
Healthy Controls p 
Age* 31.18±6.34 29.41±7.77 0.412 
Education* 12.73±3.68 14.55±2.13 0.126 
Age at Disease Onset* 21.77±6.28   
Duration of Euthymia¥ 44.95±37.39   
Duration of Illness¥ 117.95±57.18   
N
u
m
b
er
 o
f 
Total Episodes 4.05±3.12   
Manic Episodes 2.27±1.96   
Depressive Episodes 1.09±1.11   
Hypomanic Episodes 0.68±1.17   
Mean±SD, * years, ¥months 
 
 
Figure 2 shows a sample of filtered and averaged theta response at the left-frontal location. 
There was a 20% decrease in evoked oscillations and a 30% decrease in event-related 
oscillations in patients with bipolar disorder in comparison to healthy controls. 
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Figure 2. Filtered theta response in left-frontal (F3) electrode site upon simple and target 
stimuli. Grand averages of theta responses of patients with bipolar disorder are represented by 
red lines and those of healthy controls are represented by black lines. There is a 20% decrease 
in evoked oscillations and 30% decreases in event-related oscillations in patients with bipolar 
disorder compared to healthy controls. 
 
 
3.1. Slow Theta Oscillations (4–6 Hz)  
- General Features    - 
In the repeated measures of ANOVA, there was a significant stimulus-type effect [F(2,84): 
17.672; p<0.0001] in the whole group (n=44). Post-hoc comparisons showed that slow theta 
responses upon target stimuli were significantly higher than slow theta responses upon non-
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target stimuli in the whole group (p<0.0001). Furthermore, slow theta responses upon simple 
auditory stimuli were significantly higher than slow theta responses upon non-target stimuli 
(p<0.0001). No difference was detected between simple and target stimuli. The location effect 
was also significant [F(5,210): 126.738; p<0.0001] in the whole group (n=44). Post-hoc 
comparisons showed that, regardless of the stimulus type, slow theta responses at frontal and 
central electrodes were higher than temporal, temporoparietal, parietal and occipital electrodes 
(p<0.0001 for all comparisons). Furthermore, slow theta responses at temporal and 
temporoparietal electrodes were higher than those at parietal and occipital electrodes (p<0.0001 
for all comparisons). There was a significant [location × stimulus-type] effect (F(10,420): 
7.352; p<0.0001) in the whole group (n=44). Post-hoc comparisons showed that fast theta 
responses to target stimuli were significantly higher than fast theta responses to auditory non-
target stimuli at frontal, central and occipital electrode sites (p<0.002; p<0.002; p<0.0001). It 
is also note that in all electrodes slow theta responses of non-target stimuli were lower than the 
slow theta responses of target and simple auditory stimuli. 
- Comparison of the patient and healthy control groups  - 
Slow theta response differed significantly between the patient and control groups (F(1,42): 
5.686; p<0.05). The t-test showed that patients had significantly lower slow theta activity in 
response to simple stimuli (EP) at F3 (p<0.01), F4 (p<0.01), C3 (p<0.01), C4 (p<0.05), T7 
(p<0.05), T8 (p<0.05) and P3 (p<0.05) electrodes. Also for the target stimulus, the patients had 
significantly lower values at the same locations [F3 (p<0.05), F4 (p<0.05), C3 (p<0.05), C4 
(p<0.05)]. For the non-target stimuli, the difference was significant at T7 (p<0.05) and T8 
(p<0.05) locations. Differences between groups are represented in Figure 3.   
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Figure 3. Mean amplitudes of patients with bipolar disorder and healthy controls in 4–6 Hz 
frequency range. Red bars represent patients with bipolar disorder and blue bars represent 
healthy controls. “*” sign represent p values less than 0.05; “×” sign represent p values less 
than 0.001. 
 
3.2. Fast Theta Oscillations (6–8 Hz) 
General Features   -  
ANOVA showed that fast theta responses differed significantly between stimulus-type effects 
[F(2,84): 9.691; p<0.0001] in the whole group (n=44). Post-hoc comparisons showed that fast 
theta responses upon target stimuli were significantly higher than fast theta responses upon non-
target stimuli (p<0.0001). Furthermore, fast theta responses upon simple auditory stimuli were 
significantly higher than fast theta responses upon non-target stimuli (p<0.0001). No significant 
difference was detected between simple and target stimuli. The location effect was also 
significant [F(5,210): 93.298; p<0.0001] in the whole group (n=44). Post-hoc comparisons 
showed that fast theta responses at frontal and central electrodes were higher than at temporal, 
temporoparietal, parietal and occipital electrodes (p<0.0001 for all electrodes). Furthermore, 
fast theta responses at temporal and temporoparietal electrodes were higher than those at 
parietal and occipital electrodes (p<0.001; for all comparisons). 
(Frontal=Central>temporal>temporoparietal>Parietal>Occipital) There was a significant 
[location × stimulus-type] effect [F(10,420): 2.882; p<0.05] in the whole group (n=44). Post-
hoc comparisons showed that fast theta responses to target stimuli were significantly higher 
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than fast theta responses to auditory non-target stimuli at frontal, central and occipital electrode 
sites (p<0.003; p<0.007; p<0.0001). It is also note that in all electrodes fast theta responses of 
non-target stimuli were lower than the fast theta responses of target and simple auditory stimuli. 
- Comparison of the patient and healthy control groups  - 
The ANOVA of fast theta responses revealed significant [stimulus × location × group] effect 
[F(10.420): 2.867; p<0.05). Post-hoc comparisons showed that, upon simple stimuli, fast theta 
responses of healthy controls were greater than patients with BD only in right temporal region 
(p<0.01 for all sites); upon target stimuli, fast theta responses of healthy controls were greater 
than patients with BD at frontal, central, right temporal and right parietal regions (p<0.001, 
p<0.001, p<0.01 and p<0.05 respectively). Upon non-target stimuli, healthy controls showed 
greater fast theta responses than patients with BD only in the temporal region (p<0.05). 
Comparison of [stimuli × location × hemisphere] revealed that the responses of the healthy 
control group were significantly higher than the patient group [F(10.420): 2.093; p<0.05]. T-
test results showed that patients had significantly lower theta activity in response to simple 
stimuli (EP) only at site T8 (p<0.01). In response to the target stimuli, the patients had 
significantly lower values at locations F3 (p<0.05), F4 (p<0.01), C3 (p<0.05), C4 (p<0.01), T8 
(p<0.01) and P4 (p<0.05). No significant difference was found between the groups in response 
to the non-target stimuli. Inter-group differences are represented in Figure 4. 
Figure 4. Mean amplitudes of patients with bipolar disorder and healthy controls in 6–8 Hz 
frequency range. Red bars represent patients with bipolar disorder and blue bars represent 
healthy controls. “*” sign represent p values less than 0.05; “×” sign represent p values lower 
than 0.001. 
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3.3. Behavioral Data 
During the elicitation period of event-related oscillations, subjects were instructed to count the 
target stimuli as a cognitive task. It was found that 18 of 22 members of the patient group 
(mean=3.82±7.39, range:1–26) made errors, compared with 11 of the 22 control subjects 
(mean=6.56±9.54, range:1–40).  
3.4. Correlation Analyses 
Each subjects’ frontal, central, temporal, temporo-parietal, parietal and occipital electrodes 
were used to obtain correlations between clinical variables such as age, education, age at disease 
onset, duration of euthymia, duration of the disease, total numbers of episodes, total numbers 
of manic and depressive episodes. Slow theta and fast theta responses to simple, target and non-
target stimuli correlated significantly with age and age at disease onset (Table 2).  
Table 2. Correlations between mean amplitudes of averaged filtered theta response and clinical 
variables. Spearman’s Correlation test; r values. *p<0.05; ¥p<0.001. Education, age at disease 
onset, duration of euthymia, total numbers of episodes, total numbers of manic and depressive 
episodes did not show any correlation. 
 
Frontal Central Temporal 
Temporo-
parietal 
Parietal Occipital 
Simple 
Stimulus 
4-6 Hz 
Age -0.49* -0.70¥ -0.50* -0.60¥ -0.55¥ -0.43* 
Age at Disease Onset -0.40 -0.52* -0.13 -0.36 -0.55¥ -0.49* 
6-8 Hz 
Age -0.33 -0.58¥ -0.40 -0.42 -0.40 -0.42 
Age at Disease Onset -0.28 -0.38 -0.05 -0.17 -0.43* -0.33 
Duration of Last Episode 0.28 0.16 0.51* 0.34 0.06 0.14 
Target 
Stimulus 
4-6 Hz 
Age -0.53* -0.53* -0.51* -0.39 -0.53* -0.35 
Age at Disease Onset -0.26 -0.30 -0.21 -0.22 -0.40 -0.13 
6-8 Hz 
Age -0.23 -0.50* -0.42* -0.50* -0.43* -0.38 
Age at Disease Onset -0.17 -0.47* -0.23 -0.30 -0.47* -0.25 
Duration of Last Episode 0.32 0.17 0.41 0.27 0.27 0.15 
Non-target 
Stimulus 
4-6 Hz 
Age -0.36 -0.48* -0.48* -0.57¥ -0.54¥ -0.50* 
Age at Disease Onset -0.43* -0.52* -0.18 -0.44* -0.61¥ -0.29 
6-8 Hz 
Age -0.16 -0.28 -0.35 -0.48* -0.43* -0.41 
Age at Disease Onset -0.16 -0.29 -0.17 -0.25 -0.38 -0.22 
Duration of Last Episode 0.32 0.30 0.44* 0.35 0.34 0.01 
Spearman’s Correlation test. r values. L: left, R: right, ns: non-significant *p<0.05; 
¥p<0.001. Education, age at disease onset, duration of euthymia, total numbers of episodes, 
total numbers of manic and depressive episodes did not show any correlation. 
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4. Discussion 
The major finding of the present study is that patients with bipolar disorder showed significantly 
lower theta oscillatory responses upon auditory stimulation and in response to target and simple 
stimuli during an oddball paradigm in comparison to healthy controls. Patients presented 
different slow (4–6 Hz) and fast (6–8 Hz) theta response patterns. As the slow theta (4–6 Hz) 
responses of the patients were significantly lower upon simple auditory stimulation and target 
stimuli during the oddball paradigm at bilateral frontal, central, right temporal and right parietal 
regions, the 6–8 Hz activity of the patients showed significant reductions in the same locations 
compared to healthy controls only upon target stimulus. 
A comparison of Figures 3 and 4 clearly imposes the following reasoning: in the slow theta 
frequency window (4–6 Hz), all cortical areas react with significant increase, which is 
independent of the modality of stimulation. Simple stimulation and target stimulation both 
show significant increases of as much as 50%. In contrast, within the fast theta frequency band 
(6–8 Hz), all locations showed significant responses upon target stimulus; however, for except 
T8, none of the cortical areas are increased upon simple stimulation. These results clearly 
indicate that both theta responses are involved with different functional processing.  
Theta frequency bands have been extensively studied and are believed to be involved in 
cognitive functions such as working memory (Başar-Eroğlu and Demiralp 2001; Başar et al. 
2001; Başar 1998, 1999; Klimesch 1999; Kahana et al. 1999; Klimesch et al. 1996, 1997, 2001a, 
2001b). According to the model of Klimesch et al. (1996), short-term memory demands lead to 
synchronization in the theta band, manifested as an increase in band power, and occurs at the 
anterior limbic system. Oscillations in the theta and alpha band may provide the basis for 
encoding, accessing and retrieving cortical codes that are stored in the form of widely 
distributed but intensively interconnected cell assemblies (Başar 1999). In a recent study, 
Caravaglios and colleagues (2010) compared theta frequency responses (to oddball paradigm) 
of patients with Alzheimer disease and healthy controls by means of oddball paradigm. They 
found that although responses of healthy controls were responsive to target stimuli, theta 
frequency activity of the patients was not responsive to target or non-target stimuli. Patients 
showed increased pre-stimulus theta frequency activity, and no enhancement was detected in 
the early (0–250 ms) or late (250–500 ms) post-stimulus interval. The authors commented that 
patients had insufficient resources for adequate attention. It was also indicated that, unlike the 
healthy controls, patients did not have prominent frontal lobe activity during stimulus 
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processing. Theta and delta are the most affected frequencies upon oddball paradigm in 
Alzheimer disease and mild cognitive impairment as instances of cognitive dysfunctions (Başar 
et al. 2010). The authors suggested that cognitive impairment in Alzheimer disease was 
particularly manifested by reduced coherences in delta and theta frequency ranges.  
Event-related oscillations in the theta band are prolonged and/or have a second time-window 
approximately 300 ms after the presentation of the target stimulus in oddball experiments 
(Başar-Eroğlu and Demiralp 2001; Başar et al. 2001). Prolongation of theta response is 
interpreted as the reflection of the correlation with selective attention. Başar-Eroğlu and 
Demiralp (2001) further showed that the second theta window is more associated with target 
stimuli. In addition, mental count of the target stimuli is associated with sustained attention and 
working memory. Patients with bipolar disorder are known to suffer from cognitive 
dysfunctions, particularly in sustained attention, executive functions, working memory, verbal 
learning and verbal memory sub-domains of cognitive functions (see meta-analyses, Robinson 
et al. 2006; Bora et al. 2009).  
In general, theta frequency responses upon visual stimuli increase diffusely, including frontal, 
parietal, occipital and vertex sites; in contrast, auditory stimulus increases theta responses at 
frontal and parietal sites (Başar 1999; Demiralp and Başar 1992). The CA3 layers of the 
hippocampus, frontal- and parietal lobes are interconnected. The CA3 layer of hippocampus is 
shown to produce theta oscillations upon cognitive functions such as attention, perception, 
learning and memory in intracranial recordings from the cat brain (Başar-Eroğlu and Başar 
1991). Distribution of theta responses at frontal and parietal lobes upon auditory stimulus may 
also be related to the hippocampus (Başar 1999). Therefore, these findings are strong 
quantitative indicators of dysfunctional cognitive processes occurring in cortico-subcortical 
loops in bipolar disorder. Başar-Eroğlu and colleagues (2008) showed that distribution of theta 
and alpha responses upon a visual paradigm had a different pattern from healthy controls in 
schizophrenia. Healthy controls’ responses upon simple and non-target stimuli were distributed 
over the occipital lobe, while patients’ responses were distributed over fronto-central sites. The 
authors’ comment this on altered topography of the late theta response was that, even with 
simple task, patients required high cognitive effort to process stimuli.    
Functional neuroimaging studies showed association between discrimination of auditory 
stimulation and frontoparietal activation, particularly over the right hemisphere (Paquette et al. 
1996; Boucher and Bryden 1997; Zatorre 2001). In 6–8 Hz responses, the difference between 
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groups became more prominent in response to target stimuli on the right hemisphere, which is 
a marker of activation deficit among patients with bipolar disorder when perceiving and 
discriminating pitch. Hence, the decreased theta responses of the patients indicate disruptions 
in the frontoparietal networks. In addition, these results suggest that, rather than 4–6 Hz, the 6–
8 Hz band is more specific to the cognitive components of the oddball paradigm.  
According to Yener and Başar (2010), sensory event may evoke brain areas reacting sensory 
inputs, whereas cognitive processes may evoke areas to respond to both sensory and cognitive 
inputs. According to this assumption, 4–6 Hz may include both sensory and cognitive 
components, whereas 6–8 Hz may include only cognitive components. In our study, the 4–6 Hz 
responses of the patient group were significantly decreased upon both simple and target stimuli; 
however, 6–8 Hz responses differed only upon target stimulus. Therefore, 4–6 Hz may be 
related to sensory events (Aftanas et al 2001a, 2001b, 2003a, 2003b), while 6–8 Hz may be 
related to cognitive processing (Aftanas et al. 2003b). Previous studies found that 4–6 Hz is 
more prominent in posterior sites, while 6–8 Hz is greater in frontal sites (Kamarajan et al. 
2008; Krause et al. 2000). Loops integrating hippocampus and prefrontal cortices may serve 
cognitive functions via 6–8 Hz activity.  
Several previous studies by our group reported that patients with bipolar disorder showed 
activation and synchronization deficits in different frequency ranges including delta, alpha, beta 
and gamma bands (Özerdem et al. 2008, 2010, 2011; Başar et al. 2012). This is the first study 
in the theta frequency range. A major strength of this study is the inclusion of medication-free 
patients, whereas the relatively small sample size is a limitation. 
Concluding Remarks 
The results of this study represent a specific feature for BD: Auditory processing deficiency 
may indicate disruption of synchronization during auditory cognitive activity. These findings 
provide neurophysiological evidence of auditory processing dysfunction in BD. On the other 
hand, the oscillatory brain dynamics of patients with BD differ from healthy controls in both 
auditory and visual paradigms.  
The results suggest that fast theta (6–8 Hz) frequency responses are associated with cognitive 
functions, and that slow theta (4–6 Hz) frequency responses are more closely associated with 
sensory functions than with cognitive functions. Theta frequency should be analyzed in two 
different bands, including 4–6 and 6–8 Hz bands.  
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Abstract 
Decreased delta oscillation upon cognitive load is common in patients with Alzheimer’s 
disease, mild cognitive impairment, and schizophrenia (Başar and Güntekin, 2013). However, 
there is no previous study analyzing the delta responses in euthymic medication-free patients 
with bipolar disorder. Twenty-two DSM-IV diagnosed euthymic medication-free patients with 
bipolar disorder and twenty-one healthy controls who were matched for sex, age, and education, 
were enrolled in the study. EEG was recorded at 30 electrode sites using an application of an 
auditory oddball paradigm. The maximum peak-to-peak amplitudes for each subject’s averaged 
delta response (0.5–3.5 Hz) were measured. There was a significant inter-group difference in 
evoked and event-related delta (0.5–3.5 Hz) responses (p=0.002). Post-hoc comparisons 
revealed that event-related delta oscillatory responses of the bipolar patient group were 
significantly lower than the healthy control group over the temporoparietal and occipital 
electrode sites. Euthymic bipolar patients showed reduced event-related delta oscillatory 
responses in comparison to healthy subjects upon cognitive load. Decrease of delta oscillations 
can be a common phenomenon that can be observed in different neuropsychiatric disorders with 
cognitive dysfunction.  
Key Words: Bipolar Disorder, EEG, Delta Oscillations, Event-Related Potentials, Auditory 
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1. Introduction 
Although bipolar disorder (BD) is characterized by manic and depressive episodes, patients 
also suffer from cognitive dysfunctions that cannot be explained only by mood episodes (Bora 
et al., 2009). Cognitive task-based neuroimaging methods including electroencephalography 
(EEG) may provide valuable information in understanding the pathophysiology of 
neuropsychiatric diseases. The EEG is a cheap, noninvasive method with high temporal 
resolution that may provide a unique opportunity to observe cognitive processes over longer 
periods of time. The hemodynamic response is an indirect indicator of neuronal activity; 
whereas EEG can measure the bioelectrical activity of neuron populations. Poor spatial 
resolution is the major disadvantage of the EEG. 
Some studies of the event-related potential in bipolar disorder have identified reduced P300 
amplitudes (Muir et al., 1991; Salisbury et al., 1998, 1999; El-Badri et al., 2001; O’Donnell et 
al., 2004a, 2004b; Fridberg et al., 2009), whereas other studies reported no difference between 
healthy controls and patients with bipolar disorder (Souza et al., 1995; Strik et al., 1998; Hall 
et al., 2007; Kaya et al., 2007; Schulze et al., 2007, 2008). Furthermore, three studies reported 
prolonged P300 latency (O’Donnell et al., 2004; Turetsky et al., 2007; Schulze et al., 2008), 
whereas Salisbury et al. (1999) did not detect any delay in P300 latency. These divergent results 
may be related to the variable nature of bipolar disorder. Many confounders (clinical state, 
history of psychotic episodes, family history, medication status, etc.) may have influenced the 
study results.  
The global P300 activity of the brain is the superimposition of multiple oscillations in delta 
(0.5–3.5 Hz), theta (4–7 Hz), alpha (8–13 Hz), beta (18–30 Hz) and gamma (30–70 Hz) 
frequencies, which are selectively distributed in various parts of the brain (Başar, 1998). Delta 
oscillations are the major component of the P300 responses (Stampfer and Başar, 1985). All 
brain functions are controlled by the complex integration of various parts of the brain via these 
oscillatory activities (Başar et al., 2001). Disturbed sensory or cognitive processing might have 
reflections in various frequency responses and connectivity deficits between involved brain 
regions may influence a certain frequency response (Başar, 2006).  
Oscillatory brain responses are widely studied in schizophrenia and dementias, but studies of 
bipolar disorder are less common (Başar and Güntekin, 2008; Başar et al., 2012). Most 
consistent findings regarding bipolar disorder are obtained via auditory paradigms. For 
example, three studies reported decreased evoked power upon auditory steady state stimulation 
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(O’Donnell et al., 2004a; Spencer et al., 2008; Oda et al., 2012). Euthymic patients with bipolar 
disorder showed reduced mean trial power and phase-locking factor (PLF) upon auditory 
steady-state stimulation (Rass et al., 2010). Medication-free euthymic patients with bipolar 
disorder showed decreased amplitude in slow (4–6 Hz) and fast (6–8 Hz) theta frequency bands 
upon application of an auditory oddball paradigm (Atagün et al., 2013). Reite et al. (2009) 
detected abnormal lateralization of auditory cortices in auditory steady state responses in 
euthymia. Furthermore, the authors indicated that medicated patients showed decreased PLF in 
comparison to medication-free subjects. With an auditory dual-click paradigm, Hall et al. 
(2011) showed that the power of the gamma response was reduced in euthymic and depressed 
patients with bipolar disorder. Compared to healthy subjects or patients with schizophrenia, 
euthymic patients with bipolar disorder had higher (20–45 Hz) responses to speech sounds 
(Oribe et al., 2010). Another recent study reported significant differences between 
schizophrenia and bipolar disorder in an auditory oddball paradigm (Ethridge et al., 2012). The 
authors indicated that N200 responses to target stimuli differentiated patients with bipolar 
disorder and schizophrenia from healthy subjects; late beta response power to auditory target 
and standard stimuli differentiated bipolar patients from schizophrenia and healthy controls. 
Hamm et al. (2012) showed that N100 differentiated the group with schizophrenia from bipolar 
and healthy control groups; and late beta responses differentiated the bipolar patient group from 
schizophrenia and healthy control groups.  
To our knowledge, only one study reported that ‘medicated’ euthymic patients with bipolar 
disorder (n=10) had increased delta (2-4 Hz) synchronization at frontal sites (Chen et al., 2008). 
Many excellent pharmaco-EEG studies have examined the effects of medications on brain 
bioelectrical activity. Our research group previously showed that oscillatory responses can be 
influenced by mood stabilizers such as valproate (Özerdem et al., 2008). It has also been shown 
that cholinergic treatment affects oscillatory brain responses in patients with Alzheimer’s 
disease (Yener et al., 2007). This study examines oscillatory delta responses in medication-free 
euthymic patients with bipolar disorder. It is hypothesized that, upon application of auditory 
simple and oddball paradigms, oscillatory delta responses might be altered in patients with 
bipolar disorder.  
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2. Methods 
a. Subjects 
The study enrolled 22 euthymic, medication-free patients with bipolar disorder (19 Bipolar I, 3 
Bipolar II disorder) and 21 healthy control participants matched for age, education and gender 
(Table 1). Diagnoses were checked by the Structured Clinical Interview (SCID) (First et al., 
1996); and clinical evaluation tools for bipolar patients were Young Mania Rating Scale 
(YMRS) (Young et al., 1978), and Hamilton Depression Rating Scale (HAM-D) (Hamilton, 
1960). Inclusion criteria for the patient group were: to have been diagnosed with bipolar 
disorder, euthymic for at least eight weeks and unmedicated for at least two weeks. Good 
medical health, as confirmed by a physical examination and routine laboratory tests, was 
required for participation. Exclusion criteria were: pregnancy, lactation, consumption of 
alcohol or substances two weeks prior to the recordings, axis I and II psychiatric co-morbidity, 
and neurological conditions such as neurodegenerative diseases, epilepsy, or brain surgery. 
Volunteers who proved to have no present or past psychiatric condition on the SCID-I interview 
and were reported as medically healthy on physical examination were enrolled in the control 
group. All participants were right-handed. All subjects were asked to avoid sleep deprivation 
before the experiments. All the experiments were done at the same time of day (1 pm to 5 pm). 
The study design was reviewed and approved by the ethical committee and an appropriate 
informed consent of the participants was obtained after the nature of the procedures had been 
clearly explained. 
b. Stimuli and procedures 
The tests were conducted in a dimly-lit isolated room. Two types of auditory stimuli—simple 
and oddball paradigm—were presented to the subjects via two loud-speakers positioned 50 cm 
in front of the subject. The auditory stimuli had 1000 ms duration. One type of stimulus (80 dB, 
1600 Hz tone) was presented in the simple stimuli and no instructions were given to the 
subjects. Subsequently, the classical auditory oddball paradigm comprised 40 task-relevant 
target tones (80 dB, 1600 Hz) and 80 task-irrelevant non-target (80 dB, 1500 Hz) stimuli were 
presented in a random sequence. The interval between tones varied randomly between three 
and seven seconds. Subjects were asked to discriminate and mentally count the number of target 
stimuli. 
c. EEG recording 
An elastic cap (easy-cap) was used, containing 30 Ag-AgCl electrodes according to the 
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international 10–20 system. Two linked earlobe electrodes (A1- A2) were used for references 
and another pair for electrooculography (EOG) were placed on the medial upper and lateral 
orbital rim of the right eye. All electrode impedances were less than 10 kΩ. The EEG was 
amplified by means of a BrainAmp 32-channel DC device with band limits of 0.01–250 Hz. 
The EEG was digitized on-line at a sampling rate of 500 Hz.  
d.  Data analyses 
Artifacts in the EOG recordings were eliminated by manual off-line selective averaging. The 
epochs (between -500 and 1000 ms) of each subject were averaged and then digital Fast Fourier 
Transform (FFT) based power spectrum analysis was performed (Figure 1; 10% Hanning 
windowing function) in order to calculate the oscillatory delta frequency peak.  
 
Figure 1. Power spectra of response upon auditory simple and oddball stimuli. (C4 location) 
Black lines represent healthy controls; red lines represent patients with bipolar disorder.   
 
 
Subject averages and grand averages were calculated for each electrode site and experimental 
condition. Averaged evoked and event-related potentials were filtered in 0.5–3.5 Hz ranges. 
The event-related oscillatory delta responses to the target auditory stimuli were analyzed and 
compared. The maximum peak-to-peak amplitudes of oscillatory delta responses were 
calculated. Delta frequency is a slow frequency that lasts for 400 to 500 milliseconds; therefore 
the window was determined as 0–600 milliseconds.  
e. Statistical analyses 
Statistical analyses were performed by Statistica Software. Repeated measures of ANOVA 
were used to identify significant group differences in oscillatory delta responses for different 
conditions, locations and between the bipolar patient and healthy control groups. Repeated 
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measures ANOVA included the bipolar patient and the healthy control groups as the between-
subject factor. Stimulus types (simple, target and non-target) at three levels, locations [frontal 
(F3–F4), central (C3–C4), temporal (T7–T8), temporo-parietal (Tp7–Tp8), Parietal (P3–P4) 
and Occipital (O1–O2)] at six sites and two hemispheres (left–right) were included as within-
subject factors. Greenhouse–Geisser corrected p-values were reported. Bonferroni test was used 
for post-hoc comparisons. Planned comparisons were performed to analyze the differences 
between groups for six different locations upon application of target stimulation; it was also 
aimed to find the most effected electrode site. Bonferroni corrections were also performed while 
comparing locations between different groups during target stimulation. The number of errors 
by each subject was noted and, due to extreme values, logarithmic transformation was applied; 
the log-transformed numbers of errors are compared via the t-test. Subjects were grouped as 
error-positive or error-negative and compared via the chi-square test. Spearman’s correlation 
test was conducted for each group to detect any correlation between clinical and behavioral 
parameters and mean amplitude values in evoked and event-related responses. 
 
3. Results 
Groups were age, gender, and education matched (Table 1).  
 
Table 1. Sociodemographic and clinical characteristics of the groups. 
 Patients with Bipolar 
Disorder (n=22) 
Healthy Controls 
(n=21) 
p 
Age 30.82 ± 6.46 29.10 ± 7.87 0.436a 
Education  11.77 ± 3.61 13.41 ± 2.69 0.097a 
Gender (f/m) 16/6 16/5 0.795b 
Age at disease onset 21.86 ± 6.30   
Duration of euthymia 48.64 ± 37.71   
Duration of disorder 10.05 ± 4.96   
Total 
number of 
Episodes 3.91 ± 3.13   
Mania 1.77 ± 1.54   
Depression 1.14 ± 1.08   
at test bChi-Square test (χ2=0.068) f/m: female/male 
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There was a significant inter-group difference in evoked and event-related delta (0.5–3.5 Hz) 
responses (p=0.002). Post-hoc comparisons revealed that event-related delta oscillatory 
responses of the bipolar patient group were significantly lower than the healthy control group 
over the temporoparietal and occipital electrode sites. Repeated measures ANOVA revealed a 
significant stimulus type interaction [F(2,82): 63.26, p<0.001]. Post-hoc comparisons showed 
that oscillatory delta responses upon auditory target stimuli (8.71±3.99) were significantly 
higher than both simple stimuli (4.93±2.19) (p<0.00001) and non-target stimuli (4.78±2.26) 
(p<0.00001). ANOVA revealed significant results for location [F(5,205)=50.86, p<0.001]. 
Post-hoc comparisons showed that amplitudes of frontal, central and parietal locations were 
significantly higher than amplitudes of temporal, temporo-parietal and occipital locations. 
ANOVA revealed significant results for [stimulus × location] [F(5,205):11.51, p<0.001] 
interaction. Post-hoc comparisons showed that the difference between target stimulation versus 
simple stimuli (p<0.00001) and versus non-target stimuli (p<0.00001) were most prominent at 
parietal location.  
The ANOVA revealed [stimulus × laterality] difference [F(2,82)=4.36, p=0.016]. Post-hoc 
comparisons showed that amplitude values of right hemispheric responses upon auditory target 
stimuli were significantly greater than left hemispheric responses (p=0.002).  
Delta oscillatory responses differed significantly between the bipolar patient and healthy 
control groups [F(1,41)=11.17, p=0.002]. The stimulusXgroupXlocation or groupXlocation 
interactions were not significant thus showing that this difference between groups were found 
in overall electrode sites. However, we have also observed that this difference could be more 
prominent in some of the electrodes, especially upon target stimulation. Accordingly we have 
run planned comparisons in which we have analyzed delta oscillatory responses only for target 
stimulation and for frontal, central, temporal, temporo-parietal and occipital locations. After 
Bonferroni correction the significance level for p value was determined as p=0,008. The 
planned comparisons showed that healthy subjects had higher delta responses than bipolar 
disorder patients over central (p=0.04), temporal (p=0.01), temporo-pariteal (p=0.006), parietal 
(p=0.03) and occipital (p=0.008) locations. After Bonferroni correction, it was seen that healthy 
subjects had higher delta responses than bipolar patients only for temporo-parietal (p=0.006), 
and occipital (p=0.008) locations upon target stimulation. Differences between groups are 
presented in Figure 2.  
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Figure 2. Event-related delta (0.5–3.5 Hz) oscillatory responses upon auditory target stimuli. 
Red lines represent patients with bipolar disorder and green bars represent healthy subjects. 
Statistically significant differences are marked with * sign (for comparison of temporoparietal 
location p=0.006, for occipital location p=0.008).  
 
Analysis of behavioral data showed that 18 out of 22 patients with bipolar disorder made errors, 
whereas 9 out of 21 healthy controls made errors (p=0.013, 2=6.19). The number of errors (log 
transformed) differed significantly between groups (p=0.004, Z=-2.85). No correlation was 
identified between the number of errors and the amplitudes of target responses.  
Correlation analysis showed that age and age at disease onset significantly correlated with the 
amplitude of target responses in the bipolar group (Table 2). Young Mania Rating Scale scores 
correlated with amplitude at the right temporo-parietal (p<0.05, r=0.45) and occipital (p<0.05, 
r=0.45) locations. Education negatively correlated with the number of errors in target detection 
(p<0.05, r=-0.48). Duration of disease correlated with number of errors in target detection 
(p<0.05, r=0.51). Other variables (education, HAM-D scores, duration of disease, duration of 
euthymia and number of total/manic/depressive episodes) did not show any correlation with 
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mean amplitude values. However, these significant correlations were not significant after 
Bonferroni correction.  
 
Table 2. Correlations in the bipolar disorder group 
 
Type of 
Stimuli 
F3 F4 C3 C4 T7 T8 Tp7 Tp8 P3 P4 O1 O2 
Age 
Simple -0.31 -0.25 -0.42 -0.42* -0.33 -0.36 -0.12 -0.22 -0.46* -0.39 -0.14 -0.25 
Target -0.33 -0.12 -0.49* -0.49* -0.33 -0.50* -0.38 -0.56¥ -0.45* -0.47* -0.41 -0.48* 
YMRS target 0.16 0.03 0.14 0.14 0.16 0.21 0.29 0.45* 0.26 0.28 0.32 0.45* 
Age of 
Onset 
target -0.35 -0.27 -0.45* -0.47* -0.45* -0.30 -0.43* -0.36 -0.41 -0.43* -0.21 -0.34 
Spearman’s Rho Correlation Test, r values. *p<0.05, ¥p<0.01. YMRS: Young Mania Rating 
Scale. Education, Hamilton depression rating scale score, duration of disease, duration of 
euthymia and number of (total/manic/depressive) episodes did not show any correlation with 
amplitudes of delta oscillations.  
 
4. Discussion 
The findings show that evoked and event-related delta oscillations in patients with bipolar 
disorder are significantly lower than in healthy controls at central, parietal, temporal, temporo-
parietal and occipital regions. Oscillatory delta responses upon cognitive tasks have also been 
reported to be significantly decreased in different groups such as schizophrenia (Ergen et al., 
2008; Ford et al., 2008; Bates et al., 2009; Doege et al., 2010), Alzheimer’s disease (Güntekin 
et al., 2008; Yener et al., 2008; Başar et al., 2010; Yener et al., 2012) and elderly healthy 
subjects (Schmiedt-Fehr and Başar-Eroğlu, 2011). This suggests that delta oscillations might 
play a critical role in cognition, which might be commonly influenced by neuropathology of 
various neuropsychiatric disorders, as proposed by Başar and Güntekin (2013).  
Delta oscillations are related to focused attention, signal detection, recognition, and decision-
making (Başar-Eroğlu et al., 1992; Başar et al., 1998, 1999, 2001; Schürmann et al., 2001). 
Additionally, delta oscillations are also involved in cortical communication over long distances 
(Bruns and Eckhorn, 2004). Yener et al. (2010, 2012) suggested there were two different 
networks activated in delta frequency in response to different stimulus modalities, according to 
the stimulation characteristics and requirements (i.e. sensory or cognitive demands). Although 
the groups differed in event-related delta oscillations, there was no difference between healthy 
controls and patients with Alzheimer’s disease in their evoked responses (Yener et al. 2012). 
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Evoked oscillations do not include cognition related components and event-related oscillations 
include cognitive task related responses. 
Independent of the group (n=43), event-related delta oscillations were higher in frontal, central 
and parietal locations compared with temporal and occipital locations. This pattern may indicate 
that operations with delta oscillations spread to fronto-parietal regions upon cognitive demands 
of the oddball paradigm (Schürmann et al., 1995; Başar, 1998, 1999; Ishii et al., 2009; Mathes 
et al., 2012). However, despite the general trend, the between-group difference in delta 
oscillations in the oddball paradigm was not significant at frontal locations.  
Dysfunction of certain networks might have several sub-cellular, cellular or tissue level reasons 
(such as synaptic transmission, axonal transfer, myelination), that may cause disrupted 
connectivity (Tkachev et al., 2003; Uranova et al., 2004), and therefore synchronization deficits 
in various neuropsychiatric diseases (Güntekin et al., 2008; Özerdem et al., 2010, 2011; 
Schmiedt-Fehr and Basar-Eroglu, 2011; Başar-Eroğlu et al., 2008; Başar and Güntekin, 2008; 
Uhlhaas et al., 2011). However, although these neuropsychiatric diseases have common 
characteristics in their physiopathology, the spatial distribution and temporal dynamics of 
connectivity deficits may determine the clinical course of the disorder.  
The major limitation of the present study is the relatively small sample size. The number of 
female subjects in the groups was higher than male participants (n=43, female/male: 32/11). 
The study included three patients with bipolar disorder II, and it is still not clear whether there 
is a difference between bipolar I and II disorders in terms of oscillatory brain responses. Most 
of the patients were mild cases and therefore they were off-medications. On the other hand, 
medication-free patients can be seen as the major strength of the study, because of providing 
the chance to understand de novo neurophysiology of bipolar disorder. In addition, all patients 
were euthymic and none of the patients had sub-threshold depressive or manic symptoms.  
Conclusion 
It can be suggested that delta oscillations are critically important in cognitive functions, and 
that diminished oscillatory delta responses may be a common characteristic of cognitive 
dysfunction in neuropsychiatric diseases (Başar and Güntekin, 2013; Başar, 2011). 
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Table 3. Brain oscillations studies by our group in medication-free patients with bipolar 
disorder.  
Study 
(Chronological 
Order) 
Clinical 
State Major Findings 
Özerdem et al., 2008 Mania Increased visual event-related beta (18–30 Hz) and reduced event-related 
alpha (8–13 Hz) responses 
Özerdem et al., 2010 Mania Reduced gamma (28–48 Hz) coherence   
Özerdem et al., 2011 Euthymia Reduced gamma (28–48 Hz) coherence  
Başar et al., 2012 Euthymia Decreased spontaneous alpha (8–13 Hz) activity and visual-evoked alpha 
(8–13 Hz) responses   
Atagün et al., 2013 Euthymia Decreased evoked and event-related slow (4–6 Hz) theta and decreased 
event-related fast (6–8 Hz) theta responses. Fast theta (6–8 Hz) was 
more responsive to cognitive components of the task. 
This study Euthymia Decreased auditory-evoked and event-related delta (0.5–3.5 Hz) 
responses  
 
 
Abnormalities of brain oscillations may have specific profiles in neuropsychiatric disorders and 
those profiles may potentially discriminate disorders. These profiles can only be detected by 
studies that have eliminated confounders like medications. As summarized in Table 3, to date 
we have detected increased event-related beta and decreased event-related alpha responses in 
mania (Özerdem et al., 2008), reduced gamma coherence in mania (Özerdem et al., 2010) and 
euthymia (Özerdem et al., 2011), decreased spontaneous EEG alpha activity and evoked visual 
alpha response in euthymia (Başar et al. 2012), decreased evoked and event-related slow theta 
(4–6 Hz) and event-related fast theta (6–8 Hz) responses in euthymia (Atagün et al., 2013), and 
the present study reveals that auditory-evoked and event-related delta responses are decreased 
in euthymic medication-free patients with bipolar disorder. Further studies should focus on 
brain oscillations in different clinical states for bipolar disorder. Comparing bipolar disorder to 
schizophrenia and schizoaffective disorder may help to identify differences and allow us to 
investigate whether there are any biological correlates of clinical differences between these 
psychotic spectrum disorders.  
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Abstract 
Background: Previous resting-state electroencephalography studies have consistently shown 
that lithium enhances delta and theta oscillations in default mode networks. Cognitive task 
based networks differ from resting-state networks and this is the first study to investigate effects 
of lithium on evoked and event-related beta oscillatory responses of patients with bipolar 
disorder. 
 
Methods: The study included 16 euthymic patients with bipolar disorder on lithium 
monotherapy, 22 euthymic medication-free patients with bipolar disorder and 21 healthy 
participants. The maximum peak-to-peak amplitudes were measured for each subject’s 
averaged beta responses (14–28 Hz) in the 0-300 ms time window. Auditory simple and oddball 
paradigm were presented to obtain evoked and event-related beta oscillatory responses. 
 
Results: There were significant differences in beta oscillatory responses between groups 
(p=0.010). Repeated measures of ANOVA revealed location (p=0.007), lateralityXgroup 
(p=0.043) and stimulusXlocation (p=0.013) type effects. Serum lithium levels were correlated 
with beta responses.  
 
Limitations: The lithium group had higher number of previous episodes, suggesting that 
patients of the lithium were more severe cases than patients of the medication-free group.  
 
Discussion: Lithium stimulates neuroplastic cascades and beta oscillations become 
prominent during neuroplastic changes. Excessively enhanced beta oscillatory responses in the 
lithium-treated patients may be indicative of excessive activation of the neuron groups of the 
certain cognitive networks and dysfunctional GABAergic modulation during cognitive activity.   
 
Key Words: Bipolar Disorder, Brain Oscillations, Event-Related Oscillations, Lithium, 
Euthymia 
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1. Introduction 
Lithium has several neurotrophic and neuroplastic effects that may trigger long-term changes 
on synaptic plasticity and networking functions (Kim and Thayer, 2009). Increasing volume 
and density of gray matter (Bearden et al., 2007; Moore et al., 2000a), improving white matter 
connectivity (Benedetti et al., 2013) and increasing brain levels of N-acetyl-aspartate, a marker 
of neuronal function and viability (Moore et al., 2000b) are some instances of lithium’s 
beneficial effects on neuronal integrity.  
Electroencephalography (EEG) is an electrophysiological method with a high temporal 
resolution that may provide valuable advantages for research areas that focus on cognitive 
networks (Başar, 2010). Either cognitive or sensory, all brain activities are operated in a specific 
oscillatory activity, thus all brain activities are governed by specific brain oscillations (Başar et 
al., 1998; Başar, 1999; Başar et al., 2001). Although dysfunction in sensory or cognitive 
processes cannot be explained by a frequency, connectivity characteristics may cause 
differences in a frequency response (Başar, 2006). Within the last two decades, brain oscillatory 
analyses have been applied to clinical pathologies, including bipolar disorder (Başar et al., 
2013; Başar and Güntekin, 2008; Basar et al., 2013).   
Despite the wealth of electroencephalography and magnetoencephalography studies in bipolar 
disorder, very limited studies reported beta frequency abnormalities (O’Donnell et al., 2004; 
Rass et al., 2010; Özerdem et al., 2008; Hamm et al., 2012; Ethridge et al., 2012; Lee et al., 
2010). Patients with bipolar disorder in either manic or mixed mood state showed deficits in 
responses of beta and gamma frequency ranges upon auditory steady-state stimulation 
(O’Donnell et al., 2004; Rass et al., 2010). Manic patients showed increased beta and alpha 
oscillations upon a visual oddball paradigm, and treatment of the episode with valproate 
reduced the responses (Özerdem et al., 2008). Late beta response power to auditory target and 
standard stimuli was increased in bipolar disorder group and this finding differentiated 
psychotic bipolar patients from schizophrenia and healthy control groups (Hamm et al., 2012; 
Ethridge et al., 2012). Ethridge and colleagues (2012) also reported that depression scores were 
correlated with the beta frequency increase in bipolar disorder group, which suggest a 
relationship between emotional dysregulation and increased beta responses in the bipolar 
disorder group. Similarly, in comparison to major depression or healthy control groups, bipolar 
disorder group had increased alpha and beta oscillatory responses upon an emotional task (Lee 
et al., 2010). Most of these studies had mixed samples and medicated patients. However, both 
medications and clinical state may substantially alter neurophysiology, particularly beta 
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oscillations are more vulnerable to neurochemical changes in particular Gamma-Amino-
Butyric-Acid (GABA) and n-Methyl-d-Aspartate (NMDA) receptor activities (Arai and 
Natsume, 2006; Traub et al., 2004).  
Previous studies by our group with medication-free patients with bipolar disorder also showed 
that in euthymia evoked and event related theta (Atagün et al., 2013b) and delta oscillations 
(Atagün et al., 2014) decreased upon auditory oddball paradigm. Resting state alpha activity 
and evoked alpha responses decreased (Başar et al., 2012). Gamma coherence is reduced in 
mania (Özerdem et al., 2010) and euthymia (Özerdem et al., 2011). It can be concluded that 
medication-free patients with bipolar disorder have a reduction in neural activation energy and 
reduced coherence values, which may mean a loss of functional connectivity and activation 
deficits. 
The most consistent finding of previous lithium resting state EEG studies is increased power of 
resting state delta and theta activity in patients with bipolar disorder (Schulz et al., 2000; 
Zakowska-Dabrowska and Rybakowski, 1973; Hyun et al., 2011) or in healthy volunteers 
(Karniol et al., 1978; Thau et al., 1988). Ulrich and colleagues (Ulrich et al., 1987; Ulrich et al., 
1990) detected enhanced alpha power in healthy male volunteers. Most of the abovementioned 
lithium-EEG studies were with mixed samples; patients were also taking various additional 
psychotropic medications.  
However, it has recently been shown that task based networks differ from default-mode 
networks (Moussa et al.,2012; Kirschner et al., 2012). Accordingly, cognitive tasks may trigger 
activities that require the brain to reorganize and establish distinct networks with distinct 
characteristics. For instance, fast frequencies are related to cognitive activity in local networks 
(Başar et al., 2013), whereas slow frequencies -either in rest and activity- are related with 
activities of longer distances and larger amounts of neurons (Bruns and Eckhorn, 2004). There 
has not yet been a study that evaluates whether lithium has any different effect on cognition 
based networks. The effects of external manipulations (like medications) may become 
observable in responses to stimuli of either a bottom-up or a top-down task (Kenemans and 
Kähkönen, 2011).  
Although it needs to be translated into human neuroscience, neuroplasticity drives networks to 
oscillate with beta frequency, instead of gamma frequency in animal studies (Whittington et al., 
2000). As mood stabilizers induce neuroplastic cascades (Kim and Thayer, 2009; Soiero-de-
Souza et al., 2012), and since beta oscillations are related to neuroplastic changes (Whittington 
et al., 2000), it could be expected that lithium may alter beta responses in cognitive networks. 
In addition to neuroplasticity cascades, lithium also reduces excitatory neurotransmission 
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(dopamine or glutamate) and increases inhibitory neurotransmission (GABA) (Malhi et al., 
2013). Given the fact that EEG signal consists of excitatory-end-synaptic potentials, then it 
would be quite possible that psychotropic medications may alter the EEG signal. Cognitive 
processes demand broader range of oscillations that may include fast frequencies as well as 
slow frequencies, thus beta oscillatory responses could be investigated under cognitive tasks.  
2. Methods 
2.1. Subjects 
All patients were euthymic for at least six months. 22 patients were medication-free (19 Bipolar 
I, three Bipolar II disorder) and 16 patients were on lithium monotherapy. 21 healthy 
participants were enrolled to the control group (Table 1). Diagnoses were confirmed with the 
Structured Clinical Interview According to DSM-IV (SCID) (First et al., 1996). The Young 
Mania Rating Scale (YMRS) (Young et al., 1978) and Hamilton Depression Rating Scale 
(HDRS) (Hamilton, 1960) were the clinical evaluation tools. All subjects were right handed. 
Clinical data and previous history of the disorder was assessed by the psychiatrist, taking into 
account available charts and case notes. Patients enrolled into the lithium group were required 
to be on lithium monotherapy for at least eight weeks (Average= 114.87±208.06 weeks, Range: 
8 – 832 weeks), and on effective serum lithium levels (Average= 0.79±0.12 mEq/dl, Range: 
0.59-1.08 mEq/dl). Exclusion criteria were: Comorbid axis I diagnosis, mental retardation, 
pregnancy, lactation, consumption of alcohol or substances two weeks prior to the recordings, 
axis-I psychiatric co-morbidity and neurological conditions such as neurodegenerative diseases, 
history of ECT in the last six months, epilepsy and brain surgery. Subjects were asked to avoid 
from sleep deprivation, not to smoke cigarettes or consume coffee or energy drinks two hours 
prior to the experiment. After providing a complete description of the study to the participants, 
written informed consent was obtained from each participant. The local Ethical Committee 
approved the study. 
2.2. Experiments 
Experiments were performed in a dimly-lit isolated and shielded room. Subjects were seated in 
front of a desk and two loud speakers were located at a 50 cm distance in front of the subject. 
Electrodes were located on an elastic cap (easy-cap) containing 30 Ag-AgCl electrodes 
according to the international 10-20 system. Two linked earlobe reference electrodes (A1- A2) 
and electrooculography (EOG), placed on medial upper and lateral rim of the right eye, were 
used. All electrode impedances were lower than 10 kΩ. The EEG was amplified by means of a 
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BrainAmp 32-channel DC device with band limits of 0.01–250 Hz. The EEG was digitized on-
line at a sampling rate of 500 Hz.  
Initially, simple stimuli were given in the first session, and in the second session the oddball 
paradigm, which included two types of auditory stimuli including target and non-target stimuli 
were presented to the subjects. The auditory simple stimuli were tones of 80 dB and 1,500 Hz. 
The inter-stimulus intervals varied randomly between 3 and 7 s. The total number of stimuli 
was 60. In a random sequence, task-relevant target (80 dB, 1600 Hz tone) and task- irrelevant 
non–target (80 dB, 1500 Hz) stimuli were the components of the classical auditory oddball 
paradigm (40 target, 80 non-target). The interval between tones varied randomly between three 
to seven seconds. Subjects were instructed to carefully listen, discriminate the two tones, and 
mentally count the number of target stimuli. Total counts were noted as behavioral data.  
2.3. Data Analysis  
EEG was segmented between -500 and +1000 ms time period for each subject and for each 
stimulation. Then the artifacts due to eye blinks, detected by the EOG electrodes were 
eliminated by semi-automatic procedure in the Brain vision Analzyer program. The program 
showed us the excessive epochs which were above 200 Hz frequency and 50 μV amplitude. We 
have manually removed the artifacts. Artifact free epochs then segmented again in the 0-800ms 
time periods and averaged and FFT with a 10 % Hanning window was applied to the averaged 
ERPs (Figure 1). Looking at the FFT we have determined the filter limits of the beta frequency 
window as 14-28 Hz. These information was use to filter the averaged ERP responses. The 
band pass filter was used with a 14-28 Hz frequency window and 48 dB/Oct slope. The 
maxiumum peak to peak amplitude of filtered beta responses in 0-300 ms time period was then 
investigated for each subject, for each electrode and for each stimulation manually by the 
investigator.  
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Figure 1. Power spectrum analyses with Fast Fourier Transform at beta frequency oscillations 
(F4 location).  
 
 
The amplitude of the largest peak on the filtered waveform within 0-300 ms between negative 
and positive maximum-peak points of the beta frequency oscillations was accepted as the 
maximum peak-to-peak amplitudes of the beta oscillations (Figure 2). Beta oscillations upon 
simple, target and non-target stimuli were measured in 0-300 ms time interval after stimuli 
(Figure 2). Electrodes locations were F3, F4, C3, C4, T7, T8, Tp7, Tp8, P3, P4, O1, O2. Additionally, 
timing of the earlier one of the largest peaks was noted in order to compare latency of the beta 
oscillations between groups.  
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Figure 2. Grand-averaged simple (1st line) and target (2nd line) beta responses upon auditory 
oddball stimulation (F4 location). Healthy control group is shown with black lines, medication-
free patients with bipolar disorder are shown with red lines and patients with bipolar disorder 
on lithium monotherapy are shown with green lines. Responses to target stimuli in the lithium 
group are significantly higher than both healthy controls and medication-free patients. 
 
2.4. Statistical Analysis 
Sociodemographic variables were compared with t-test or Mann Whitney U test for continuous 
variables according to the distribution characteristics. Categorical variables were analyzed with 
chi-square test. Repeated measures ANOVA were used to compare groups. Both ANOVAs 
included three groups (medication-free patients with bipolar disorder, healthy controls and 
patients with bipolar disorder on lithium monotherapy) as between subjects factor. Three 
stimuli (simple, target and non-target stimuli), two hemispheres (right and left) and six locations 
(frontal, central, temporal, temporoparietal, parietal and occipital) were used as within-subjects 
factor in the repeated measures ANOVA. All variances were homogeneous in the Levene’s test, 
so Tukey and t tests were chosen for the post-hoc comparisons. Greenhouse-Geisser corrected 
p values were reported. Behavioral data were analyzed with one-way ANOVA. Correlations 
between the clinical and behavioral data and the EEG data were performed with Spearman’s 
correlation test.  
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3. Results 
3.1. Clinical Results 
As presented in Table 1, groups were similar in terms of age and gender. Education differed 
between groups (p<0.001). The healthy control group had significantly longer duration of 
education compared to the lithium and the drug-free patient groups. Duration of the disorder 
and number of episodes were higher in the lithium group, in comparison to the medication-free 
bipolar patient group. The HDRS scores differed significantly between patient groups; the 
medication-free group had higher scores than the lithium group (p=0.013). The lithium group 
had significantly higher number of total (p=0.039), manic (p=0.046) and depressive (p=0.009) 
episodes than the medication-free group. The patients enrolled in the lithium group had optimal 
levels of serum lithium concentrations (mean= 0.803 mEq/lt).  
 
Table 1. Clinical and socio-demographic characteristics of the groups 
 
Lithium group  
(n=16) 
Euthymic 
Drug-free 
(n=22) 
Healthy 
Controls 
(n=21) 
F/z/2 
p 
Age 34.75 ± 9.90 30.82 ± 6.46 29.10 ± 7.87 2.33 0.107 
Educationa 9.88 ± 4.44 11.77 ± 3.61 14.67 ± 2.22 9.13 <0.001** 
Gender (f/m) 6/10 7/15 5/16 0.83 0.660 
HDRS 0.88 ± 1.09 2.45 ± 2.22  2.62 0.013 
YMRS 0.56 ± 0.96 0.73 ± 1.28  0.43 0.668 
Age at Disease Onseta 21.75 ± 7.45 21.86 ± 6.30  0.51 0.960 
Duration of the Disordera 13.36 ± 6.02 10.05 ± 4.96  -1.81 0.073 
Duration of Euthymiab 37.75 ± 45.69 48.64 ± 37.71  0.80 0.427 
Number of 
previous 
episodes 
Total  7.31 ± 6.49 3.91 ± 3.13  -2.15 0.039 
Manic 3.25 ± 2.70 1.82 ± 1.56 
 
-2.07 0.046 
Depressive 2.94 ± 2.89 1.09 ± 1.11 
 
-2.75 0.009 
Hypomanic 0.81 ± 1.17 0.77 ± 1.19 
 
-0.10 0.919 
Mixed 0.38 ± 1.26 0.23 ± 0.53 
 
-0.49 0.623 
Serum Lithium Levels 
(mEq/lt) 
0.803 ± 0.12     
One-way ANOVA, t test, Mann-Whitney U test and χ2 tests were used. f/m: female/male *Mann-
Whitney U test **Posthoc Bonferroni test, Healthy controlsdrug-free patients, p=0.022, 
Healthy controlsLithium group, p0.001. aYears, bMonths 
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3.2. Beta Frequency Results 
Target stimulus beta responses of the lithium group were 23.2% – 36.2% higher than the 
medication-free bipolar patient group and 19.5% – 40.6% higher than the healthy control group 
(Figure 3). The repeated measures ANOVA revealed significant group difference [p=0.001, 
F(2,56)=8.14; partial eta squared=0.225]. Patients on lithium therapy had higher responses than 
both medication-free patients (p=0.003) and healthy controls (p=0.002). There was a stimulus 
type effect [p<0.001, F(2.112)=17.39]; post-hoc comparisons showed that target responses 
were significantly higher than both simple and non-target stimulus (p<0.001 for both). Repeated 
measures ANOVA also revealed a location type effect [p<0.001, F(5,280)=13.43]. Post-hoc 
comparison showed that frontal location had higher amplitudes than central, temporoparietal, 
parietal and occipital locations [p<0.001 for all]. Central locations had higher amplitudes than 
temporoparietal, parietal, and occipital locations [p<0.001 for all]. Temporal locations had 
higher amplitudes than temporoparietal [p=0.001] locations. Laterality X group type effect was 
also significant [p=0.010, F(1,56)=4.99]. Post-hoc comparisons for group X laterality type 
effect showed that the amplitudes of right hemispheric responses of the lithium group (4.51 μV) 
were significantly higher than the right hemispheric responses of the healthy control group 
([2.85 μV] p=0.001) and the medication-free patient group ([2.90 μV] p=0.001). In addition, 
there was no statistical difference between groups in terms of latency [p=0.749, F(1,56)=0.291]. 
When duration of education is added to the analyses as a covariate, no difference between 
groups was observed in beta oscillations [p=0.084, F(1,55)=3.10]. 
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Figure 3. Event-related potentials (P300 responses to target stimulation). F4 location 
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Figure 4. Beta frequency responses of all groups upon auditory simple and oddball paradigm. 
Maximum peak-to-peak amplitudes of subjects were measured and then averaged. The graphic 
represents Stimulus X Group X Location type effect. There was no statistically significant 
difference between groups in this type of interaction.   
 
 
3.3. Correlation analyses 
Correlation analyses showed correlations between clinical parameters and beta oscillatory 
responses (Table 2). 
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Table 2. Correlations between clinical variables and amplitudes in the lithium group 
 Location r value p value 
Number of total episodes F3 target 0.663 0.005 
Number of depressive episodes 
F3 ep 0.581 0.018 
F4 ep 0.512 0.043 
F3 target 0.557 0.025 
F3 non-target 0.587 0.017 
O1 nontarget 0.602 0.014 
O2 nontarget 0.588 0.017 
Serum lithium levels  
F3 ep -0.529 0.043 
T7 ep -0.532 0.041 
T8 ep -0.586 0.022 
Tp8 ep -0.821 <0.001 
O1 ep -0.686 0.005 
O2 ep -0.614 0.015 
T8 target -0.590 0.021 
Tp8 target -0.661 0.007 
T7 non-target -0.718 0.003 
T8 non-target -0.614 0.015 
Tp8 non-target -0.564 0.028 
O1 non-target -0.545 0.036 
Spearman’s correlation analyses. Variables in the correlation analyses: Amplitudes of beta 
oscillatory responses upon auditory simple and oddball stimuli, age, education, age at disorder 
onset, number of total/manic/depressive episodes, duration of the disorder, serum lithium 
levels, scores of Hamilton Depression Rating Scale and Young Mania Rating Scale. 
Correlations between clinical variables and amplitudes of beta oscillations in the drug-free 
patients with bipolar disorder were duration of euthymia was correlated to non-target stimulus 
responses at T7 (r=0.495, p=0.019) and Tp7 (r=0.560, p=0.007) locations and HAM-D scores 
were correlated to simple stimulus responses at F4 (r=-0.539, p=0.010) and O1 (r=-0.453, 
p=0.034) locations.  
 
3.4. Behavioral Data Analyses 
Behavioral data analyses showed that there were no difference between the lithium 
(37.94±7.49), medication-free patients (39.91±10.33) and healthy control (40.90±6.02) groups 
in terms of the total number of mental counts of the target stimuli (p=0.564, F=0.580).  
 
 
 71 
L
IT
H
IU
M
 E
X
C
E
S
S
IV
E
L
Y
 E
N
H
A
N
C
E
S
 E
V
E
N
T
 R
E
L
A
T
E
D
 B
E
T
A
 O
S
C
IL
L
A
T
IO
N
S
 IN
 P
A
T
IE
N
T
S
 W
IT
H
 B
IP
O
L
A
R
 D
IS
O
R
D
E
R
 
4 
4. Discussion 
4.1. Enhanced beta oscillations 
Event related beta responses of the lithium group were significantly higher than medication-
free patients and healthy controls. Previous resting EEG studies consistently showed amplified 
delta and theta activity; however, findings of this study suggest that cognition related networks 
are influenced by lithium as well as default mode networks. Findings of this study may reflect 
rearrangements in brain networks stimulated by lithium; however, it is not clear whether these 
EEG changes are correlates of neuroplastic processes. Many other factors may also be involved 
in the changes stimulated by an external manipulation as discussed below.   
Differences in beta oscillations were significant only in target responses in this study and this 
finding may suggest that lithium influences cognitive activity in cognition based networks. 
Attention load of responses to target stimulations are higher than non-target stimulations, 
therefore the amount of the arisen energy during the processing of target stimulation should be 
higher than the amount of the energy of processing simple and non-target stimuli. Additionally, 
in target detection tasks, stimulus saliency has been associated with increased beta activity 
(Brenner et al., 2013). A recent study in patients with mild cognitive impairment reported that 
target responses were significantly greater than non-target responses in beta frequency band 
(Guntekin et al., 2013), supporting the idea that beta frequency responses are related to 
cognitive load and stimulus saliency. Beta oscillations are also related to attention (Marrufo et 
al., 2001), emotion processing (Güntekin and Başar, 2010) movements (Engel and Fries, 2010) 
and memory formation (Özgören et al., 2005; Başar et al., 2007; Weiss and Mueller, 2012). 
Elevated baseline EEG activity might be a reason of increased activation energy in 
pharmacological neuroimaging studies. For example, increased signal/noise ratio in 
pharmacological neuroimaging studies could be related with hippocampal or cortical 
dysfunction as well as GABA and glutamatergic dysfunction in schizophrenia (Gandal et al., 
2012). GABAergic system is also disturbed in bipolar disorder (Petty, 1995; Benes and Beretta, 
2001; Brady et al., 2013) and therefore modulation of bioelectrical activity may be disturbed in 
bipolar disorder as well. This approach also suggests that increased amplitudes by lithium might 
be related to the noise due to the elevated background brain activity as well as other effects of 
lithium on networks. Lithium inhibits presynaptic 2 receptors non-selectively (Lenox and 
Hahn, 2000; Manji et al., 1991) so inhibition of task irrelevant brain cites may become harder 
and thus signal/noise ratio might be altered. Modulation of the electrical activity or -fine tuning- 
is a function of GABAergic interneurons (Basar and Guntekin, 2008; Buzsaki, 2006) and it is 
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possible that dysfunction of GABAergic neurons may negatively influence the modulation of 
the activity and excessively increase the responses. 
Although lithium does not deteriorate cognitive functions (Wingo et al., 2009; Balanzá-
Martínez et al., 2010), except some mild disturbances in motor functions (Wingo et al., 2009; 
Atagün et al., 2013a); the question to be answered here is: are these excessively increased 
amplitudes related to an effect, or a cognitive side effect of lithium? Clinical data of this cross-
sectional study is not sufficient to extract consequences about clinical response to lithium. 
Although it has been largely accepted that lithium has neuroprotective and neurotrophic effects 
(Kim and Thayer, 2009), from the perspective of the neurotoxicity hypothesis (Fountoulakis et 
al., 2008) excessively enhanced beta oscillations could be evaluated as an adverse effect.  
4.2. Correlation Data 
Serum lithium levels were negatively correlated with beta frequency responses. This negative 
correlation suggests a dose-dependent amplification of activation energy in the networks. Low 
doses of lithium may not stimulate GABAergic neurotransmission as much as high 
concentrations (Otero-Lasada and Rubio, 1986). GABAergic dysfunction in bipolar disorder 
(Petty, 1995) is suggested to be the reason of the noise increase in neuroimaging studies in 
bipolar disorder (Gandal et al., 2012) and lithium may reverse the GABAergic dysfunction in 
a dose dependent manner. If so, then it will be possible to speculate that higher doses of lithium 
might be more beneficial than lower doses. Relations of serum lithium concentrations and brain 
oscillations deserve to be pursued in future studies to investigate underlying mechanisms. These 
mechanisms potentially contribute to optimize treatment strategies of lithium.  
4.3. Limitations 
The lithium and the medication-free bipolar patient groups were not matched in terms of 
education and clinical data. Target responses are related to cognitive processes and thus 
education difference may become an important limitation, because main differences in this 
study were at event-related beta oscillations. Patients of the lithium group had higher number 
of previous episodes, which may suggest more severe disorder than patients of the medication-
free group. Besides, evaluation of clinical lithium response with follow up may be useful. Many 
confounders like episodic nature of the disorder, medication effects, subthreshold symptoms, 
and difficulty in obtaining homogeneous samples, may preclude obtaining consistent results 
when studying bipolar disorder. Therefore, studying with euthymic, medication-free patients 
with bipolar disorder is the major strength of this study.  
 73 
L
IT
H
IU
M
 E
X
C
E
S
S
IV
E
L
Y
 E
N
H
A
N
C
E
S
 E
V
E
N
T
 R
E
L
A
T
E
D
 B
E
T
A
 O
S
C
IL
L
A
T
IO
N
S
 IN
 P
A
T
IE
N
T
S
 W
IT
H
 B
IP
O
L
A
R
 D
IS
O
R
D
E
R
 
4 
4.4. Conclusion Remarks 
This is the first study to evaluate effects of lithium on oscillatory brain responses to auditory 
simple and oddball paradigm, and the study showed that lithium increases the amplitudes of the 
auditory event-related beta-responses in the target stimulus condition. These findings are in line 
with the previous studies that reported increased white matter connectivity (Benedetti et al, 
2013), increased gray matter volumes and density (Bearden et al., 2007, Moore et al. 2000a) or 
improvements in brain chemistry (Moore et al., 2000b) by lithium. The correlation data may 
suggest that higher doses of lithium might be more useful than low doses. Just as the earlier 
attempt (Hegerl et al., 1987), future studies should focus on the clinical response to lithium and 
cognitive functionality in lithium EEG studies. This method may potentially facilitate 
predicting or evaluating dose and effectiveness of lithium in bipolar disorder. For the further 
steps in search of improved treatments, treatments should be considered in a broader 
perspective including neurophysiological aspects (Kam et al., 2011), to achieve greater success 
in the treatment of psychiatric disorders. 
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Abstract 
The ability of the brain to reduce the amount of trivial or redundant sensory inputs is called 
gating function. Dysfunction of sensory gating may lead to cognitive fragmentation and poor 
real-world functioning. The auditory dual-click paradigm is a pertinent neurophysiological 
measure of sensory gating function. This meta-analysis aimed to examine the subcomponents 
of abnormal P50 waveforms in bipolar disorder and schizophrenia to assess P50 sensory gating 
deficits and examine effects of diagnoses, illness states (first-episode psychosis vs 
schizophrenia, remission vs episodes in bipolar disorder), and treatment status (medication-free 
vs medicated). Literature search of PubMed between Jan 1st 1980 and March 31st 2019 
identified 2091 records for schizophrenia, 362 for bipolar disorder. 115 studies in schizophrenia 
(4932 patients), 16 in bipolar disorder (975 patients) and 10 in first-degree relatives (848 
subjects) met the inclusion criteria. P50 sensory gating ratio (S2/S1) and S1-S2 difference were 
significantly altered in schizophrenia, bipolar disorder and their first-degree relatives. First-
episode psychosis did not differ from schizophrenia, however episodes altered P50 sensory 
gating in bipolar disorder. Medications improve P50 sensory gating alterations in schizophrenia 
significantly and at trend level in bipolar disorder. Future studies should examine longitudinal 
course of P50 sensory gating in schizophrenia and bipolar disorder.   
 
Key Words: EEG, sensory gating, bipolar disorder, schizophrenia 
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1. Introduction 
The ability to reduce the amount of trivial or redundant sensory inputs is called sensory gating 
function (Baker et al., 1987; Boutros et al., 1991; Freedman et al., 1997). Diminished sensory 
gating may lead to cognitive fragmentation and poor real-world functioning (Ancin et al., 2011; 
Johannesen et al., 2013; Martin et al., 2007b). The auditory dual-click (also called 
conditioning–testing task) paradigm is a pertinent neurophysiological measure of the sensory 
gating function, which represents a good marker for translational and clinical studies (Smucny 
et al., 2013). In the dual-click paradigm, paired successive clicks (separated by an interval of 
500 milliseconds) are presented and two positive-polarity brain responses occurring 
approximately between 45-75 milliseconds after the stimuli (P50 potential) are measured. An 
example of typical normal responses to dual-click paradigm is shown in Figure 1. The relative 
decrease of the P50 waveform to the second click (S2) compared with the first (S1) is typically 
used as a measure of P50 sensory gating and quantified as the S2/S1 ratio or S1-S2 difference.  
Figure 1. An example of typical normal responses to dual-click paradigm. The left column 
shows response to the conditioning (S1) click and the right column shows response to the testing 
(S2) click. The P50 ERP wave is marked by two vertical lines. In a dual-click paradigm 
experiment, a set of stimuli consisting of click-pairs (two successive clicks, S1 and S2 stimulus 
with an interval of 500 ms between the click-pairs) is presented to the subject and the responses 
of the second stimulus (S2) compared to the first stimulus (S1) of the pair is proposed to be the 
neurophysiological manifestation of the gating function. The Figure is adopted from Hall et al. 
2008. 
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It is believed that hippocampus and prefrontal cortices participate in the inhibitory processes 
underlying mechanisms of P50 sensory gating (Bak et al., 2014). Neurobiological mechanisms 
of sensory gating deficit and its clinical associations have been widely investigated in 
schizophrenia and bipolar disorder (Hall et al., 2008; Jin et al., 1998; Johannesen et al., 2013; 
Martin et al., 2007a); however, findings have been inconsistent that might be partly due to 
confounding effects of medications, clinical symptoms (positive or negative symptoms), 
neuropsychological test performance and illness state (Potter et al., 2006; Swann et al., 2013; 
Vuillier et al., 2015). Despite clinical variations, schizophrenia and bipolar disorder may share 
similar pathological mechanisms in their etiology (Guloksuz and van Os, 2018; Kato, 2019; 
Lieberman and First, 2018) leading to similarities in research findings (Tamminga et al., 2013). 
Consistently, electroencephalography (EEG) studies with schizophrenia, bipolar disorder and 
their first-degree relatives revealed overlap in auditory-oddball paradigm (Mokhtari et al., 
2016; Narayanan et al., 2015) or resting-state (Narayanan et al., 2014) EEG alterations. 
Likewise, it has been shown that sensory gating examinations with dual-click paradigm are 
altered in both schizophrenia and bipolar disorder (Bramon et al., 2004; Cheng et al., 2016; de 
Wilde et al., 2007b; Patterson et al., 2008). However, despite similarities between schizophrenia 
and bipolar disorder suggesting the disorders to be on a continuum and likely overlapping in 
etiology, variation in clinical symptoms and medications are suggestive of partially distinct 
pathological mechanisms sensory gating. Various underlying mechanisms might be involved 
with different components of P50 sensory gating ratio, for example amplitudes of S1 and S2 
waveforms might be differentially influenced by neural synchrony and inhibitory neural circuits 
(Adler et al., 1994; Aidelbaum et al., 2018; Ancin et al., 2011; Freedman, 2014; Freedman et 
al., 1987; Oranje and Glenthoj, 2014). Medications and clinical progress may influence the P50 
in patients with schizophrenia and bipolar disorder. Meta-analyses have confirmed a robust P50 
sensory gating alteration in schizophrenia (Bramon et al., 2004; Chang et al., 2011; Cheng et 
al., 2016; de Wilde et al., 2007b; Patterson et al., 2009). However, 38 new studies (with 2230 
schizophrenia patients, 1809 healthy controls) are published since the last meta-analysis in 
schizophrenia (Chang et al., 2011). There is only one meta-analysis of P50 sensory gating in 
bipolar disorder, which also reports robust P50 S2/S1 ratio alterations (Cheng et al., 2016).  
Each meta-analysis report published thus far focused on only single disorder (schizophrenia or 
bipolar disorder). To our knowledge, no meta-analysis includes studies of both disorders to 
compare and evaluate the sensory gating alterations in patients with either disorder. In addition, 
only one meta-analysis report has included the unaffected relatives of patients to examine 
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whether P50 sensory gating deficit is an endophenotype for schizophrenia and bipolar disorder 
(Bramon et al., 2004). This study aimed to extend previous meta-analyses to 1) clarify the 
magnitude of sensory gating alterations in bipolar disorder and schizophrenia compared to 
healthy controls; 2) examine the differences in P50 sensory gating alterations between illness 
states; 3) examine the differences in P50 sensory gating alterations between patients who were 
medicated and those who were drug-free; 4) evaluate the differences in P50 sensory gating 
between bipolar disorder patients in remission and those in episodes. Finally, to evaluate 
whether P50 sensory gating deficit is an endophenotype for schizophrenia and bipolar disorder, 
we presented a meta-analysis of first-degree relatives in this report.   
2. Methods  
The meta-analysis was performed according to recommendations of the Meta-analysis of 
Observational Studies in Epidemiology (MOOSE) group (Stroup et al., 2000). A review 
protocol, structured according to the PRISMA statement (Moher et al., 2009) was followed for 
data acquisition, analysis and reporting procedures. 
2.1. Search and study selection 
We performed a systematic literature search in Medline database. Human species, English 
language and publication dates (between Jan 1st 1980 and March 31st, 2019) were the activated 
filters. The key words [(schizophrenia OR psychosis) AND (P50 OR sensory gating)] retrieved 
2091 records in schizophrenia and keywords [(bipolar disorder OR mania) AND (P50 OR 
sensory gating)] retrieved 362 records in bipolar disorder (Please see the flow-chart in Figure 
2 for details). Studies were assessed according to the following criteria: I. Study groups should 
include a healthy control group and a schizophrenia and/or a bipolar disorder group, II. 
Electroencephalography should be recorded in the study, III. Paradigm of the study should be 
the dual-click paradigm, IV. Data analysis should be performed with a classical P50 analysis 
within the 1-20 Hz frequency range, V. Means and standard deviations should be reported in 
the article. Of the schizophrenia studies, 1921 were excluded after reading the titles and 
abstracts and 29 were eliminated after reading the full-text because of methodological reasons 
[i.e. difference in paradigm, data analysis, patient sample and device (magnetoencephalography 
studies were excluded)]. In addition, 26 articles were excluded in the next step because of 
inappropriate data (i.e. studies that do not report means and standard deviations were excluded). 
Of the bipolar disorder studies, 332 were excluded after reading the titles and abstracts. 8 studies 
were excluded because of methodological differences and 6 studies were excluded because of 
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inappropriate data. In addition, studies with overlapping samples were excluded from further 
analysis, furthermore only first estimation was included from the studies that had repeated 
estimations of P50 sensory gating in a group. 115 articles (Adler et al., 2005; Adler et al., 1990a; 
Adler et al., 2004; Adler et al., 1982; Adler et al., 1985; Adler et al., 1990b; Arango et al., 2003; 
Arnfred et al., 2003; Arnfred et al., 2004; Bak et al., 2014; Baker et al., 1987; Becker et al., 
2004; Becker et al., 2011; Boutros et al., 1999; Boutros et al., 2009; Boutros et al., 2004; 
Boutros et al., 1991; Braff et al., 2007; Brenner et al., 2009; Brockhaus-Dumke et al., 2008a; 
Brockhaus-Dumke et al., 2008b; Brunstein et al., 2005; Buchanan et al., 2003; Cabranes et al., 
2013; Chen et al., 2011; Clementz and Blumenfeld, 2001; Clementz et al., 1997a; Clementz et 
al., 1997b, 1998a, b; Cullum et al., 1993; Dalecki et al., 2016; de Wilde et al., 2007a; Demily 
et al., 2016; Devrim-Ucok et al., 2008; Domjan et al., 2012; During et al., 2014; El-Kaim et al., 
2015; Franks et al., 1983; Freedman et al., 1987; Fresan et al., 2007; Ghisolfi et al., 2006; 
Ghisolfi et al., 2004; Ghisolfi et al., 2002; Gjini et al., 2010; Gjini et al., 2011; Griffith and 
Freedman, 1995; Griffith et al., 1998; Griffith et al., 1993; Hall et al., 2015a; Hall et al., 2014; 
Hong et al., 2008a; Hong et al., 2004; Hong et al., 2007; Hong et al., 2009; Hsieh et al., 2004; 
Jin et al., 1998; Johannesen et al., 2005; Johannesen et al., 2013; Judd et al., 1992; Kathmann 
and Engel, 1990; Keri et al., 2010; Kim et al., 2018; Kisley and Cornwell, 2006; Koike et al., 
2005; Light et al., 2000; Louchart-de la Chapelle et al., 2005a; Louchart-de la Chapelle et al., 
2005b; Lu et al., 2007; Martin et al., 2007a; Mazhari et al., 2011; Micoulaud-Franchi et al., 
2015a; Micoulaud-Franchi et al., 2012; Micoulaud-Franchi et al., 2015b; Micoulaud-Franchi et 
al., 2014; Micoulaud-Franchi et al., 2015c; Moran et al., 2012; Myles-Worsley, 2002; 
Nagamoto et al., 1996; Nagamoto et al., 1999; Nagamoto et al., 1989; Nagamoto et al., 1991; 
Neuhaus et al., 2014; Olincy et al., 2010; Olincy and Martin, 2005; Olincy et al., 2000; Oranje 
and Glenthoj, 2014; Patterson et al., 2009; Price et al., 2006; Rentzsch et al., 2007; Ringel et 
al., 2004; Sanchez-Morla et al., 2008; Sanchez-Morla et al., 2013; Sanchez-Morla et al., 2009; 
Santos et al., 2010; Shan et al., 2013; Siegel et al., 1984; Smith et al., 2010; Smith et al., 2013; 
Smucny et al., 2013; Song et al., 2014; Storozheva et al., 2016; Thoma et al., 2003; Thoma et 
al., 2008; Toyomaki et al., 2015; Turetsky et al., 2009; Vinogradov et al., 1996; Waldo et al., 
1992; Waldo et al., 1988; Waldo et al., 1994; Waldo et al., 2010; Waters et al., 2009; Williams 
et al., 2011; Wonodi et al., 2014; Yee et al., 1998; Yee et al., 2010; Zhang et al., 2012) were 
included in schizophrenia, 16 studies (Adler et al., 1990a; Ancin et al., 2011; Cabranes et al., 
2013; Carroll et al., 2008; Domjan et al., 2012; Franks et al., 1983; Hall et al., 2015a; Hall et 
al., 2014; Hall et al., 2008; Johannesen et al., 2013; Lijffijt et al., 2009; Martin et al., 2007a; 
Olincy and Martin, 2005; Patterson et al., 2009; Sanchez-Morla et al., 2008; Schulze et al., 
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2007) were included in bipolar disorder, 10 studies in first-degree relatives (Clementz et al., 
1998b; de Wilde et al., 2007a; Hall et al., 2008; Hong et al., 2008b; Louchart-de la Chapelle et 
al., 2005b; Myles-Worsley, 2002; Olincy et al., 2010; Schulze et al., 2007; Siegel et al., 1984) 
and 110 studies included healthy controls (Adler et al., 1990a; Adler et al., 2004; Adler et al., 
1982; Adler et al., 1985; Adler et al., 1990b; Arnfred et al., 2003; Arnfred et al., 2004; Bak et 
al., 2014; Baker et al., 1987; Becker et al., 2004; Becker et al., 2011; Boutros et al., 1999; 
Boutros et al., 2009; Boutros et al., 2004; Braff et al., 2007; Brenner et al., 2009; Brockhaus-
Dumke et al., 2008a; Brockhaus-Dumke et al., 2008b; Cabranes et al., 2013; Carroll et al., 2008; 
Chen et al., 2011; Clementz and Blumenfeld, 2001; Clementz et al., 1997a; Clementz et al., 
1997b, 1998a, b; Cullum et al., 1993; Dalecki et al., 2016; de Wilde et al., 2007a; Demily et al., 
2016; Devrim-Ucok et al., 2008; Domjan et al., 2012; During et al., 2014; El-Kaim et al., 2015; 
Franks et al., 1983; Freedman et al., 1987; Fresan et al., 2007; Ghisolfi et al., 2006; Ghisolfi et 
al., 2004; Ghisolfi et al., 2002; Gjini et al., 2010; Gjini et al., 2011; Griffith and Freedman, 
1995; Griffith et al., 1993; Hall et al., 2015a; Hall et al., 2014; Hall et al., 2008; Hong et al., 
2004; Hong et al., 2008b; Hong et al., 2007; Hong et al., 2009; Hsieh et al., 2004; Hsieh et al., 
2012; Jin et al., 1998; Johannesen et al., 2005; Johannesen et al., 2013; Judd et al., 1992; 
Kathmann and Engel, 1990; Keri et al., 2010; Kisley and Cornwell, 2006; Koike et al., 2005; 
Lijffijt et al., 2009; Louchart-de la Chapelle et al., 2005a; Louchart-de la Chapelle et al., 2005b; 
Lu et al., 2007; Martin et al., 2007a; Mazhari et al., 2011; Micoulaud-Franchi et al., 2015a; 
Micoulaud-Franchi et al., 2012; Micoulaud-Franchi et al., 2014; Moran et al., 2012; Myles-
Worsley, 2002; Nagamoto et al., 1989; Nagamoto et al., 1991; Neuhaus et al., 2014; Olincy et 
al., 2010; Olincy and Martin, 2005; Olincy et al., 2000; Oranje and Glenthoj, 2014; Price et al., 
2006; Rentzsch et al., 2007; Ringel et al., 2004; Sanchez-Morla et al., 2008; Sanchez-Morla et 
al., 2013; Sanchez-Morla et al., 2009; Santos et al., 2010; Schulze et al., 2007; Shan et al., 2013; 
Siegel et al., 1984; Smith et al., 2010; Smith et al., 2013; Smucny et al., 2013; Song et al., 2014; 
Storozheva et al., 2016; Thoma et al., 2003; Thoma et al., 2008; Turetsky et al., 2009; Waldo 
et al., 1992; Waldo et al., 1988; Waldo et al., 1994; Waters et al., 2009; Williams et al., 2011; 
Wonodi et al., 2014; Yee et al., 1998; Yee et al., 2010; Zhang et al., 2012). Both study selection 
and data extraction were performed by two authors independently for both schizophrenia (IKA 
and MIA) and bipolar disorder (SZT and MIA), a third author (MHH) made final decisions for 
conflicts. First-degree relatives of both schizophrenia and bipolar disorder were pooled to 
obtain a sufficient number of studies for the meta-analysis.    
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Figure 2. Flow-chart indicating the algorithm of literature search and study selection 
procedures  
 
2.2. Data extraction 
Means and standard deviations of the groups and sub-groups were extracted from all studies 
and independent effect sizes were obtained from each of the groups and sub-groups. Data were 
collected to form diagnostic groups, illness state subgroups, medication subgroups, and 
psychotic and non-psychotic groups in bipolar disorder.  
2.3. Outcome measures 
In a dual-click paradigm experiment, a set of stimuli consisting of click-pairs (two successive 
clicks [S1-conditioning stimulus and S2-test stimulus] with an interval of 500 milliseconds 
between the click-pairs) is presented to the subject and the reduction in the responses of the 
second stimulus (S2) of the pair is proposed to be the neurophysiological manifestation of the 
sensory gating function, see Figure 1 for an example. Variation of the two responses might be 
better monitored with a ratio of the two responses (S2/S1) or by the difference between the S1 
and S2 amplitudes (S1–S2). (Hall et al., 2006) Lower S2/S1 ratio or larger S1–S2 difference 
reflect more sensory gating. S2/S1 ratio is a coherent measure of the change in the magnitude 
of the test stimulus in comparison to the conditioning stimulus. In particular, S2/S1 and 
amplitude of the S1 response were the most consistently reported measures in studies.  
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1921 studies were eliminated by 
title and abstract
170 sensory gating studies in 
schizophrenia
29 studies were eliminated 
(methodological differences)
141 P50 studies in schizophrenia
16 articles were included in bipolar disorder 
26 articles were excluded 
(inappropriate data)
115 studies were included in schizophrenia
362 records in bipolar disorder,  
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2.4. Data Analysis 
Main grouping variables 
The following study groups were schizophrenia, bipolar disorder, healthy controls, first-degree 
relatives (diagnostic groups). Schizophrenia included two illness states: (chronic) schizophrenia 
and first episode psychosis. A period of time a person is experiencing psychotic symptoms for 
the first time in her life (and that episode should have lasted less than 6 months in time and no 
relapse into a new psychotic episode have occurred) is described as first-episode psychosis in 
the literature (de Wilde et al., 2007a). First-degree relatives include participants that are parents, 
siblings and offsprings of the patients with bipolar disorder and schizophrenia. Bipolar disorder 
included two illness states: remission and episodes (both mania and depression are labeled as 
episode). Studies that include first-degree relatives groups in both bipolar disorder (Hall et al., 
2008; Schulze et al., 2007) and schizophrenia (Clementz et al., 1998b; de Wilde et al., 2007a; 
Hong et al., 2008b; Myles-Worsley, 2002; Olincy et al., 2010) were pooled as first-degree 
relatives. Healthy controls and first-degree relatives did not include subgroups. Medication 
states were medicated, medication-free, and medication naïve. Only the diagnostic group 
bipolar disorder had subgroups for psychotic symptoms (yes / no / not-specified). 
Statistical analyses 
All analyses were performed using Stata version 15 (StataCorp., 2017). In all meta-analysis 
commands, the random-effects option (a more conservative approach to deal with 
heterogeneous data across studies) was used.  To study whether there were differences in the 
outcomes (S1 amplitude, S2 amplitude, S2/S1 ratio, S1-S2 difference) between the diagnostic 
groups, meta-regression analyses were performed using the Stata command ‘metareg’; healthy 
controls were the reference category. Postestimation, schizophrenia was directly compared with 
bipolar disorder using an F-test (Stata command: ‘test’). To illustrate these results, forest plots 
were generated, stratified by diagnostic group. In the above analyses, all available data were 
included. A small subgroup of included studies assessing both schizophrenia patients and 
bipolar disorder patients was used to perform within study comparisons (Figure 5).  
To study the second, third and fourth aim, meta-regression analyses were performed, and forest 
plots were generated. To analyze the second aim, data were stratified by illness state subgroups 
(again healthy controls were the reference group). For the third aim, data were stratified by 
medication use and diagnostic group and for the fourth aim data were stratified by psychotic 
symptoms within the bipolar patient group.  
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All analyses below were performed for each diagnostic group separately (schizophrenia, bipolar 
disorder, healthy controls, relatives). Influences of each single study on the meta-analysis 
results were examined using the ‘metainf’ command (how much does the outcome parameter 
change when omitting one study?). To assess publication bias, funnel plots were generated and 
Eggers tests were performed (Stata commands ‘metafunnel’ and ‘metabias’, respectively). Trim 
and fill analysis (‘metatrim’) was performed to estimate the effects of publication bias. To study 
whether there were differences in the outcomes (S1 amplitude, S2 amplitude, S2/S1 ratio, S1-
S2 difference) between the diagnostic groups, meta-regression analyses were performed using 
the Stata command ‘metareg’; healthy controls were the reference category. The regression 
coefficients (B) present the difference between the patient group and the comparison group. 
Stimulus duration, stimulus intensity (of stimulus 1 and 2, respectively), number of stimuli, 
illness state subgroup, medication status and psychotic symptoms were a priori selected as 
modifiers in the meta-analyses. In other words, these variables were hypothesized to be 
responsible for heterogeneity. First, these variables were added to the meta-regression, one at a 
time and all simultaneously. Subsequently, forest plots were generated after stratifying the data 
by modifiers (when continuous, recoded into quartiles) that were statistically significant in the 
meta-regression to find out whether this reduced heterogeneity. The modifiers, illness state 
subgroup and medication status, were excluded when analyzing healthy controls and first-
degree relatives. Psychotic and non-psychotic patients with bipolar disorder were also 
compared. 
3. Results  
3.1. Characteristics of the Included Studies 
A total of 130 studies were included in the analyses. 115 studies (4932 patients) were 
schizophrenia reports, 16 studies (975 patients) had bipolar disorder groups, 10  first-degree 
relative groups (848 participants) and 110 studies (4127 subjects) included healthy controls. 
Table 1 presents numbers of studies and numbers of subjects included in each analysis. Eight 
studies included both schizophrenia (541 subjects) and bipolar disorder (581 subjects) groups 
(Cabranes et al., 2013; Domjan et al., 2012; Hall et al., 2015a; Hall et al., 2014; Johannesen et 
al., 2013; Martin et al., 2007a; Olincy and Martin, 2005; Patterson et al., 2009).  
3.2. Diagnostic Groups 
Meta-regression analysis showed that S2/S1 ratio [B= 26.18 (95% CI: 21.20, 31.15), p<0.001] 
and S1-S2 difference [B= -0.63 (95% CI: -0.98, 0.29), p<0.001] were significantly different 
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between schizophrenia patients and healthy controls. S2/S1 ratio [B= 22.52 (95% CI: 12.86, 
32:28), p<0.001] and S1-S2 difference [B= -0.94 (95% CI: -1.51, -0.37), p=0.002] were also 
significantly different in bipolar disorder than healthy controls (Table 1). Schizophrenia 
patients had smaller S1 [B= -0.45 (95% CI: -0.90, -0.01), p=0.048] and larger S2 [B= 0.51 (95% 
CI: 0.29, 0.74), p<0.001] amplitudes than healthy controls. First-degree relatives had higher 
S2/S1 ratio [B= 13.91 (95% CI: 1.98, 25.83), p=0.022] compared to healthy controls (Table 1). 
Figure 3 and 4 are summarizing the forest-plots of all four outcomes. Full forest-plots are 
available in the supplementary material (Figure S1). When postestimation comparing bipolar 
disorder with schizophrenia, there were no differences in any of the four outcomes (Figure 5). 
Numbers in the within study meta-analyses were far smaller (Table 2). Results showed that S1 
amplitudes were lower and S2/S1 ratio was higher in schizophrenia patients than in bipolar 
disorder patients, while there were no significant differences in the other two outcomes (Figure 
5). 
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Table 1. Numbers of study groups and participants per analysis and meta regression results: 
difference in outcome between any diagnostic group and healthy controls 
Between studies 
B 
95% 
Confidence 
Interval 
p-
value 
D
ia
g
n
o
st
ic
 G
ro
u
p
s 
S1 Amplitude 
(Figure 3-A) 
SZ (112 study groups, 3833 participants) vs  
HCs (90 study groups, 4383 participants) 
-0.45 -0.90, -0.003 0.048 
BD (11 study groups, 700 participants) vs  
HCs (90 study groups, 4383 participants) 
-0.37 -1.36, 0.63 0.466 
FDR (8 study groups, 725 participants) vs  
HCs (90 study groups, 4383 participants) 
-0.87 -1.99, 0.26 0.132 
 
SZ (112 study groups, 3833 participants) vs 
BD (11 study groups, 700 participants) 
F=0.03 df=1, 221 p=0.87 
S2 Amplitude 
(Figure 3-B) 
SZ (91 study groups, 3461 participants) vs  
HCs (73 study groups, 3250 participants) 
0.51 0.29, 0.74 <0.001 
BD (13 study groups, 744 participants) vs  
HCs (73 study groups, 3250 participants) 
0.36 -0.06, 0.79 0.091 
FDR (8 study groups, 769 participants) vs  
HCs (73 study groups, 3250 participants) 
0.30 -0.22, 0.82 0.260 
 
SZ (91 study groups, 3461 participants) vs BD 
(13 study groups, 744 participants) 
F=0.50 df=1,185 p=0.48 
S2/S1 
(Figure 4-A) 
SZ (132 study groups, 3666 participants) vs  
HCs (102 study groups, 3464 participants) 
26.18 21.20, 31.15 <0.001 
BD (19 study groups, 656 participants) vs  
HCs (102 study groups, 3464 participants) 
22.57 12.86, 32.28 <0.001 
FDR (8 study groups, 769 participants) vs  
HCs (102 study groups, 3464 participants) 
13.91 1.98, 25.83 0.022 
 
SZ (132 study groups, 3666 participants) vs 
BD (19 study groups, 656 participants) 
F=0.54 df=1, 263 p=0.46 
S1-S2 
(Figure 4-B) 
SZ (34 study groups, 1476 participants) vs  
HCs (32 study groups, 1620 participants) 
-0.63 -0.98, 0.29 <0.001 
BD (7 study groups, 226 participants) vs  
HCs (32 study groups, 1620 participants) 
-0.94 -1.51, -0.37 0.002 
FDR (6 study groups, 612 participants) vs  
HCs (32 study groups, 1620 participants) 
-0.31 1.61, 2.10 0.309 
  SZ (34 study groups, 1476 participants) vs BD 
(7 study groups, 226 participants) 
F=1.11 df=1,77 p=0.29 
S
u
b
g
ro
u
p
s 
b
y
 I
ll
n
e
ss
 S
ta
te
 
S1 Amplitude 
(Figure 3-C) 
SZ (101 study groups, 3416 participants) vs 
HCs (90 study groups, 3250 participants) 
-0.46 -0.92, -0.01 0.047 
FEP (11 study groups, 368 participants) vs  
HCs (90 study groups, 3250 participants) 
-0.33 -1.33, 0.67 0.514 
BD remission (9 study groups, 606 
participants) vs HCs (90 study groups, 3614 
participants) 
-0.71 -1.78, 0.37 0.195 
BD episodes (2 study groups, 104 participants) 
vs HCs (90 study groups, 3614 participants) 
1.29 -0.98, 3.57 0.264 
FDR (8 study groups, 769 participants) vs  
HCs (90 study groups, 3614 participants) 
-0.87 -1.99, 0.26 0.131 
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S2 Amplitude 
(Figure 3-D) 
SZ (81 study groups, 3077 participants) vs 
HCs (73 study groups, 3250 participants) 
0.49 0.25, 0.72 <0.001 
FEP (10 study groups, 384 participants) vs  
HCs (73 study groups, 3250 participants) 
0.72 0.21, 1.23 0.006 
BD remission (11 study groups, 650 
participants) vs HCs (73 study groups, 3250 
participants) 
0.24 -0.21, 0.68 0.296 
BD episodes (2 study groups, 94 participants) 
vs HCs (73 study groups, 3250 participants) 
1.19 0.11, 2.26 0.031 
FDR (73 study groups, 769 participants) vs  
HCs (73 study groups, 3250 participants) 
0.30 -0.22, 0.82 0.257 
S2/S1 
(Figure 4-C) 
SZ (121 study groups, 4267 participants) vs 
HCs (102 study groups, 4162 participants) 
26.34 21.24, 31.44  <0.001 
FEP (11 study groups, 397 participants) vs  
HCs (102 study groups, 4162 participants) 
24.51 12.51, 36.52 <0.001 
BD remission (13 study groups, 787 
participants) vs HCs (102 study groups, 4162 
participants) 
20.49 9.24, 31.74 <0.001 
BD episodes (6 study groups, 137 participants) 
vs HCs (102 study groups, 4162 participants) 
27.94 10.47, 45.40 0.002 
FDR (10 study groups, 848 participants) vs  
HCs (102 study groups, 4162 participants) 
13.90 1.94, 25.87 0.023 
S1-S2 
(Figure 4-D) 
SZ (29 study groups, 1296 participants) vs 
HCs (32 study groups, 1620 participants) 
-0.60 -0.97, -0.23 0.002 
FEP (5 study groups, 180 participants) vs  
HCs (32 study groups, 1620 participants) 
-0.84 -1.53, -0.15 0.018 
BD remission (4 study groups, 147 
participants) vs HCs (32 study groups, 1620 
participants) 
-1.05 -1.79, -0.31 0.006 
BD episodes (3 study groups, 79 participants) 
vs HCs (32 study groups, 1620 participants) 
-0.79 -1.62, 0.04 0.062 
FDR (6 study groups, 612 participants) vs  
HCs (32 study groups, 1620 participants) 
-0.31 -0.91, 0.29 0.313 
S
u
b
g
ro
u
p
s 
b
y
 M
ed
ic
a
ti
o
n
 S
ta
tu
s S1 Amplitude 
(Figure 3-E) 
SZ medicated (89 study groups, 3130 
participants) vs SZ non-medicated (16 study 
groups, 383 participants) 
-0.21 -0.94, 0.52 0.564 
SZ medicated (89 study groups, 3130 
participants) vs SZ med. naive (12 study 
groups, 330 participants) 
-0.08 -1.12, 0.96 0.876 
BD medicated (7 study groups, 529 
participants) vs BD non-medicated (5 study 
groups, 178 participants) 
-0.96 -2.69, 0.76 0.237 
S2 Amplitude 
(Figure 3-F) 
SZ medicated (71 study groups, 2781 
participants) vs SZ non-medicated (13 study 
groups, 350 participants) 
-0.07 -0.59, 0.46 0.803 
SZ medicated (71 study groups, 2781 
participants) vs SZ med. naive (7 study 
groups, 330 participants) 
0.25 -0.42, 0.92 0.468 
BD medicated (9 study groups, 573 
participants) vs BD non-medicated (4 study 
groups, 171 participants) 
-0.17 -1.11, 0.78 0.701 
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S2/S1 
(Figure 4-E) 
SZ medicated (109 study groups, 3876 
participants) vs SZ non-medicated (16 study 
groups, 459 participants) 
11.87 0.76, 22.97 0.036 
SZ medicated (109 study groups, 3876 
participants) vs SZ med. naive (7 study 
groups, 330 participants) 
6.10 -9.37, 21.56 0.437 
BD medicated (12study groups, 634 
participants) vs BD non-medicated (7 study 
groups, 290 participants) 
13.00 -6.63, 32.62 0.180 
S1-S2 
(Figure 4-F) 
SZ medicated (26 study groups, 1187 
participants) vs SZ non-medicated (4 study 
groups, 125 participants) 
-0.77 -1.33, -0.21 0.008 
SZ medicated (26 study groups, 1187 
participants) vs SZ med. naive (4 study 
groups, 164 participants) 
-0.21 -0.77, 0.35 0.454 
BD medicated (2 study groups, 70 
participants) vs BD non-medicated (5 study 
groups, 156 participants) 
-1.33 -2.40, -0.29 0.022 
P
sy
ch
o
ti
c 
sy
m
p
to
m
s 
S1 Amplitude 
(Figure 3-G) 
BP without psychotic symptoms (1 study, 30 
participants) vs BD with psychotic symptoms 
(5 study groups, 303 participants) 
1.00 -1.60, 3.60 0.38 
S2 Amplitude 
(Figure 3-H) 
BP without psychotic symptoms (2 study 
groups, 45 participants) vs BD with psychotic 
symptoms (6 study groups, 332 participants) 
-0.15 -1.64, 1.34 0.82 
S2/S1 
(Figure 4-G) 
BP without psychotic symptoms (4 study 
groups, 68 participants) vs BD with psychotic 
symptoms (7 study groups, 345 participants) 
10.7 -19.2, 40.6 0.46 
S1-S2 
(Figure 4-H) 
BP without psychotic symptoms (1 study, 16 
participants) vs BD with psychotic symptoms 
(4 study groups, 138 participants) 
-0.35 -1.09, 0.38 0.23 
 
Table 2. Numbers of study groups and participants per analysis in the within study groups 
meta-analysis 
D
ia
g
n
o
st
ic
 G
ro
u
p
s S1 Amplitude 
(Figure 5-A) 
6 study groups, 439 SZ and 400 BD participants 
S2 Amplitude 
(Figure 5-B) 
7 study groups, 451 SZ and 415 BD participants 
S2/S1 
(Figure 5-C) 
9 study groups, 574 SZ and 545 BD participants 
S1-S2 
(Figure 5-D) 
2 study groups, 70 SZ and 70 BD participants 
Sz: Schizophrenia, BD: Bipolar Disorder, HCs: healthy controls, FDR: First-Degree 
Relatives, FEP: First episode psychosis. B: Regression coefficient 
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Figure 3. Meta-analysis results of S1 and S2 responses. Representative averaged effect sizes 
and confidence intervals are presented. 
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Figure 4. Meta-analysis results of S2/S1 ratio and S1 - S2 difference. Representative averaged 
effect sizes and confidence intervals are presented. For details, please see Figure S1. 
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Figure 5. Meta-analysis results of the study groups comparing schizophrenia and bipolar 
disorder (e.g. when in Hall et al. 2015 S1 amplitude is lower in SZ than in BD SMD is below 0) 
 
 
3.3. Robustness of results and publication bias 
Omitting single studies did not change the results of the forest-plots (figures available upon 
request). Egger Tests in schizophrenia patient groups and healthy controls did indicate 
publication bias for most outcomes, while Egger Tests in bipolar disorder groups did not show 
publication bias. Schizophrenia and healthy control funnel plots included far more studies and 
funnel plots were in agreement with the Egger test results showing a gap at the place of small-
study-null-findings in all funnel-plots. Despite this, in S1 amplitudes trim and fill did not add 
extra studies (Figure S3). In most other outcomes, trim and fill did add extra studies. When trim 
and fill added studies, the difference decreased but remained statistically significant (p<0.001, 
Figure S3). 
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3.4. Heterogeneity and modifiers 
Heterogeneity (between study results) was large with I-square ranging between 79.6% and 
100% in the full samples. Of the a priori selected modifiers only a few were statistically 
significant. For example, stimulus duration (p=0.024) and number of stimuli (p=0.030) were 
modifiers for S1 amplitudes and number of stimuli (p=0.060) was a trend level modifier for S2 
amplitudes in schizophrenia (Table S2) and illness state subgroup (p=0.040) was a modifier in 
bipolar disorder. When stratifying by a modifier, heterogeneity remained large in all strata 
(Table S2) with the exception of a few strata with a limited number of studies. 
In healthy controls, there were no modifiers and in first-degree relatives, modifiers could not 
be analyzed because data were not available. 
3.5. Illness State Subgroups 
The results are presented in Table 1, Figure 3 and Figure 4. In schizophrenia, S1 amplitudes 
[B= -0.46 (95% CI: -0.92, -0.01), p=0.047] and S1-S2 difference [B= -0.60 (95% CI: -0.97, -
0.23), p=0.002] were lower and S2 amplitudes [B= 0.49 (95% CI: 0.25, 0.72), p<0.001] and 
S2/S1 ratio [B= 26.34 (95% CI: 21.24, 31.44), p<0.001] compared with healthy controls. In 
first episode psychosis, S1-S2 difference [B= -0.84 (95% CI: -1.53, -0.15), p=0.018] were lower 
and S2 amplitudes [B= 0.72 (95% CI: 0.21, 1.23), p=0.006] and S2/S1 ratio [B= 24.51 (95% 
CI: 12.51, 36.52), p<0.001] compared with healthy controls Of all these, only the difference 
between first episode and healthy controls was not statistically significant. 
In remission phase of bipolar disorder, S2/S1 ratio was higher [B= 20.49 (95% CI: 9.24, 31.74), 
p<0.001] and S1-S2 difference was lower [B= -1.05 (95% CI: -1.79, -0.31), p=0.006] in 
comparison with healthy controls. Whereas in episodes of bipolar disorder, S2 amplitudes [B= 
1.19 (95% CI: 0.11, 2.26), p=0.031] and S2/S1 ratio [B= 27.94 (95% CI: 10.47, 45.40), 
p=0.002] were greater compared with healthy controls. There was difference between episodes 
and remission in bipolar disorder because of the differences in S1 (slightly enhanced in 
episodes, slightly decreased in remission) and S2 amplitudes between remission and episodes. 
In first-degree relatives, only effect size of S2/S1 ratio [B= 13.90 (95% CI: 1.94, 25.87), 
p=0.023] was significantly greater than healthy controls. 
3.2.Medication Subgroups  
Results are presented in the Table 1 and Figures 3 and 4. In schizophrenia, compared with 
medication-free patients medicated patients had higher S2/S1 ratio [B= 11.87 (95% CI: 0.76, 
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22.97), p=0.036] and lower S1-S2 difference [B= -0.77 (95% CI: -1.33, -0.21), p=0.008]. In 
bipolar disorder, S1-S2 differences were higher [B= -1.33 (95% CI: -2.40, -0.29), p=0.022] in 
patients on medication in comparison with medication-free subjects.  
3.6. Psychotic symptoms in bipolar disorder 
In bipolar disorder, there were no significant differences in any of the outcomes between 
patients without and with psychotic symptoms (Table 1, Figure 2 and Figure 3). 
4. Discussion 
This study yielded several insights into the sensory gating alteration in schizophrenia and 
bipolar disorder. First, P50 sensory gating measured by dual-click paradigm is altered in both 
bipolar disorder and schizophrenia. Second, in line with the literature (Franks et al., 1983), we 
found that bipolar disorder patients, either in episodes or euthymic phases, exhibited P50 
sensory gating alterations and the corresponding effect sizes were larger in episodes of bipolar 
disorder. In other words, sensory gating alteration in patients with bipolar disorder becomes 
more prominent during exacerbation phases of bipolar disorder. Third, P50 sensory gating 
alterations were similarly present in both first-episode psychosis patients and schizophrenia 
patients. Fourth, sensory gating alteration of first-degree relatives was at intermediate level 
between healthy controls and patients. Fifth, patient groups on medications had lower effect 
sizes in P50 sensory gating and medications seem to improve sensory gating ability in both 
schizophrenia and bipolar disorder. Finally, comparison between schizophrenia and bipolar 
disorder showed that schizophrenia showed greater P50 sensory gating alterations than bipolar 
disorder.   
P50 sensory gating is altered in both schizophrenia and bipolar disorder; and our recent results 
confirmed this finding consistent with prior meta-reports (Bramon et al., 2004; Chang et al., 
2011; Cheng et al., 2016; de Wilde et al., 2007b). S2/S1 sensory gating ratio was the main 
measure of sensory gating and both schizophrenia (ranging between 0.93-1.56) and bipolar 
disorder (0.85 for psychotic bipolar disorder, 0.59 for non-psychotic bipolar disorder) had high 
effect sizes in the meta-analyses. Consistently, schizophrenia had higher effect sizes than 
bipolar disorder in all measures in our study. Alterions of inhibitory mechanisms may underlie 
sensory gating alterations in schizophrenia and bipolar disorder (Cross-Disorder Group of the 
Psychiatric Genomics, 2013). The study results were more consistent in schizophrenia. P50 
sensory gating alterations may differentiate individuals with and without schizophrenia better 
than those with bipolar disorder. The level of P50 sensory gating ratio (S2/S1) alteration in 
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first-degree relatives [56.11 (52.44, 59.77)] were higher than healthy subjects [42.46 (38.81, 
46.12)] but lower than schizophrenia [68.91 (65.44, 72.37)] schizophrenia and bipolar disorder 
[66.09 (54.54, 77.65)] and significantly higher than healthy controls [B=13.91, (95%CI: 1.98, 
25.83)] in this study, consistent with the literature (de Wilde et al., 2007b; Earls et al., 2016; 
Hall et al., 2007b; Hall et al., 2008; Myles-Worsley et al., 2004). Although first-degree relatives 
do not experience psychiatric symptoms, partial inheritance of the traits related with cognitive 
mechanisms may participate in veiled alterations of brain function. Deviation of the brain 
function might still remain within the variance limits of normal ranges or a mixture of normal 
and abnormal outcomes may alter the results slightly in first-degree relatives (Freedman et al., 
1997; Greenwood et al., 2016). On the other hand, in an estimation of P50 sensory gating, P300 
and mismatch negativity in first degree relatives of schizophrenia patients, P50 sensory gating 
had highest effect sizes and most consistently influenced measure in first-degree relatives of 
schizophrenia patients (Earls et al., 2016).  
Our meta-analysis results indicate that P50 sensory gating alterations are both trait and state 
dependent markers. P50 sensory gating alterations do not progress with time in schizophrenia, 
remains stable during remission periods and deteriorate during acute exacerbation periods in 
bipolar disorder (Potter et al., 2006). This pattern is comparable with the lifetime course of 
neurocognitive alteration in schizophrenia and bipolar disorder (Lewandowski et al., 2011). 
Neurocognitive alterations that appear with premorbid (Trotta et al., 2015), prodromal 
(Hawkins et al., 2008) or first-episode phases (Hill et al., 2001; Hoff et al., 1998; Zanelli et al., 
2010), remain stable over time (Irani et al., 2011) and deteriorate with symptomatic 
exacerbations (Bortolato et al., 2015; Milev et al., 2005) in schizophrenia. However, some 
cognitive domains are altered across all phases (working memory, attention, cognitive control) 
or some domains (auditory perception, verbal fluency) are disturbed in early phases of the 
disease (Kelly et al., 2018). In bipolar disorder, neurocognitive deficits become observable with 
first episode (Hirayasu et al., 1998; Zanelli et al., 2010), alleviate in remission periods (Torres 
et al., 2014) and effect sizes of neurocognitive alterations increase in episodes (Kurtz and 
Gerraty, 2009; Martinez-Aran et al., 2004) or with chronicity of the symptoms (de Almeida 
Rocca et al., 2008; Frangou et al., 2005). In addition, psychosis is a deteriorating symptom 
dimension for bipolar disorder. A recent meta-analysis revealed that psychotic patients had 
higher effect sizes in P50 sensory gating than non-psychotic patients with bipolar disorder 
(Cheng et al., 2016). Since inhibitory mechanisms of sensory gating provide resistance to 
interference and early cognitive inhibition at the encoding stage, we hypothesize that similar 
 100 
M
E
T
A
-A
N
A
L
Y
S
IS
 O
F
 A
U
D
IT
O
R
Y
 P
5
0
 S
E
N
S
O
R
Y
 G
A
T
IN
G
 I
N
 S
C
H
IZ
O
P
H
R
E
N
IA
 A
N
D
 B
IP
O
L
A
R
 D
IS
O
R
D
E
R
 
5 
mechanisms may disturb both neurocognitive and P50 sensory gating alterations in 
schizophrenia and bipolar disorder (Jones et al., 2016; Potter et al., 2006).  
Illness course effects have been examined in schizophrenia with other paradigms in EEG. For 
example, Mismatch Negativity (MMN) studies show that chronic patients with schizophrenia 
had greater alteration than first-episode psychosis patients (Erickson et al., 2016). Auditory 
P300 measures could discriminate patients with schizophrenia, their first-degree relatives and 
healthy controls (Bramon et al., 2004; Earls et al., 2016; Niznikiewicz, 2019) and transition to 
psychosis was predicted by auditory P300 abnormalities in ultra-high-risk individuals (Tang et 
al., 2019). The trajectory of auditory P300 deterioration was corelated with disease conversion 
to psychosis among ultra-high-risk individuals (O'Donnell et al., 1995; Oribe et al., 2015). 
According to our results, auditory P50 sensory gating differs from auditory MMN and P300 
ERPs, such that there is only slight difference between first-episode psychosis and 
schizophrenia, which did not reach statistical significance. Great variation in first-episode 
psychosis may have led this result. Larger samples and longitudinal studies are needed to 
determine potential changes of auditory P50 sensory gating in the course of psychosis.  
In this meta-analysis, we were able to stratify patients according to medication status and 
compared medication subgroups. We found that medicated patient groups had better auditory 
P50 sensory gating compared to medication-free patients and interestingly that medication 
improve sensory gating function but did not normalize it. Several hypotheses have been tested 
in terms of neurotransmitters for P50 sensory gating. Nicotinic (Aidelbaum et al., 2018; 
Freedman, 2014), serotonergic (Mann et al., 2008; Oranje et al., 2011), dopaminergic (Adler et 
al., 2004; Devrim-Ucok et al., 2008; Oranje et al., 2013), noradrenergic (Adler et al., 1994; 
Witten et al., 2016) neurotransmission have been found to influence P50 sensory gating. 
Psychotropic medications alter neurophysiology with several mechanisms (Atagun, 2016; 
Atagun et al., 2015a; Vita et al., 2015; Yoshimura et al., 2007). Lithium amplifies event related 
oscillations in patients with bipolar disorder (Atagun et al., 2015a; Tan et al., 2016) and 
enhances sensory gating by stimulating norepinephrine and GABAergic neurotransmission in 
mice models (O'Neill et al., 2003). Two distinct mechanisms have been observed in 
enhancement of P50 sensory gating ratio by medications. One mechanism is amplification of 
evoked responses and the other mechanism is suppression of S2 response by supporting 
inhibitory mechanisms (Freedman, 2014). Stimulation of nicotinic alfa-7 receptors provide 
reduction in S2 amplitude and S2/S1 ratio (Adler et al., 1998; Aidelbaum et al., 2018) and 
clozapine may enhance sensory gating ratio by enhancing S1 amplitude (Nagamoto et al., 1996; 
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Nagamoto et al., 1999). Globally medications seem to enhance S1 amplitudes prominently and 
S2 amplitudes slightly. Since P50 sensory gating is associated with exacerbation of symptoms, 
medications may have direct and indirect influences on P50 sensory gating measures in 
schizophrenia and bipolar disorder.  
Although confounded by several factors including patients and medication combinations, a 
number of studies investigated medication effects on P50 sensory gating in schizophrenia and 
bipolar disorder. Various studies have reported that atypical antipsychotics improve (Adler et 
al., 2004; Csomor et al., 2014; de Wilde et al., 2007b; Devrim-Ucok et al., 2008; Holstein et 
al., 2011; Light et al., 2000; Oranje et al., 2013) or do not alter (Arango et al., 2003; Becker et 
al., 2004; During et al., 2014; Hong et al., 2009; Sanchez-Morla et al., 2009) P50 sensory gating. 
An early meta-analysis reported no significant effect of antipsychotics on pooled standardized 
effect sizes in schizophrenia (Bramon et al., 2004), however many studies are published 
afterwards. Medication may have differential effects, for example antipsychotics improve P50 
sensory gating in people with sensory gating alterations, whereas do not affect P50 sensory 
gating ratio in people with normal P50 sensory gating (Csomor et al., 2009; Oranje et al., 2002; 
Ucar et al., 2012). These results indicate a global improvement in S2/S1 ratio and S1 – S2 
difference in medicated patients compared to medication-free patients in schizophrenia and 
bipolar disorder. It has been suggested that medications can alleviate the findings of functional 
or structural neuroimaging studies (Hafeman et al., 2012), medication results of this study are 
consistent with this concept. 
These results are limited with publication bias and heterogeneity and should therefore be 
interpreted cautiously. Clinical state variations between studies may account for the 
heterogeneous results, since P50 sensory gating ratio had correlation with clinical rating scales 
in studies (Potter et al., 2006). Clinical heterogeneity might be related with age at onset, illness 
duration, psychosis in bipolar disorder, comorbidities and substance use disorders. Variable 
results may also be related with variable responses to medications (de Wilde et al., 2007b; 
Patterson et al., 2008). Clinical characteristics such as age at onset, duration of the illness and 
cumulative effects of number of episodes could not be controlled in this study, since subject-
by-subject data was not available. Differences in methodological applications between 
laboratories may have caused variable results and heterogeneity (Johannesen et al., 2013; 
Patterson et al., 2008). A meta-analysis have reported that methodological differences such as 
stimulus intensity or filter settings are influential factors for study results (de Wilde et al., 
2007b). Furthermore, test-retest reliability of P50 sensory gating ratio is controversial, some 
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authors reported low (Rentzsch et al., 2008) or high (Hall et al., 2006; Sandman and Patterson, 
2000) reliability for P50 sensory gating ratio. Since the dual-click paradigm is a passive 
listening task, physical properties of the stimuli are highly critical. The majority of the studies 
have been performed with similar analysis methods, although there were differences between 
studies in terms of paradigms. However, it is proposed that P50 sensory gating studies may also 
be contaminated by the analysis procedures even when using the same analysis method. For 
instance, analyses might be confounded by the several components within the designated time 
range. It has been shown that selection of the S2 component significantly changes the P50 
analysis results (Clementz et al., 1997b). Therefore, heterogeneity is possibly related with 
clinical characteristics of the patients, paradigms, EEG recordings and data analysis procedures. 
The stimulus characteristics (i.e., the number of stimuli, the duration of stimuli, and the intensity 
of stimuli) were significant modifiers for S1 amplitudes in this study. Stimulus sound intensity 
was found  a significant modifier in a meta-analysis (de Wilde et al., 2007b), but two other 
meta-analyses showed no effect for the stimulus sound intensity (Chang et al., 2011; Patterson 
et al., 2008). Moreover, two meta-analyses reported that data analysis methods and research 
centers influenced the study results, and thus methodological differences may explain a 
proportion of the heterogeneity (Chang et al., 2011; Patterson et al., 2008). Physical properties 
of the stimuli are associated with S1 and S2 responses and thus are critically important, in 
particular, if the influence is different between S1 and S2.  
To conclude, this meta-analysis examined the current literature of P50 sensory gating in 
schizophrenia and bipolar disorder. In addition, illness state and medication effects were also 
assessed. Findings showed that symptomatic exacerbations deteriorate, and medications 
alleviate alterations in the sensory gating mechanism. First-degree relatives had intermediate 
level sensory gating alteration between patients and healthy controls. Overall, this study 
suggests that P50 sensory gating alteration is a robust index in schizophrenia and affective 
psychosis spectrum disorders, and medications, to a small degree, seem to alleviate P50 sensory 
gating alteration. Although several studies assessed specific mechanisms of psychotropic 
medications, this meta-analysis presents an overall picture of global medication effect. Future 
studies with specific designs may systematically investigate potential effects of clinical 
dimensions and medications on P50 sensory gating.  
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Supplementary Material  
Table S1. Eggers’ Test bias per outcome per disease group 
 Bias coefficient p-value 
a. S1 amplitudes, schizophrenia 3.59 <0.001 
b. S1 amplitudes, bipolar disorder 5.28 0.069 
c. S1 amplitudes, healthy controls 5.86 <0.001 
c1. S1 amplitudes, relatives -4.22 0.089 
d. S2 amplitudes, schizophrenia 3.87 <0.001 
e. S2 amplitudes, bipolar disorder 2.94 0.089 
f. S2 amplitudes, healthy controls 4.14 <0.001 
f1. S2 amplitudes, relatives 1.19 0.47 
g. S2/S1 ratio, schizophrenia 0.86 0.12 
h. S2/S1 ratio, bipolar disorder 3.36 0.10 
i. S2/S1 ratio, healthy controls 2.42 0.029 
i1. S2/S1 ratio, relative -1.23 0.27 
j. S1- S2 difference, schizophrenia 1.87 0.013 
k. S1- S2 difference, bipolar disorder 2.93 0.21 
l. S1- S2 difference, healthy controls 5.02 0.001 
l1 S1- S2 difference, relatives -0.36 0.94 
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Figure S2. Funnel plots 
a. S1 amplitudes (Schizophrenia) 
 
b. S1 amplitudes (Bipolar disorder) 
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5 
c. S1 amplitudes (Healthy controls) 
 
d. S1 amplitudes (First-degree relatives) 
 
 
 
 
 
 
 
 127 
M
E
T
A
-A
N
A
L
Y
S
IS
 O
F
 A
U
D
IT
O
R
Y
 P
5
0
 S
E
N
S
O
R
Y
 G
A
T
IN
G
 IN
 S
C
H
IZ
O
P
H
R
E
N
IA
 A
N
D
 B
IP
O
L
A
R
 D
IS
O
R
D
E
R
 
5 
e. S2 amplitudes (Schizophrenia) 
 
f. S2 amplitudes (Bipolar disorder) 
 
 
 
 
 
 
 
 
 128 
M
E
T
A
-A
N
A
L
Y
S
IS
 O
F
 A
U
D
IT
O
R
Y
 P
5
0
 S
E
N
S
O
R
Y
 G
A
T
IN
G
 I
N
 S
C
H
IZ
O
P
H
R
E
N
IA
 A
N
D
 B
IP
O
L
A
R
 D
IS
O
R
D
E
R
 
5 
 
g. S2 amplitudes (Healthy controls) 
 
h. S2 amplitudes (First-degree relatives) 
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i. S2/S1 ratio (Schizophrenia) 
 
j. S2/S1 ratio (Bipolar disorder) 
 
  
 
 
 
 
 
 130 
M
E
T
A
-A
N
A
L
Y
S
IS
 O
F
 A
U
D
IT
O
R
Y
 P
5
0
 S
E
N
S
O
R
Y
 G
A
T
IN
G
 I
N
 S
C
H
IZ
O
P
H
R
E
N
IA
 A
N
D
 B
IP
O
L
A
R
 D
IS
O
R
D
E
R
 
5 
k. S2/S1 ratio (Healthy controls) 
 
l. S2/S1 ratio (First-degree relatives) 
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m. S1- S2 difference (Schizophrenia) 
 
  
n. S1- S2 difference (Bipolar disorder) 
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5 
o. S1- S2 difference (Healthy controls) 
 
p. S1-S2 difference (First-degree relatives) 
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Figure S3. Trim and fill Analysis  
a. S1 amplitudes (Schizophrenia) 
 
b. S1 amplitudes (Bipolar disorder) 
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c. S1 amplitudes (Healthy controls) 
 
 
d. S1 amplitudes (First-degree relatives) 
 
 
 
 
 
 
 
Filled funnel plot with pseudo 95% confidence limits
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e. S2 amplitudes (Schizophrenia) 
   
f. S2 amplitudes (Bipolar disorder) 
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g. S2 amplitudes (Healthy controls) 
 
h. S2 amplitudes (First-degree relatives) 
 
 
 
 
 
 
 
Filled funnel plot with pseudo 95% confidence limits
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i. S2/S1 ratio (Schizophrenia) 
   
j. S2/S1 ratio (Bipolar disorder)   
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k. S2/S1 ratio (Healthy controls) 
 
l. S2/S1 ratio (First-degree relatives) 
 
 
 
 
 
 
 
Filled funnel plot with pseudo 95% confidence limits
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m. S1- S2 difference (Schizophrenia) 
  
n. S1- S2 difference (Bipolar disorder) 
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o. S1- S2 difference (Healthy controls) 
  
p. S1 - S2 difference (First-degree relatives) 
 
Filled funnel plot with pseudo 95% confidence limits
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CHAPTER 6 
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Investigation of Heschl's gyrus and planum temporale in 
patients with schizophrenia and bipolar disorder: 
A proton magnetic resonance spectroscopy study 
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Abstract 
Background: Superior temporal cortices include brain regions dedicated to auditory 
processing and several lines of evidence suggest structural and functional abnormalities in both 
schizophrenia and bipolar disorder within this brain region. However, possible glutamatergic 
dysfunction within this region has not been investigated in adult patients. 
 
Methods: Thirty patients with schizophrenia (38.67±12.46 years of age), 28 euthymic 
patients with bipolar I disorder (35.32 ± 9.12 years of age), and 30 age-, gender- and education-
matched healthy controls were enrolled. Proton magnetic resonance spectroscopy data were 
acquired using a 3.0 T Siemens MAGNETOM TIMTrioMR system and single voxel Point 
REsolved Spectroscopy Sequence (PRESS) in order to quantify brain metabolites within the 
left and right Heschl's gyrus and planum temporale of superior temporal cortices. 
 
Results: There were significant abnormalities in glutamate (Glu) (F(2,78)=8.52, p < 0.0001), 
N-acetyl aspartate (tNAA) (F(2,81)=5.73, p=0.005), creatine (tCr) (F(2,83)=5.91, p=0.004) and 
inositol (Ins) (F(2,82)=8.49, p < 0.0001) concentrations in the left superior temporal cortex. In 
general, metabolite levels were lower for bipolar disorder patients when compared to healthy 
participants. Moreover, patients with bipolar disorder exhibited significantly lower tCr and Ins 
concentrations when compared to schizophrenia patients. In addition, we have found significant 
correlations between the superior temporal cortex metabolites and clinical measures. 
 
Conclusion: As the left auditory cortices are associated with language and speech, left 
hemisphere specific abnormalities may have clinical significance. Our findings are suggestive 
of shared glutamatergic abnormalities in schizophrenia and bipolar disorder. 
 
Keywords: Schizophrenia, Bipolar disorder, Glutamate, Glutamine, Magnetic resonance 
spectroscopy, Superior temporal cortex 
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1. Introduction 
Emil Kraepelin's dichotomous approach to discriminate schizophrenia and bipolar disorder 
relies on their different clinical courses. However, there has been discrepancy between 
Kraepelin's approach and studies showing co-aggregation of schizophrenia and bipolar disorder 
in families as well as shared susceptibility genes (Bramon and Sham, 2001; Craddock and 
Owen, 2005). The challenge arises due to the presence of overlapping symptoms between 
schizophrenia and bipolar disorder, but yet the desire for clear diagnostic categorization. 
Dimensional concepts suggest focusing on symptom domains rather than diagnostic categories 
(Cuthbert, 2014; Keshavan and Ongur, 2014). These symptom domains in conjunction with 
biological findings may provide insight for shared and distinct mechanisms underlying the 
disorders. Superior temporal cortices host primary, secondary and association auditory cortices 
and have been implicated in the pathophysiology of  schizophrenia. Both postmortem and in 
vivo measurements have shown reductions in volume, thickness and gray matter content of the 
superior temporal cortex in schizophrenia (Vita et al., 2012; Modinos et al., 2013). Longitudinal 
studies report progressive gray matter loss in the superior temporal gyrus and more precisely 
the Heschl's gyrus and planum temporale with progression to psychosis and development of 
delusions (Vita et al., 2012).Moreover, left superior temporal cortices have been associated 
with symptom domains such as auditory hallucinations (Dierks et al., 1999; Jardri et al., 2011; 
Kuhn and Gallinat, 2012; Modinos et al., 2013; Shinn et al., 2013) and thought disorder (Seese 
et al., 2011; Shenton et al., 1992) in psychosis. These findings suggest the superior temporal 
gyrus as a highly relevant location for the neurobiology and development of psychosis (Shenton 
et al., 1992; Rajarethinam et al., 2000; Takahashi et al., 2006; Seese et al., 2011). On the other 
hand, two meta-analyses of volumetric studies of superior temporal cortices did not report any 
significant differences between patients with bipolar disorder and healthy participants 
(Kempton et al., 2008; Arnone et al., 2009). However, primary and secondary auditory cortices 
are located in the region and functional studies consistently reported auditory processing 
disturbances in both schizophrenia (Dierks et al., 1999;Umbricht and Krljes, 2005; Domjan et 
al., 2012) and bipolar disorder (Hall et al., 2009; Oribe et al., 2010). Since glutamate is the 
major excitatory neurotransmitter and since the EEG signal consists of excitatory end synaptic 
potentials, auditory processing deficits detected in both schizophrenia (Umbricht and Krljes, 
2005; Oribe et al., 2010) and bipolar disorder (Hall et al., 2009; Ethridge et al., 2012; Atagun 
et al., 2014) could potentially be due to glutamatergic dysfunction in the auditory cortices 
(Javitt, 2009). Glutamate-modulating agents have been found to be efficacious in the treatment 
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6 
of mood disorders both in pre-clinical (Skolnick et al., 2009) and clinical studies (Sanacora et 
al., 2008; Machado-Vieira et al., 2012). Current psychotomimetics also modulate different 
components of the glutamatergic system (for reviews: (Machado-Vieira et al., 2012; Sanacora 
et al., 2008)). Chronic treatment with lamotrigine, valproate or lithium is likely to effect 
glutamatergic system through a variety of mechanisms (for reviews: (Colla et al., 2009; Gigante 
et al., 2012; Schifitto et al., 2009; Soeiro-de-Souza et al., 2013; Yatham et al., 2009)). 
Therefore, the nature and extent of the glutamatergic system abnormalities in patients with 
schizophrenia and mood disorders require further clarification. Proton magnetic resonance 
spectroscopy (1HMRS) is a non-invasive neuroimaging technique that can quantify in vivo 
neurochemical metabolites, including those related to the glutamatergic system. Glutamatergic 
neurotransmission is thought to be disturbed in both schizophrenia (Goff and Coyle, 2001; Paz 
et al., 2008; Javitt, 2009, 2010) and bipolar disorder (Sanacora et al., 2008; Machado-Vieira et 
al., 2012). Moreover, altered glutamatergic metabolites have been reported both in 
schizophrenia (Brugger et al., 2011; Marsman et al., 2013; Poels et al., 2014a,b) and bipolar 
disorder (Yildiz-Yesiloglu and Ankerst, 2006; Moore et al., 2007; Yuksel and Ongur, 2010; 
Ongur et al., 2011). Frontal, anterior cingulate and hippocampal regions are the most frequently 
studied brain regions and the findings were consistent across these brain regions. Only one 
study has investigated brain metabolites within the superior temporal gyrus (Seese et al., 2011) 
and reported a correlation between N-acetyl aspartate (NAA) concentrations and thought 
disorder in children with schizophrenia. However, to our knowledge, no single 1H MRS study 
has investigated the superior temporal region and compared the findings in adult patients with 
schizophrenia and patients with bipolar disorder. Hence, in this study, we utilized 1H MRS to 
examine neurometabolic changes within superior temporal cortices of adults with schizophrenia 
or bipolar disorder. Studies by different research modalities consistently report structural and 
functional abnormalities of auditory cortices, thus we expected to see abnormalities within the 
neurochemical profile of this region in schizophrenia and/or bipolar disorder. 
 
2. Methods 
2.1. Participants and study procedures 
Thirty-five stable patients with paranoid schizophrenia (male or female; between ages of 18–
59 years old) and 37 euthymic patients with bipolar disorder (male or female; between ages of 
20–54 years old) were recruited for the study from the outpatient unit of Ankara Ataturk 
Training and Education Hospital, Ankara, Turkey. Five of the schizophrenia and 3 of the bipolar 
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6 
patients could not attend the MRI session and hence were excluded. Moreover, 5 of the bipolar 
patients had bipolar disorder II and therefore were not included in the analysis and we could 
not acquire neuroimaging data from 1 of the bipolar patients due to technical issues. In addition, 
30 age-, gender-, and education matched healthy participants (male or female; between ages of 
18–58 years old) were enrolled in the study. All participants provided written consent upon 
receiving detailed information about the study. The Ethical Committee of Yıldırım Beyazıt 
University approved the study. 
All participants underwent a clinical interview administered by a psychiatrist (MIA) and 
diagnoses were checked with the Structured Clinical Interview according to the DSM-IV 
(SCID-I) (First et al., 1996). The clinical interview assessed the participants' demographics and 
medical/psychiatric history. Patients with bipolar disorder were evaluated using the Young 
Mania Rating Scale (YMRS) (Young et al., 1978) and the Hamilton Depression Rating Scale 
(HDRS) (Hamilton, 1960). Schizophrenia patients were evaluated with Scale for the 
Assessment of Positive Symptoms (SAPS) (including subscores for delusion and hallucination) 
(Andreasen, 1984) and Scale for the Assessment of Negative Symptoms (SANS) (Andreasen, 
1983). All patients were also evaluated with the Brief Psychiatric Rating Scale (BPRS) (Overall 
and Gorham, 1962) and the Edinburgh Handedness Inventory (EHI) (Oldfield, 1971). All 
participants were free of any brain damage/surgeries or metabolic systemic diseases such as 
diabetes mellitus or hypertension or current or lifetime psychiatric comorbidity or substance 
abuse. Psychotropic medications except for benzodiazepines were allowed. Exclusion criteria 
also included any contraindications to MRI scan. In addition deafness or heading aids were 
excluded to avoid any possible plasticity effects as a result of hearing disabilities, as we are 
particularly interested in the temporal lobe. Finally, all participants completed an MRI scanning 
session. 
 
2.2. NeuroImaging data acquisition 
Data were acquired on a 3.0 T Siemens MAGNETOMTIM Trio whole body MR system 
(Siemens, Erlangen, Germany) with a thirty two channel phased-array head coil at the UMRAM 
National Magnetic Resonance Research Center, Ankara, Turkey. T1-weighted anatomical. 
MRI (MPRAGE sequence, 256 Å~ 256 voxels, TR: 2000 ms, TE: 3.02 ms, FOV read: 215, 
FOV phase: 100, slice thickness: 0.84, 192 slices) were collected for diagnostic and localization 
purposes. Voxels (20mmÅ~ 20mmÅ~ 20mm)were placed consecutively in the left and right 
Heschl's gyrus and planum temporale regions (Fig. 1) and proton magnetic resonance 
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6 
spectroscopy (1H MRS) data were acquired using the single voxel Point REsolved 
Spectroscopy Sequence (PRESS) (TE=30 ms, TR=2000 ms, 128 averages) in order to quantify 
brain metabolites (Fig. 1). Manually adjusted B0 shimming was applied around the voxel as 
implemented on our MR system. 
 
2.3. NeuroImaging data analysis 
The proton spectrawere fit using LCModel (Version6.3.0) toquantify the metabolite 
concentrations. LCModel analyzes in vivo proton spectra as a linear combination ofmodel in 
vitro spectra from individualmetabolite solutions (Provencher, 1993, 2001) by utilizing built-
in (simulated) radial basis sets. The basis set used for this study included alanine, aspartate, 
creatine (Cr), phosphocreatine (PCr), γ aminobutyric acid (GABA), glucose, glutamate (Glu), 
glutamine (Gln), glycerophosphocholine (GPC), phosphocholine (PCh), glutathione (GSH), 
inositol (Ins), lactate, N-acetyl aspartate (NAA), N-acetyl aspartyl glutamate (NAAG), 
scylloinositol, taurine as well as macromolecules and lipids. Total NAA (tNAA, NAA and 
NAAG), Glu, Glx (Glu and Gln), total creatine (tCr, Cr and PCr), total choline (tCh, GPC and 
PCh), and Ins were quantified and fits with Cramer–Rao lower bounds (CRLB, estimated error 
of the metabolite quantification) of greater than 10% were classified as not reliably detected 
and excluded from further analysis. The structural T1-weighted images were segmented using 
SPM8 (Statistical Parameter Mapping—Welcome Department of ImagingNeuroscience, 
London, UK; (http://www.fil.ion.ucl.ac.uk/spm/software/spm8/)) to determine the gray matter, 
white matter and CSF contributions to the voxel of interest. 
 
2.4. Statistics 
Statistical analysis was performed using SPSS 21 (Armonk, NY: IBM Corp.). First, we 
conducted an outlier analysis for each metabolite within each group of participants. The values 
that were two standard deviations away from the mean of their corresponding groups were 
eliminated from further analysis. The remaining data were subjected to univariate ANOVA to 
compare the findings across 3 groups, i.e. schizophrenia patients vs. patients with bipolar 
disorder vs. healthy participants; and metabolite levels were the dependent factors for each 
comparison. Since we have 6 different metabolites (i.e. tNAA, Glu, Glx, tCr, tCho and Ins), to 
account for the multiple comparisons we considered p b 0.008 to be significant. We also 
performed post-hoc analyses with Bonferonni corrections and for this part of the analysis we 
considered p b 0.05 to be significant. In addition, we conducted an ANCOVA to investigate the 
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6 
potential covariates that have clinical importance and cover a range of values within each group 
(i.e. age of onset and duration of disorder as well as medication effects). Further, we conducted 
a Pearson's correlation analysis to explore the relationship between the brain metabolites and 
the clinical measures and for these analyses we considered p<0.05 to be significant. 
 
Figure 1. Representative proton spectrum and LCModel fit (red) with sample placement of voxels 
(yellow) in the left and right superior temporal gyri. 
 
 
 
 
3. Results 
3.1. Participant demographics 
Thirty remitted patients with paranoid schizophrenia (18 male; average age: 38.7±12.5 years) 
and 28 euthymic patients with bipolar disorder (13 male; average age: 35.3±9.1 years) and 30 
healthy participants (13 male; average age: 32.8±10.7 years) were included in the study. There 
were no significant differences in any of the demographic variables across the groups (p<0.05). 
Age of onset varied between the ages of 10 and 38 years for schizophrenia patients (average 
age of onset: 22.5±6.4 years), and ages of 12 and 48 years (average age of onset: 23.6±8.7 
years) for patients with bipolar disorder. Schizophrenia patients scored significantly higher than 
patients with bipolar disorder in BPRS (F(1,56)=29.45, p<0.0001). The demographic and 
clinical characteristics of the sample are listed in Table 1. In the schizophrenia group, there 
were three medication-free patients, 26 patients were on various mono-therapy antipsychotic 
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6 
medications and only 1 patient was taking both antipsychotic and valproate together. In the 
bipolar disorder group, there were five medication-free patients; the rest were on medication 
(valproate mono-therapy (n=3), combination therapy of valproate and antipsychotics (n=3), 
lithium monotherapy (n=6), combination therapy of lithium and antipsychotics (n=3), 
combination of valproate, lithium and antipsychotics (n=1), antipsychotic mono-therapy 
(n=7)). 
Table 1. Clinical characteristics of participants. 
 Schizophrenia 
(n=30) 
Bipolar Disorder 
(n=28) 
Healthy Controls 
(n=30) 
F/X2/t p 
Age 38. 7 ± 12.5 35.3 ± 9.1 32.8 ± 10.7 2.22 0.115 
Gender (F) 12 15 17 1.88 0.391 
Education 9.30 ± 3.2 10.89 ± 4.9 10.20 ± 3.4 1.24 0.294 
Age at Onset of Disorder 
(years) 
22.5 ± 6.4 23.6 ± 8.7   0.89 0.578 
Duration of Disorder 
(months) 
147.5 ± 132.1 92.2 ± 107.7   3.19 0.089 
Number of Previous 
Hospitalizations 
2.4 ± 5.1 1.4 ± 1.8  2.12 0.328 
Number of 
Previous 
Episodes 
Total   7.8 ± 5.4    
Manic  2.8 ± 2.2    
Depressive  4.2 ± 3.4    
Chlorpromazione 
Equivalent (mg) 
259.90 ± 228.54 144.4 ± 231.83  0.005 0.061 
Serum Lithium Levels 
(mEq/L) (n=9) 
 0.67 ± 0.22    
Serum Valproate Levels 
(g/ml) (n=10) 
 73.53 ± 27.08    
BPRS 7.67 ± 4.29 2.43 ± 2.86  3.20 <0.001 
YMRS  1.07 ± 1.61    
HDRS  3.46 ± 3.51    
SAPS Total 11.0 ± 6.66     
Bizarre 
Behavior 
1.16 ± 1.52     
Formal 
Thought 
Disorder 
0.47 ± 1.01     
Inappropriate 
Affect 
1.23 ± 0.73     
Delusions 5.10 ± 3.79     
Hallucination 2.60 ± 3.84     
SANS Total 14.13 ± 8.56     
Avolution 2.77 ± 2.83     
Affective 
Flattening 
4.13 ± 2.49     
Anhedonia 2.87 ± 1.83     
Alogia 2.03 ± 2.27     
Attention 2.33 ± 1.86     
Averages are reported with standard deviations. One-way ANOVA, Chi-Square test and t test. BPRS: 
Brief Psychiatric Rating Scale, HDRS: Hamilton Depression Rating Scale, SANS: Schedule for the 
Assessment of Negative Symptoms, SAPS: Schedule for the Assessment of Positive Symptoms, YMRS: 
Young Mania Rating Scale. 
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6 
3.2. Brain metabolites 
We evaluated the brain metabolites from the left and right Heschl's gyrus and planum temporale 
regions separately. Statistically significant findings are summarized in Table 2. Within the left 
hemisphere voxel, Glu (F(2,78)=8.52, p<0.0001) (Fig. 2A), tNAA (F(2,81)=5.73, p=0.005) 
(Fig. 2C), tCr (F(2,83)=5.91, p=0.004) (Fig. 2E) and Ins (F(2,82)=8.49, p<0.0001) (Fig. 2G) 
levels were statistically significantly different among the three groups. Post-hoc analysis 
revealed that tNAA, tCr and Ins levels were similar between schizophrenia patients and healthy 
participants (p N 0.1), but Glu levels were lower for schizophrenia patients than that of healthy 
comparisons at a trend level (p = 0.1). For Glu, tNAA, tCr and Ins, patients with bipolar disorder 
exhibited lower levels when compared to healthy participants (Glu: p<0.0001; tNAA: p=0.004; 
tCr: p = 0.008; Ins: p=0.003). In addition, tCr and Ins levels were higher for patients with 
schizophrenia when compared to patients with bipolar disorder (tCr: p=0.016; Ins: p=0.001). 
Due to the wide ranges in age at onset, duration of illness, and medication status, we further 
investigated the differences in Glu, tNAA, tCr and Ins among patients with bipolar disorder and 
schizophrenia patients by accounting for age onset, duration of disorder and the chlorpromazine 
equivalent values of medicated patients; results are summarized in Table 2. 
Table 2. 1H MRS findings. 
  Schizophrenia 
(n=30) 
Bipolar 
Disorder 
(n=28) 
Healthy 
Controls 
(n=30) 
F p 
Left 
Hemisphere 
      
Glu  0.00088 ± 
0.00011 
0.00082 ± 
0.00010 
0.00095 ± 
0.00013 
F(2,78)=8.52 <0.0001 
Covariates: 
(related to 
disorder) 
age onset    F(1,50)=4.39 0.041 
duration    F(1,50)=4.64 0.036 
CPZE    F(1,36)=5.78 0.021 
tNAA  0.00111 ± 
0.00016 
0.00104 ± 
0.00015 
0.00117 ± 
0.00013 
F(2,81)=5.73 0.005 
Covariates: 
(related to 
disorder) 
age onset    F(1,52)=3.53 0.066 
duration    F(1,52)=3.73 0.059 
CPZE    F(1,36)=2.83 0.101 
tCr  0.00080 ± 
0.00011 
0.00071 ± 
0.00011 
0.00080 ± 
0.00011 
F(2,83)=5.91 0.004 
Covariates: 
(related to 
disorder) 
age onset    F(1,52)=8.91 0.004 
duration    F(1,52)=7.26 0.009 
CPZE    F(1,36)=6.40 0.016 
Ins  0.00067 ± 
0.00010 
0.00057 ± 
0.00012 
0.00067 ± 
0.00011 
F(2,82)=8.49 <0.0001 
Covariates: 
(related to 
disorder) 
age onset    F(1,52)=14.48 <0.0001 
duration    F(1,52)=11.25 0.001 
CPZE    F(1,35)=6.64 0.014 
Absolute quantity averages are reported with standard deviations. Univariate ANOVA. 
CPZE: Chlorpromazione Equivalent. 
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6 
On the other hand, there were no statistically significant metabolite differences within the right 
hemisphere voxel (Glu: Fig. 2B; tNAA: Fig. 2D; tCr: Fig. 2F; Ins: Fig. 2H). Since there was no 
statistically significant differences between groups in terms of voxel tissue content (left 
hemisphere: gray matter — (F(2,84)=0.73, p=0.48), white matter — (F(2,84)=0.22, p=0.81), 
csf — F(2,84)=0.78, p=0.46; right hemisphere: gray matter — (F(2,84)=0.25, p=0.78), white 
matter — (F(2,84)=0.75, p=0.47), csf — F(2,84)=1.98, p=0.15) we did not factor gray matter/ 
white matter/csf amounts into our analysis. 
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6 
Figure 2. Absolute metabolite concentrations for patients with schizophrenia (SCH), bipolar disorder 
(BD), and healthy control participants (HC) acquired from the superior temporal gyrus using 1H MRS. 
Glutamate (Glu) from (A) left and (b) right superior temporal gyri; Total N-acetyl aspartate (tNAA) 
from (C) left and (D) right superior temporal gyri; total creatine (tCr) from(E) left and (F) right superior 
temporal gyri; inositol (Ins) from(G) left and (H) right superior temporal gyri. * denotes statistically 
significant difference between groups (p<0.008) 
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3.3. Association between brain metabolites and clinical measures 
For schizophrenia patients, we performed exploratory correlation analyses to investigate the 
relationship between the brain metabolites and SAPS (total scores and subscores for bizarre 
behavior, formal thought disorder, inappropriate affect, delusion, and hallucination) and SANS 
(total scores and subscores for avolition, affective flattening, anhedonia, alogia, and attention). 
Glu showed relationships with SANS affective flattening (r=0.44, p=0.02) and attention 
(r=0.44, p=0.02) subscores, only for the right hemisphere. tNAA exhibited inverse relationships 
with SANS alogia (r=−0.44, p=0.02) and attention subscores (r=−0.44, p=0.02) in the left 
hemisphere. tCr had inverse correlations with SAPS total score (r=−0.37, p=0.05), SAPS 
delusion subscore (r=−0.46, p=0.01), SANS anhedonia (r=−0.46, p=0.01), SANS alogia 
(r=−0.37, p=0.05) in the left hemisphere. Ins showed inverse relationships with SAPS delusion 
subscore (r=−0.42 p=0.03), SANS anhedonia (r=−0.47, p=0.01), and SANS alogia (r=−0.39, 
p=0.04) in the left hemisphere. For patients with bipolar disorder, we performed exploratory 
correlation analyses to investigate the relationship between the brain metabolites and YMRS, 
HDRS and BPRS. tNAA showed inverse relationships with HDRS for left (r=−0.46, p=0.02) 
and right hemispheres (r=−0.41, p=0.03). tCr also exhibited inverse correlation with HDRS for 
left (r=−0.39, p=0.05) and right (r=−0.44, p=0.02) hemispheres. In addition, Ins and HDRS had 
a reverse relationship in the right hemisphere (r=−0.52, p=0.005). 
 
4. Discussion 
In this study, we observed decreased Glu concentrations within the left Heschl's gyrus and 
planum temporale of the superior temporal gyrus of patients with schizophrenia and bipolar 
disorder when compared to healthy participants. On the other hand, Glu, tNAA, tCr and Ins 
concentrations of the bipolar disorder group were lower when compared to schizophrenia 
patients and healthy participants. Moreover, tCr and Ins concentrations in the left superior 
temporal gyrus of schizophrenia. Patients were significantly higher than the concentrations 
measured from patients with bipolar disorder. All of these differences in metabolite levels 
between groups reached statistical significance only in the left superior temporal cortex, 
suggesting a possible location- specific abnormality within the dominant hemisphere of 
auditory cortices for schizophrenia and bipolar disorder patients. It has been shown that 
auditory cortices are functionally lateralized (Zatorre et al., 1992; Kell et al., 2011) and the 
 154 
IN
V
E
S
T
IG
A
T
IO
N
 O
F
 H
E
S
C
H
L
'S
 G
Y
R
U
S
 A
N
D
 P
L
A
N
U
M
 T
E
M
P
O
R
A
L
E
 I
N
 P
A
T
IE
N
T
S
 W
IT
H
 S
C
H
IZ
O
P
H
R
E
N
IA
 A
N
D
 B
IP
O
L
A
R
 D
IS
O
R
D
E
R
: 
A
 P
R
O
T
O
N
 M
A
G
N
E
T
IC
 R
E
S
O
N
A
N
C
E
 S
P
E
C
T
R
O
S
C
O
P
Y
 S
T
U
D
Y
 
 
6 
auditory cortex of the dominant hemisphere is associated with psychiatric disorders (Dierks et 
al., 1999; Plaze et al., 2006; Shinn et al., 2013). 
Previous studies have reported glutamatergic abnormalities related to clinical progression in 
schizophrenia observed within different brain regions such as the anterior cingulate cortex 
(Goff and Coyle, 2001; Clinton and Meador-Woodruff, 2004; Kugaya and Sanacora, 2005; 
Javitt et al., 2012). Specifically, schizophrenia patients have exhibited increased concentrations 
of glutamatergic metabolites if the patients were in a first-episode and conversely, decreased 
concentrations if the patients had a chronic disease (Ohrmann et al., 2005; Ohrmann et al., 
2008;Marsman et al., 2013; Schwerk et al., 2014). A recent study, investigating schizophrenia 
patients showed elevated Gln and Gln-to-Glu ratio but no significant difference in Glu levels 
in patients when compared to healthy comparisons (Bustillo et al., 2014). Our findings in a 
cohort of chronic schizophrenia patients exhibited decreased Glu concentrations at trend level 
for schizophrenia patients when compared to healthy participants and no change for Glx 
concentrations were observed. 
Previous reports did not find any difference in Glu concentrations between patients with bipolar 
disorder and healthy participants (Gigante et al., 2012); however they consistently showed 
increase in Glx concentration for bipolar disorder patients, regardless of mood state (Yuksel 
and Ongur, 2010; Gigante et al., 2012). Although alterations in Glx have been suggested to 
mostly reflect changes in Glu levels (Dager et al., 2004), previous reports are suggestive of 
abnormalities in other components of the composite Glx peak, such as Gln (Moore et al., 2007), 
rather than Glu. However, our findings showed significant difference in Glu levels but not in 
Glx concentrations. 
Glutamate turnover may be altered in different ways, resulting in changes in Gln-to-Glu ratio, 
depending on the disease state, i.e. manic (Ongur et al., 2008) or depressive (Auer et al., 2000) 
phases of bipolar disorder (reviewed in (Yuksel and Ongur, 2010)). These findings suggest an 
alteration in glutamatergic dysfunction between mania and depression for bipolar disorder. 
Glial cells are responsible for Glu–Gln cycling (Tansey et al., 1991; Cooper et al., 2003); 
therefore glial abnormalities are potentially the basis of differences between mania and 
depression in bipolar disorder (Ongur et al., 1998). Unfortunately, the field strength of theMRI 
scanner used in the current study did not allow us to reliably quantify Gln concentrations. We 
can only speculate that since the Glx levels did not differ between groups, but Glu 
concentrations were lower for both schizophrenia and bipolar disorder patients when compared 
to healthy participants, Gln levels may have been elevated. Taken together, it is possible to 
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6 
suggest that abnormalities in the Gln/ Glu cycle might be a cause of the observed reduction in 
Glu levels for the patients with bipolar disorder.  
NAA is known to be lower in schizophrenia and bipolar disorder patients (Steen et al., 2005; 
Yildiz-Yesiloglu and Ankerst, 2006; Kraguljac et al., 2012a,b). Our investigation did not reveal 
any significant abnormality in tNAA concentrations in schizophrenia patients, possibly due to 
medication effects (Szulc et al., 2011; Kraguljac et al., 2012a; Szulc et al., 2013), but exhibited 
reduced tNAA levels for bipolar patients. tCr and Ins levels remain unchanged in schizophrenia 
(Schwerk et al., 2014) and our findings confirm this statement. However, there are a few studies 
that found reduced tCr levels in dorsolateral prefrontal cortex, anterior cingulate cortex, 
hippocampus and basal ganglia of schizophrenia patients (Ohrmann et al., 2005; Ohrmann et 
al., 2007; Ongur et al., 2009). In addition, the literature is not conclusive about the 
concentrations of Cr and Ins for patients with bipolar disorder (Yildiz-Yesiloglu and Ankerst, 
2006; Frey et al., 2007; Theberge et al., 2007; Ongur et al., 2009; Silverstone and McGrath, 
2009; Kraguljac et al., 2012a; Sikoglu et al., 2013). The decrease in tNAA, tCr and Ins that we 
observed in patients with bipolar disorder compared to healthy participants may be a region 
specific disturbance in this disorder, as we investigated an understudied brain area, i.e. the left 
superior temporal cortex. Regardless, these abnormalities are suggestive of abnormalities in 
neurochemicals other than glutamate in bipolar disorder.  
The comparison of findings from patients with schizophrenia and bipolar disorder revealed 
significant differences only for tCr and Ins levels. The auditory system may show different 
abnormalities at multiple levels both in schizophrenia and bipolar disorder (Skold et al., 2014). 
Our observations may imply that there exist common, i.e. glutamatergic dysfunction, as well as 
distinct abnormalities, i.e. in brain bioenergetics in schizophrenia and bipolar disorder within 
the auditory system. 
Previous studies have focused primarily on higher order cortices, such as the frontal lobe where 
different channels of information converge and hence conduct serial and parallel processing 
together. However, lower order sensory areas, such as the auditory cortices have simpler 
receptive fields with only serial processing capabilities (Yamada and Wilber, 1990; 
Rauschecker and Scott, 2009; Homan et al., 2014). Given the fact that the pathophysiology of 
psychiatric disorders is so complicated and these disorders may have different influences on 
different neural systems and circuits, investigating the primary sensory areas may provide an 
advantage. Therefore, in this study we focused on the superior temporal gyrus to acquire 1H 
MRS data. 
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6 
Previous studies in the left STG in schizophrenia revealed correlations with clinical data, which 
suggests a relationship between the region and the effects of clinical factors. A 31P MRS study 
reported correlation between the hallucination score of the Positive and Negative Syndrome 
Scale (PANSS) and phosphomonoesters and phosphodiesters (Nenadic et al., 2014). A recent 
1H MRS study comparing hallucinations in the STG reported that NAA/Cr ratio correlated with 
total and negative subscore of the PANSS in schizophrenia (Homan et al., 2014). Neuronal 
activation patterns for patients with auditory hallucinations were more prominent for the left 
hemisphere when compared to non-hallucinating patients as shown by functional neuroimaging 
studies with auditory tasks (Dierks et al., 1999; Shinn et al., 2013),which may indicate the 
relevance of the left auditory cortex. Besides, the auditory processing deficits in functional 
studies (Hall et al., 2009; Oribe et al., 2010; Domjan et al., 2012; Atagun et al., 2013; Atagun 
et al., 2014) point to abnormalities of the auditory cortices both in schizophrenia and bipolar 
disorder. In this study, both schizophrenia and bipolar disorder patients exhibited relationships 
between the studied metabolites and some of the clinical measures, especially on the left 
hemisphere. For example, HDRS scores correlated tCr and Ins concentrations in superior 
temporal cortices. This is particularly important as it may indicate a relationship between the 
metabolite levels and mood status. 
 
5. Limitations 
The current study had several limitations. First, our patients were patients with chronic disease 
and all were medicated. Although there was no statistically significant medication effect, small 
numbers of patients were taking each individual medication; therefore we cannot exclude 
medication effects conclusively. It is still possible that some of the metabolites were altered due 
to medications. Second, at 3 T magnetic field strength, some of the metabolite peaks in the 1H-
MRS spectrum cannot be decomposed. In spite of the high quality of the glutamate output, it is 
difficult to completely discriminate glutamate from glutamine and GABA signal amplitudes, 
thus we could only identify Glu and Glx levels. Third, 8 cm3 voxel volumes cover an area 
larger than the auditory cortices alone. 
 
6. Conclusion 
Overlapping symptoms and intermediate diagnoses suggest that schizophrenia and bipolar 
disorder are disorders on a continuum. Genome wide association studies have identified shared 
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6 
risk genes in schizophrenia and bipolar disorder involving glutamatergic metabolism and 
cascades (see review; Coyle, 2006), which are in line with the glutamatergic abnormalities we 
have observed. Given that neurotransmission and intracellular functions are two major 
functions of glutamatergic metabolites, future studies focusing on glutamatergic abnormalities 
may provide novel targets for treatment development for both schizophrenia and bipolar 
disorder. In addition, this study reports a significant difference between creatine and inositol 
levels in patients with schizophrenia and bipolar disorder in the left superior temporal region. 
Taken together, there may be both shared and distinct mechanistic abnormalities within 
auditory cortices underlying pathophysiologies of schizophrenia and bipolar disorder. 
Therefore, our findings may suggest biological markers that may quantitatively distinguish the 
two disorders, and might be of importance for future studies. 
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Abstract 
Background  
Despite the diagnostic challenges in categorizing bipolar disorder subtypes, bipolar I and II 
disorders (BD-I and BD-II respectively) are valid indices for researchers. Subtle 
neurobiological differences may underlie clinical differences between mood disorder subtypes. 
The aims of this study were to investigate neurochemical differences between bipolar disorder 
subtypes. 
Methods  
Euthymic BD-II patients (n=21) are compared with BD-I (n=28) and healthy comparison 
subjects (HCs, n=30). Magnetic Resonance Imaging (MRI) and proton spectroscopy (1H MRS) 
were performed on a 3T Siemens Tim Trio system. MRS voxels were located in the left/right 
superior temporal cortices, and spectra acquired with the single voxel Point REsolved 
Spectroscopy Sequence (PRESS). The spectroscopic data were analyzed with LCModel 
(Version 6.3.0) software.  
Results  
There were significant differences between groups in terms of glutamate [F=6.27, p=0.003], 
glutamate+glutamine [F=6.08, p=0.004], inositol containing compounds (Ino) (F=9.25, 
p<0.001), NAA [F=7.63, p=0.001] and creatine+phosphocreatine [F=11.06, p<0.001] in the left 
hemisphere and Ino [F=5.65, p=0.005] in the right hemisphere. Post-hoc comparisons showed 
that the BD-I disorder group had significantly lower metabolite levels in comparison to the BD-
II and the HC groups. 
Limitations  
This was a cross-sectional study with a small sample size. In addition, patients were on various 
psychotropic medications, which may have impacted the results.  
Conclusions 
Neurochemical levels, in the superior temporal cortices, measured with 1H-MRS discriminated 
between BD-II and BD-I. Although further studies are needed, one may speculate that the 
superior temporal cortices (particularly left hemispheric) play a critical role, whose pathology 
may be related to subtyping bipolar disorder.  
Key words: Magnetic resonance spectroscopy, bipolar disorder, superior temporal gyrus 
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1. Introduction 
Despite the diagnostic challenges in categorizing bipolar disorder subtypes, bipolar I disorder 
(BD-I) and bipolar II disorder (BD-II) are valid categorical indices for researchers (Phillips and 
Kupfer, 2013; Parker et al., 2014). Along with depressive episodes, presence of manic or 
hypomanic episodes is the major difference between BD-I and BD-II disorders. Despite the 
valid diagnostic boundaries, only limited studies have reported neurobiological differences 
between the subtypes (Phillips and Kupfer, 2013; Parker et al., 2014; McGrath et al., 2014).  
Genetic studies have identified differences between BD-I and BD-II (Lee et al., 2011; Uemura 
et al., 2011). Psychosis (Parker et al., 2014), neurotoxic processes (Yumru et al., 2009; Uemura 
et al., 2011) and cognitive dysfunction (Bora et al., 2011) are more prevalent in BD-I compared 
to BD-II. Magnetic resonance imaging (MRI) studies have reported that BD-I had more severe 
findings in comparison to BD-II in volumes (Hauser et al., 2000), white matter lesions (Ambrosi 
et al., 2013) and functional connectivity (Li et al., 2012). Neurochemistry may also differ 
between the subtypes. 
Proton magnetic resonance spectroscopy (1H-MRS) can quantify specific neurochemical 
compounds in the brain in vivo. It has been observed in 1H-MRS that mood state shifts and 
medications alter metabolites in BD-I (Moore et al., 2007). However, only a few MRS studies 
have compared BD-I and BD-II. No consistent finding has been reported between the subtypes 
in the frontal (Winsberg et al., 2000) or temporal (Hamakawa et al., 1998; Atagun et al., 2017) 
lobes, or the basal ganglia (Silverstone et al., 2004). Only one study detected increased choline 
concentrations in the basal ganglia in BD-II in comparison to BD-I (Kato et al., 1996).  
Patients with bipolar disorder showed fronto-temporal dysconnectivity (Ozerdem et al., 2011) 
and cortical thinning was specific to superior temporal cortex in BD-I (Hanford et al., 2016). 
Furthermore, auditory processing deficits in bipolar I disorder are related to left hemisphere 
superior temporal cortices (McCarley et al., 2008). Moreover, it has been postulated that shared 
neurochemical abnormalities in superior temporal cortices by schizophrenia and bipolar 
disorder might be a common feature of psychosis (Nudmamud et al., 2003). On the other hand, 
superior temporal cortices may have unique local metabolic disturbances in both schizophrenia 
and bipolar disorder (McNamara et al., 2014). These findings have highlighted the pathology 
of superior temporal lobes in bipolar disorder. However, it is not clear whether there is 
difference between subtypes of bipolar disorder.    
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In this study, we aimed to compare neurochemical differences between BD-I and BD-II 
disorders utilizing 1H-MRS in superior temporal cortices. Our hypothesis was that there might 
be neurochemical differences between the subtypes of bipolar disorder. To our knowledge, this 
is the first 1H-MRS study to assess superior temporal lobes in BD-I and BD-II. In vivo 
assessment of metabolite levels in superior temporal lobes may show differences in 
pathogenesis of the subtypes of bipolar disorder. 
2. Methods 
All participants provided a written informed consent before study participation. This study was 
approved by the local Ethical Committee. In a recent article, we have reported abnormal 
metabolite levels in the superior temporal lobes of participants with BD-I (Atagün et al., 2015). 
We further enrolled patients with BD-II (n=21, mean age= 38.38±13.84, 12 women/ 9 men and 
compared with our BD-I sample and healthy comparison subjects (HCs). All patients were 
euthymic during the study participation. Clinical evaluation tools were Structured Clinical 
Interview according to the DSM-IV (SCID-I) (First et al., 1996), Young Mania Rating Scale 
(YMRS) (Young et al., 1978) and Hamilton Depression Rating Scale (HDRS) (Hamilton, 
1960).  
Data acquisition processes were performed with a 3.0 T Siemens MAGNETOM TIM Trio MR 
system (Siemens, Erlangen, Germany) and a 32 channel phased-array head coil. T1 anatomical 
MRI [MPRAGE sequence, parameters were TE: 3.02, TR: 2000 ms, FOV phase: 100, FOV 
read: 215, slice thickness: 0.84, number of slices: 192] and spectroscopy voxels [single voxel 
Point REsolved Spectroscopy Sequence (PRESS); 8 cm3 voxels (2 cm X 2 cm X 2 cm); TE: 30 
ms, TR: 2000 ms, 128 averages] were recorded to evaluate left and right hemisphere superior 
temporal lobes which host Heschl’s gyrus and planum temporale (Figure 1a). B0 shimming was 
manually applied around the voxel. LCModel software (Version 6.3.0) was used to quantify the 
metabolite levels (Provencher, 2001), using water as internal reference. Representative spectra 
(Figure 1b) and quantified metabolites are presented in the supplement. Gray matter, white 
matter and cerebro-spinal fluid (CSF) contributions to the voxels were analyzed in T1 weighted 
structural MRI with Statistical Parametric Mapping-8 (SPM-8) software [Welcome Department 
of Imaging Neuroscience, London, UK; (http://www.fil.ion.ucl.ac.uk/spm/software/spm8/)] 
(for further details please see Atagün et al., 2015). Alanine, aspartate, creatine and 
phosphocreatine (Cr), γ-aminobutyric acid (GABA), glucose, glutamate (Glu), glutamine (Gln), 
choline containing compounds (Cho) [glycerophosphocholine (GPC), phosphocoline (PCh)], 
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7 
glutathione (GSH), inositol containing compounds (Ino), lactate, N-acetyl aspartate (NAA), N-
acetyl aspartyl glutamate (NAAG), scylloinositol, taurine are measurable metabolites by a 
single voxel Point Resolved Spectroscopy Sequence (PRESS) in a 3 Tesla scanner (Buonocore 
and Maddock, 2015). In this study we could be able to quantify six metabolties including Glu, 
glutamate plus glutamine (Glx), NAA, Cho, Ino and Cr.      
 
Statistical Analysis  
Statistical analyses were performed with SPSS 21 (IBM, Armonk, NY, USA) software. 
Distribution characteristics of the data are assessed with Kolmogorov-Smirnov and Shapiro-
Wilks’ Tests. Independent samples t Test or Mann-Whitney U Tests were performed for two 
independent group comparisons. Categorical variables were compared with chi-square test. 
Correlations were examined with Pearson’s and Spearman’s Correlation Tests. Univariate 
Analysis of Variance (ANOVA) and Analysis of Covariance (ANCOVA) was performed for 
three group comparisons for main effects. Chlorpromazine dose equivalents of antipsychotics, 
age, gender, age at onset, number of episodes, smoking status and alcohol consuming were 
available variables for covariate analysis. Interaction effects for grey matter, white matter and 
CSF contributions to the voxels were checked with interaction effect analysis in univariate 
ANOVA. Kruskal-Wallis Test was used for the comparison of non-Gaussian distributed 
variables. Post-hoc tests were Bonferroni or Tamhane Tests according to Levene's 
Homogeneity of Variance Test. Since 6 ANOVAs were performed for 6 metabolites 
(Glutamate, glutamate+glutamine, inositol containing compounds, creatine+phosphocreatine, 
choline containing compounds, n-Acetyl Aspartate) in the two hemispheres, a Bonferroni 
correction was applied to the p values (6 metabolites X 2 hemispheres= 12; 0.05 / 12 = 0.0041) 
and level for statistical significance was 0.0041 for metabolite level comparisons. For all other 
comparisons, cut-off for statistical significance was 0.05.   
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Figure 1. Voxel location (a) and representative spectrum (b) 
 
 
 
3. Results 
Groups were similar in terms of age, gender, and education (Table 1). Smokers were more 
frequent in the patient groups [F=6.99, p=0.030] and alcohol consumers were more frequent in 
the BD-II patient group [χ2 =9.69, p=0.008].   
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Table 1. Sociodemographic characteristics of the groups 
 BD-I (n=28) BD-II (n=21) HCs (n=30) t / F / χ2 
Age 35.32 ± 9.12 38.38 ± 13.84 
32.90 ± 
10.82 
1.47 
Gender [Women (%)] 15 (%53.6) 12 (%57.1) 17 (%56.7) 0.15 
Education* 10.89 ± 4.86 12.10 ± 4.09 9.97 ± 3.16 1.66 
Age at disease onset* 23.57 ± 8.66 24.71 ± 9.63  -0.44 
Duration of the disease** 92.21 ± 107.69 153.43 ± 126.48  -1.83 
Total Number of 
Episodes 7.82 ± 5.46 8.50 ± 6.87  -0.38 
Mania ¥ 2.77 ± 2.18 3.50 ± 3.52  -0.87 
Depression 4.22 ± 3.42 4.90 ± 4.15  -0.61 
Psychosis during episodes n (%) 18 (%64.3) 8 (%38.1)¥  3.31 
Nicotine n (%) 18 (%64.3) 14 (%66.7) 10 (%33.3) 6.99 
Alcohol n (%) 2 (%7.1) 9 (%40.9) 5 (%16.7) 9.69 
YMRS 1.07 ± 1.61 1.48 ± 1.50  -0.90 
HAM-D 3.46 ± 3.51 3.38 ± 3.20  0.09 
BD-I: Bipolar I Disorder, BD-II: Bipolar II Disorder, HCs: Healthy Controls, *Years, **Months, 
¥Hypomania for patients with bipolar II disorder. YMRS: Young Mania Rating Scale, HAM-D: Hamilton 
Depression Rating Scale. Bold characters indicate statistical significance. ¥Psychotic symptoms were 
observed in depressive episodes of BD-II.  
 
Comparison of the metabolite levels revealed that there were significant differences between 
groups in terms of glutamate [F=6.27, p=0.003], glutamate + glutamine [F=6.08, p=0.004], 
inositol containing compounds (Ino) [F=9.25, p<0.001], NAA [F=7.63, p=0.001] and creatine 
+ phosphocreatine [F=11.06, p<0.001] in the left hemisphere (Table 2). Post-hoc comparisons 
showed that the BD-I disorder group had significantly lower metabolite levels in comparison 
to the BD-II and the HC groups (Table 2). There was no significant difference between the 
groups in terms of voxel segmentation data (gray / white matter and cerebrospinal fluid content, 
results are presented in Table 2).    
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Table 2. 1H-MRS findings  
 BD-I 
(n=28) 
BD-II 
(n=21) 
HCs 
(n=30) 
F p 
Partial 
η2 
Post-hoc 
R
ig
h
t 
Glutamate 
1.31 ± 
0.16 
1.46 ± 
0.24 
1.43 ± 
0.18 
3.98 0.023 0.11  
Glx 
1.87 ± 
0.26 
1.98 ± 
0.26 
1.95 ± 
0.26 
1.19 0.311 0.04  
Inositol 
CC 
0.92 ± 
0.15 
1.02 ± 
0.21 
1.06 ± 
0.09 
5.65 0.005 0.25  
Choline 
CC 
0.29 ± 
0.05 
0.30 ± 
0.05 
0.28 ± 
0.06 
1.04 0.358 0.03  
NAA 
1.59 ± 
0.18 
1.72 ± 
0.18 
1.74 ± 
0.20 
4.94 0.010 0.13  
Cr 
1.12 ± 
0.14 
1.27 ± 
0.19 
1.18 ± 
0.18 
4.38 0.016 0.11  
Gray 
Matter* 
56.83 ± 
4.78 
57.50 ± 
13.89 
58.00 ± 
4.87 
0.14  0.870 <0.01  
White 
Matter* 
28.91 ± 
8.09 
29.01 ± 
5.11 
30.58 ± 
6.47 
0.51 0.604 0.01  
CSF* 
13.58 ± 
7.20 
13.00 ± 
11.72 
10.74 ± 
5.49 
0.93 0.401 0.02  
L
ef
t 
Glutamate 
0.82 ± 
0.11 
0.99 ± 
0.25 
0.95 ± 
0.13 
6.27 0.003 0.15 
BD-I 
<HCs,BD-II 
Glx 
1.11 ± 
0.18 
1.36 ± 
0.37 
1.25 ± 
0.18 
6.08 0.004 0.15 
BD-
I<HCs,BD-II 
Inositol 
CC 
0.57 ± 
0.12 
0.72 ± 
0.17 
0.67 ± 
0.09 
9.25 <0.001 0.21 
BD-I 
<HCs,BD-II 
Choline 
CC 
0.17 ± 
0.03 
0.20 ± 
0.04 
0.19 ± 
0.03 
4.18 0.019 0.11  
NAA 
1.02 ± 
0.13 
1.23 ± 
0.29 
1.17 ± 
0.13 
7.63 0.001 0.18 
BD-I 
<HCs,BD-II 
Cr 
0.71 ± 
0.11 
0.90 ± 
0.19 
0.81 ± 
0.10 
11.06 <0.001 0.23 
BD-I 
<HCs,BD-II 
Gray 
Matter* 
57.03 ± 
4.42 
57.05 ± 
14.84 
59.78 ± 
5.73 
0.85 0.432 0.22  
White 
Matter* 
31.06 ± 
9.46 
30.67 ± 
7.77 
30.51 ± 
6.72 
0.04 0.966 <0.01  
CSF* 
10.25 ± 
7.48 
11.85 ± 
11.27 
9.38 ± 
4.56 
0.59 0.556 0.02  
All metabolite levels are in institutional units and rounded up (X 1000). Univariate ANOVA, Bonferroni 
or Tamhane Test were picked for post-hoc comparisons. Glx: Glutamate + Glutamine, NAA: N-Acetyl-
Aspartate, Inositol CC: Inositol containing compounds, Choline CC: Choline Containing Compounds, 
Cr: Creatine + Phosphocreatine,  CSF: Cerebrospinal Fluid content. *Voxel Segmentation Data 
(percentage),  Bold  indicate statistical significance.  
 
Correlation analysis was performed with Glu, Glx, NAA, Ino, Cr, age, age at onset, duration of 
the disease, number of episodes, serum lithium levels, serum valproate levels, chlorpromazine 
equivalent doses of antipsychotics, Young Mania Rating Scale and Hamilton Depression Rating 
Scale scores variables. There were significant correlations between right hemisphere N-Acetyl 
Aspartate (NAA) levels and age at disease onset (r2=-0.58, p=0.009), number of hypomanic 
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7 
episodes (r2=-0.51, p=0.032) in the BD-II group. ANCOVA showed that right hemisphere NAA 
levels were associated with the YMRS scores [F=5.36, p=0.027], the number of life-time 
hypomanic episodes [F=8.69, p=0.022], age of disease onset [F=5.86, p=0.006] in the BD-II 
group. No other significant correlation was observed. Because we presented the BD-I group 
findings in the past, here we only present correlation analyses within the BD-II group. 
Medications are presented in Table 3.  
 
Table 3. Medications of the patients 
  BD-I (n=28) BD-II (n=21) p 
Lithium 10 (% 42.9) 5 (% 23.8) 0.752 
Serum lithium levels (mEq/L) 0.67 ± 0.22 0.54 ± 0.15 0.364 
Valproate 14 (% 50) 6 (% 28.6) 0.111 
Serum valproate levels (mg/L) 73.53 ± 27.08 61.50 ± 25.76 0.469 
Antipsychotics 14 (% 50) 11 (% 52.4) 0.549 
CPZE 297.71 ± 246.93 180.27 ± 153.33 0.120 
Antidepressants*  3 (% 10.7) 5 (% 23.8) 0.457 
*In combination with other medications. CPZE: Chlorpromazine equivalent doses of 
antipsychotics 
 
Metabolite levels did not differ between patients on/off lithium, valproate (p>0.05 for all). 
There were no significant differences between psychotic (n=26) and non-psychotic (n=23) 
patients independent of diagnostic subtypes (p>0.05 for all metabolites in both hemispheres). 
Psychosis, alcohol or nicotine consumption did not show any significant impact on the 
metabolite levels (p>0.05; Table 4 and Table 5).   
 
Table 4. Comparison between psychotic and non-psychotic patients 
  Patients with psychotic 
episodes (n=26) 
Patients without any psychotic 
episodes (n=23) 
t p 
Glu 0.85 ± 0.18 0.95 ± 0.22 1.63 0.110 
Glx 1.18 ± 0.26 1.23 ± 0.35 0.97 0.337 
NAA 1.10 ± 0.24 1.13 ± 0.25 0.55 0.582 
Ino 0.62 ± 0.15 0.65 ± 0.16 0.64 0.523 
Cr 0.78 ± 0.18 0.81 ± 0.17 0.62 0.539 
Abbreviations are as written in unabbreviated form in Table 4. Psychotic and non-psychotic 
patients regardless of diagnostic subtypes are pooled in this analysis.  
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Table 5. Covariate analysis  
  BD-I 
(n=28) 
BD-II 
(n=21) 
HCs 
(n=30) 
F p Partial 
η2 
Post-hoc 
Glu 0.82 ± 0.11 0.99 ± 
0.25 
0.95 ± 
0.13 
6.27 0.003 0.15 BD-I 
<HCs,BD-II 
CPZE       3.45 0.093 0.26   
Age       0.15 0.707 0.02   
Age at onset       1.71 0.218 0.15   
Number of episodes       2.49 0.146 0.20   
Gender       4.70 0.012 0.125   
Smokers (n)       3.83 0.079 0.28   
Alcohol consumers 
(n) 
      0.18 0.684 0.02   
Glx 1.11 ± 0.18 1.36 ± 
0.37 
1.25 ± 
0.18 
6.08 0.004 0.15 BD-
I<HCs,BD-II 
CPZE       2.70 0.131 0.21   
Age       0.10 0.754 0.01   
Age at onset       0.55 0.474 0.05   
Number of episodes       2.55 0.141 0.20   
Gender       2.02 0.186 0.17   
Smokers (n)       0.95 0.352 0.09   
Alcohol consumers 
(n) 
      0.77 0.401 0.07   
Inositol CC 0.57 ± 0.12 0.72 ± 
0.17 
0.67 ± 
0.09 
9.25 <0.001 0.21 BD-I 
<HCs,BD-II 
CPZE       0.15 0.709 0.02   
Age       0.78 0.398 0.07   
Age at onset       1.29 0.283 0.11   
Number of episodes       0.05 0.835 <0.01   
Gender       3.53 0.090 0.07   
Smokers (n)       0.59 0.461 0.06   
Alcohol consumers 
(n) 
      0.52 0.825 0.06   
NAA 1.02 ± 0.13 1.23 ± 
0.29 
1.17 ± 
0.13 
7.63 0.001 0.18 BD-I 
<HCs,BD-II 
CPZE       0.01 0.921 <0.01   
Age       0.40 0.544 0.04   
Age at onset       0.87 0.374 0.09   
Number of episodes       0.07 0.805 <0.01   
Gender       4.62 0.060 0.34   
Smokers (n)       1.59 0.239 0.15   
Alcohol consumers 
(n) 
      0.25 0.627 0.03   
Cr 0.71 ± 0.11 0.90 ± 
0.19 
0.81 ± 
0.10 
11.06 <0.001 0.23 BD-I 
<HCs,BD-II 
CPZE       0.35 0.569 0.03   
Age       0.23 0.645 0.02   
Age at onset       0.82 0.387 0.07   
Number of episodes       0.16 0.690 0.02   
Gender       3.87 0.078 0.28   
Smokers (n)       0.71 0.419 0.07   
Alcohol consumers 
(n) 
      0.09 0.776 0.01   
Univariate ANCOVA. CPZE: Chlorpromazine equivalent doses of antipsychotics. Only 
metabolites which had significant differences between the groups are presented in this table. 
Glu: Glutamate, Glx: Glutamate and glutamine, Inositol CC: Inositol containing compounds, 
NAA: N-Acetyl Aspartate, Cr: Creatine and phosphocreatine 
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4. Discussion 
In this study metabolite levels in the superior temporal cortices differed between the BD-I and 
BD-II groups. The BD-I group had significantly lower metabolite levels in comparison to the 
BD-II group. Further analysis showed that clinical factors such as psychosis, number of 
episodes and nicotine or alcohol consumption did not have any impact on metabolite levels. 
HDRS scores had inverse relationship between NAA and Cr in both right and left hemispheres 
and Ino and HDRS had correlation in the right hemisphere in BD-I (Atagun et al., 2015). 
Whereas NAA levels were negatively correlated with age at onset, number of hypomanic 
episodes and YMRS scores in the BD-II group.  
Glutamatergic neurotransmission is maintained by glutamate to glutamine cycle and glial cells 
serve for the cycle. This cycle is differentially altered in manic and depressive states (Yüksel 
and Öngür, 2010). Globally Glx is elevated (Dager et al., 2004), however Glu levels are not 
significantly elevated in bipolar disorder (Yüksel and Öngür, 2010; Atagun et al., 2015). Since 
Glx consist of glutamate plus glutamine, elevation of Glx is probably associated with increased 
glutamine levels. Quantification of glutamine is not possible with low magnetic field scanners, 
and thus there are not much studies in the literature. Glutamine levels in anterior cingulate 
cortex were found to be increased in bipolar disorder (Ongur et al., 2008). These findings may 
indicate that glutamate to glutamine cycle is disturbed in bipolar disorder. There may be a 
difference in glial physiopathology in BD-I and BD-II.  
Inositol levels are found to be changed in bipolar disorder and mood stabilizers alter inositol 
levels by influencing phospho-inositol cycle (Silverstone and McGrath, 2009). However, the 
1H-MRS literature regarding Ino levels is mixed (Silverstone and Mcgrath, 2009). Controlling 
for voxel locations, medications, field strength might be useful in future studies. NAA is a 
marker of mitochondrial function for oxidative metabolism and neuronal function/viability; 
decrease of NAA levels indicate neuronal dysfunction (Moffett et al., 2007). Cr metabolites are 
involved in energy metabolism by transporting high energy phosphorous groups; Cr 
compounds are highly diffusible and are considered to be stable throughout the brain. However, 
it has been determined that Cr is not stable in bipolar disorder and schizophrenia (Ongur et al., 
2009). Thus, the use of Cr as an internal reference might be erroneous in bipolar disorder and 
schizophrenia. Correlation analysis revealed differences between BD-I and BD-II. NAA levels 
are negatively correlated with number of hypomanic episodes and age at disease onset in BD-
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II. Whereas in BD-I HDRS scores were negatively correlated with Ino and NAA (reported in 
Atagun et al., 2015).   
Small sample size and being a cross-sectional study are major limitations of this study. 
Furthermore, patients were on various psychotropic medications and medications are known to 
alter the metabolites measured by 1H-MRS (Moore et al., 2000; Moore et al., 2007). Because 
of its anatomical adjacency to cranium, B0 and B1 inhomogeneity are high in temporal lobe 
(Juchem and de Graff, 2016). B0 shimming was performed, however B1 shimming was not 
available in this study.  
To conclude, levels of metabolites are decreased in BD-I in comparison to BD-II and healthy 
controls in this study. These findings may indicate that neuronal dysfunction and metabolic 
decline in the left (dominant) hemisphere superior temporal lobe is specific to BD-I. Although 
further studies are needed, it can be postulated that pathology of the left hemispheric superior 
temporal lobe might be more severe in BD-I in comparison to BD-II. Our findings indicate that 
the left hemispheric superior temporal lobe metabolite levels in BD-I are declined similar to 
psychotic spectrum disorders rather than BD-II. Further studies comparing manic and 
hypomanic episodes of BD-I and BD-II may reveal metabolic differences between the subtypes.   
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Abstract 
The aim of this study is to measure GABA levels of perisylvian cortices in schizophrenia and 
bipolar disorder patients, using proton magnetic resonance spectroscopy (1H-MRS). Patients 
with schizophrenia (n=25), bipolar I disorder (BD-I; n=28) and bipolar II disorder (BD-II; 
n=20) were compared with healthy controls (n=30). 1H-MRS data was acquired using a 
Siemens 3 Tesla whole body scanner to quantify right and left perisylvian structures’ (including 
superior temporal lobes) GABA levels. Right perisylvian GABA values differed significantly 
between groups [χ²=9.62, df: 3, p = 0.022]. GABA levels were significantly higher in the 
schizophrenia group compared with the healthy control group (p=0.002). Furthermore, 
Chlorpromazine equivalent doses of antipsychotics correlated with right hemisphere GABA 
levels (r2=0.68, p=0.006, n=33). GABA levels are elevated in the right hemisphere in patients 
with schizophrenia in comparison to bipolar disorder and healthy controls. The balance between 
excitatory and inhibitory controls over the cortical circuits may have direct relationship with 
GABAergic functions in auditory cortices. In addition, GABA levels may be altered by brain 
regions of interest, psychotropic medications, and clinical stage in schizophrenia and bipolar 
disorder. 
 
Key words: Schizophrenia, Bipolar Disorder, GABA, Magnetic Resonance Spectroscopy, 
Auditory Cortex 
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8 
 
1. Introduction 
Several lines of evidence have converged that as an inhibitory neurotransmitter, Gamma-Amino 
Butyric Acid (GABA) neurotransmission serves for network integrity by facilitating neural 
synchronization in the brain (Bartos et al., 2007). Postmortem studies have shown abnormalities 
in GABAergic cells (Benes and Berretta, 2001; Ishikawa et al., 2005; Mizukami et al., 2000) 
and these findings suggested that disturbances in the early phases of brain development may 
lead to abnormalities of GABAergic neurotransmission possibly causing dysregulation in the 
inhibitory and excitatory neurotransmission in cortical circuitries (Benes and Berretta, 2001). 
Disturbed GABAergic neurotransmission may lead to abnormalities in integrative brain 
functions and cognitive dysfunction (Gonzalez-Burgos et al., 2011).  
Irregularities in GABA neurotransmission have critical roles in the pathophysiology of 
schizophrenia and bipolar disorder (Benes and Berretta, 2001). Altered RNA, protein and 
neurochemical markers of interneurons (Torrey et al., 2005), decreased number (Wang et al., 
2011) and disturbed maturation of GABAergic cells (Gandal et al., 2012) have indicated 
GABAergic dysfunction in schizophrenia and bipolar disorder. Measurements of GABA levels 
using proton magnetic resonance spectroscopy (1H-MRS) have reported altered GABA levels 
in schizophrenia (Öngür et al., 2010; Wijtenburg et al., 2015) and bipolar disorder (Bhagwagar 
et al., 2007; Brady et al., 2013; Kaufman et al. 2009). However, the findings are inconsistent 
possibly due to a number of reasons including different MRS methods, variability between 
brain regions of interest, medication effects and clinical course [10]. Most studies have focused 
on frontal, prefrontal, parietal or occipital cortices, medicated patients and clinically remitted 
patients, and all of these factors, including brain regions of interest, psychotropic medications, 
and clinical stage, may have significant effects on GABA levels.  
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The auditory cortices have a long and delicate developmental trajectory (Moore, 2002), which 
is vulnerable to the pathophysiology of schizophrenia and bipolar disorder (Mccarley et al., 
2002). Since auditory hallucinations are one of the most frequent symptoms of schizophrenia 
and abnormalities of the auditory cortices are associated with hallucinations (Jardri et al., 2011), 
auditory cortices are among the most relevant brain regions in schizophrenia. In a recent 1H-
MRS study, we have detected metabolic abnormalities within the left hemisphere superior 
temporal lobe in both schizophrenia and bipolar disorder (Atagun et al., 2015). Neural 
synchronization deficits with auditory tasks may indicate GABAergic abnormalities in auditory 
cortices in bipolar disorder and schizophrenia (Atagun, 2016). In addition, a recent 1H-MRS 
study report decreased GABA levels in the left perisylvian cortices in autism, this is consistent 
with the theory of excitatory-inhibitory balance dysregulation in autism spectrum disorders 
(Rojas et al., 2019).  
In this study, we aimed to investigate GABA levels within the auditory belt and parabelt regions 
located around the Sylvian (Lateral) Fissure, which host primary and association auditory 
cortices. To our knowledge, this is the first study that measure GABA levels at the perisylvian 
structures in schizophrenia and bipolar disorder. Since there are abnormalities in excitatory 
neurotransmission and GABAergic cells (Bernstein et al., 2015), we hypothesized that GABA 
levels might be altered in schizophrenia and bipolar disorder. 
2. Materials and methods 
2.1. Participants 
The local Ethical Committee of Ankara Yıldırım Beyazıt University Medical School has 
approved the study. All participants provided written consent after the study procedures were 
fully explained. Remitted patients with schizophrenia (n=25), bipolar I disorder (BD-I) (n=28), 
bipolar II disorder (BD-II) (n=20) and a healthy control group (HC) (n=30) were enrolled. 
Socio-demographic features are presented in Table 1. Exclusion criteria were history of brain 
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8 
damage or surgery, MR incompatible metallic implants or prosthesis, systemic diseases, 
hearing disability, lifetime history of psychiatric comorbidity and/or substance abuse. All 
medications were allowed except benzodiazepines. The following clinical evaluations were 
administered by MIA: Structured Clinical Interview according for the DSM-IV (SCID-I) (First 
et al., 1996), Young Mania Rating Scale (YMRS) (Young et al., 1978), Hamilton Depression 
Rating Scale (HDRS) (Hamilton, 1960), Scale for the Assessment of Positive Symptoms 
(SAPS) (Andreasen, 1984), Scale for the Assessment of Negative Symptoms (SANS) 
(Andreasen, 1983) and Brief Psychiatric Rating Scale (BPRS) (Overall, 1962). All subjects 
completed an MR data acquisition session immediately following the clinical evaluations.  
2.2. Magnetic Resonance Imaging Data acquisition 
Data were acquired on a 3.0 Tesla Siemens MAGNETOM TIM Trio whole-body MR system 
(Siemens, Erlangen, Germany) with a thirty two-channel phased-array head coil at the 
UMRAM National Magnetic Resonance Research Center, Ankara, Turkey. T1-weighted 
anatomical MRI (MPRAGE sequence, 256 X 256 voxels, TR: 2000 msec, TE: 3.02 msec, FOV 
read: 215, FOV phase: 100, slice thickness: 0.84, 192 slices) were collected for diagnostic and 
localization purposes. Proton Magnetic Resonance Spectroscopy (1H MRS) data was acquired 
using the single voxel Point REsolved Spectroscopy Sequence (PRESS) (TE = 30 msec, TR = 
2000 msec) to quantify brain creatine (Cr) levels and MEscher-GArwood Point-REsolved 
Spectroscopy Sequence (MEGAPRESS) (Mescher et al., 1998; Waddell et al., 2007) (TE = 68 
msec, TR = 2000 msec) to quantify brain GABA levels. Voxels (PRESS: 20 mm X 20 mm X 
20 mm; MEGAPRESS: 30 mm X 30 mm X 20 mm) were placed in the structures around 
Sylvian Fissure including superior temporal lobe and inferior parietal lobe.  
2.3. Magnetic Resonance Imaging Data analysis 
The proton spectra were fit using LCModel (Version 6.3.0) to quantify the creatine levels 
(Provencher, 1993; Provencher, 2001) and GANNET software to quantify the GABA-to-
 187 
P
E
R
IS
Y
L
V
IA
N
 G
A
B
A
 L
E
V
E
L
S
 IN
 S
C
H
IZ
O
P
H
R
E
N
IA
 A
N
D
 B
IP
O
L
A
R
 D
IS
O
R
D
E
R
 
8 
creatine ratio (GABA/Cr) (Dydak et al., 2010; Edden et al., 2007; Edden et al., 2013; Zhu et 
al., 2011; Sikoglu et al., 2015; Cochran et al., 2015). The structural T1-weighted images were 
segmented using SPM8 [Statistical Parameter Mapping– Welcome Department of Imaging 
Neuroscience, London, UK; (http://www.fil.ion.ucl.ac.uk/spm/software/spm8/)] to determine 
the gray matter, white matter and CSF contributions to the voxel of interest. Absolute Cr values 
(Jardri et al., 2011) were corrected for voxel tissue content and then multiplied with the GABA-
to-Cr to determine the absolute GABA levels (Chowdury et al., 2014). 
2.4. Statistical Analysis 
Statistical analyses were performed using SPSS 22.0 software (Chicago, Illinois, USA). Outlier 
analysis was conducted and GABA values two standard deviations away from the mean of the 
corresponding groups were eliminated from further analysis. Chi-square test was used for the 
comparison of categorical variables. Shapiro-Wilk’s tests for normality were performed for 
continuous variables. Two tailed independent samples t-test or Mann-Whitney U test were used 
for comparisons between independent groups. Group comparisons including more than two 
groups were performed by Univariate ANOVA or Kruskal-Wallis tests. Mann-Whitney U tests 
were performed for post-hoc comparisons after Kruskal-Wallis test. Since we had 4 groups and 
performed 6 Mann-Whitney U tests for posthoc comparisons between groups, we determined 
significance level as 0.0083 (0.05 / 6 = 0.0083) according to Bonferroni correction. In addition, 
Pearson’s correlation analysis was performed to determine the relationship between GABA 
levels and clinical assessments.  
3. Results 
The demographic and clinical characteristics of the sample are listed in Table 1. There were no 
significant demographic differences in sociodemographic variables. All patients were clinically 
stable. However, schizophrenia patients scored significantly higher than the bipolar disorder 
groups on BPRS (F(2,63)=21.76, p<0.0001). 
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Table 1. Clinical characteristics of the participants. 
 SZ 
(n = 25) 
BD-I  
(n = 28) 
BD-II  
(n = 20) 
HCs  
(n = 30) 
F/χ²/t P 
Age (Years) 38.4 ± 13.25  35.32 ± 9.13 38.85 ± 
14.03 
32.77 ± 
10.65 
1.58 0.207 
Sex (M) 13 13 9 13 0.44 0.931 
Education 9.16 ± 3.85 10.89 ± 4.85 12.40 ± 3.95 12.20 ± 
3.36 
2.67 0.052 
Age at Onset of Disorder 
(years) 
22.58 ± 6.89 23.57 ± 8.66  24.85 ± 9.86  0.389 0.679 
Duration of Disorder 
(months) 
142.54 ± 
130.37 
95.21 ± 
107.69  
156.85 ± 
127.86 
 1.95 0.151 
Number of Hospitalizations 1.36 ± 1.77 1.36 ± 1.76 0.40 ± 0.68  2.20 1.18 
N
u
m
b
er
 
o
f 
E
p
is
o
d
es
 
Total   7.82 ± 5.64 8.68 ± 7.00  -
0.474 
0.638 
Manic*  2.77 ± 2.18 3.63 ± 3.56  -
1.006 
0.320 
Depressive  4.22 ± 3.42 4.95 ± 4.26  -
0.639 
0.526 
BPRS 8.00 ± 4.41 2.43 ± 2.86 2.25 ± 1.77  24.51 < 
0.001 
YMRS  1.07 ± 1.61 1.55 ± 1.50  -
1.044 
0.302 
HDRS  3.46 ± 3.51 3.35 ± 3.28  0.114 0.910 
SAPS Total 11.52 ± 6.90      
SANS Total 13.28 ± 9.04      
SZ: Schizophrenia, BD-I: Bipolar I Disorder, BD-II: Bipolar II Disorder, HCs: Healthy 
Controls, BPRS: Brief Psychiatric Rating Scale, HDRS: Hamilton Depression Rating Scale, 
SANS: Schedule for the Assessment of Negative Symptoms, SAPS: Schedule for the Assessment 
of Positive Symptoms, YMRS: Young Mania Rating Scale. * Hypomania for the Bipolar II 
Disorder.  
 
GABA levels at the right hemisphere significantly differed between the groups [χ²=9.62, df: 3, 
p=0.022] (Table 2). Posthoc comparisons revealed that GABA levels in the schizophrenia group 
were significantly higher than the BD-I (p=0.02), BD-II (p=0.02) and HC (p=0.002, Z=-3.08) 
groups (Figure 1). Difference between the groups was significant only between schizophrenia 
and HC after Bonferroni correction (p=0.002). There were no significant differences in the left 
hemisphere GABA levels between the groups [χ²=1.63, df: 3, p=0.652] (Table 2). GABA levels 
did not differ between the hemispheres within each group (p>0.05). 
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Figure 1. GABA levels in groups. There was significant difference between groups at right 
hemisphere. Schizophrenia group had significantly higher GABA levels in comparison to 
healthy controls. There was no significant difference between groups at left hemisphere. BD-I: 
Bipolar I Disorder, BD-II: Bipolar II Disorder, SZ: Schizophrenia, HC: Healthy Controls. 
GABA levels are in international units (IU). 
 
 
Table 2. GABA concentrations. 
 SZ BD-I BD-II HCs χ² (df) P 
Left GABA 0.12 (0.11 - 0.17) 0.11 (0.09 - 0.14) 0.13 (0.11 - 0.16) 0.12 (0.10 - 0.14) 1.63 (3) 0.652 
Right GABA 0.23 (0.20 - 0.27) 0.18 (0.16 - 0.22) 0.18 (0.15 - 0.21) 0.18 (0.15 - 0.20) 9.62 (3) 0.022 
Kruskal-Wallis Test. Median (25-75 percentiles) values are reported. SZ: Schizophrenia, BD-
I: Bipolar I Disorder, BD-II: Bipolar II Disorder, HCs: Healthy Controls. 
 
Patients with schizophrenia were on significantly more atypical anti-psychotics than the BD-I 
or BD-II groups (χ²(2,73)=8.874, p<0.012) (Table 3). Chlorpromazine equivalents of 
antipsychotic doses were correlated positively with right hemisphere GABA levels (r2=0.68, 
p=0.006, n=33: schizophrenia, BD-I and BD-II groups). Serum valproate levels correlated 
positively with left hemisphere GABA levels (r2 =0.8, p=0.016, n=14: BD-I and BD-II groups).  
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Table 3.Medication statuses of the patient groups. 
 SZ 
(n = 25) 
BD-I  
(n = 28) 
BD-II  
(n = 20) 
χ²/Z P 
Atypical 
Antipsychotics (n) 
22 14 12 8.87 0.012 
Chlorpromazine 
Equivalent (mg) 
225 (145.75 - 
400) 
267 (133 - 400) 150 (50 - 267) 
6.39 
(2) 
0.041 
Lithium (n) 0 11 10 0.54 0.461 
Serum Lithium Levels 
(mEq/L) 
 
0.70 (0.45 - 
0.85) 
0.70 (0.45 - 
0.85) 
-0.47 0.658 
Valproate (n) 0 11 7 -0.86 0.650 
Serum Valproate 
Levels (mcg/ml)  
 72.2 (56 - 99.35) 
57.3 (44.8 - 
83.6) 
0.91 0.386 
Kruskal-Wallis test, Chi-square test and Mann-Whitney U test. Median (25-75 percentiles) 
values are reported. In the post-hoc comparisons of the chlorpromazine equivalent doses of 
antipsychotics, there were no significant differences between the groups.  
 
There was a correlation between left hemisphere GABA levels and the alogia subscale of the 
SANS (r2=0.8, p<0.05, n=10). There was no significant correlation between GABA levels and 
YMRS (r 2=0.48, p=0.158, n=39) however, there was a trend for a negative correlation with 
HDRS (r2=0.53, p=0.08, n=39) in the bipolar disorder groups. 
 
4. Discussion 
GABA levels in the right perisylvian structures were higher in schizophrenia patients in 
comparison to bipolar disorder and healthy control groups. There was positive correlation 
between antipsychotic medications and GABA levels at right hemisphere. Previous 1H-MRS 
studies have reported inconsistent results regarding GABA levels in schizophrenia. In first 
episode psychosis patients, GABA levels were lower within left basal ganglia (Goto et al., 
2010) and bilateral calcarine sulci (Kelemen et al., 2013) and approximately the same within 
frontal and parieto-occipital lobes (Chowdury et al., 2014) in comparison to healthy controls. 
Moreover, a study comparing young schizophrenia patients and healthy controls reported that 
GABA levels were lower within anterior cingulate region for the schizophrenia patients and 
same within centrum semiovale (Rowland et al., 2013). Whereas in chronic schizophrenia 
patients, GABA levels were higher within anterior cingulate and parieto-occipital cortices [9], 
and normal within anterior cingulate cortex and left basal ganglia regions (tayoshi et al., 2010). 
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Variations of the GABA levels might be due to differences in brain regions, psychotropic 
medications, and clinical states in the previous 1H-MRS studies (Wijtenburg et al., 2015; Brady 
et al., 2013; Maddock and Buonocore, 2012). 
The balance of the excitatory and inhibitory impulses may determine the GABAergic cell 
activity (Bernstein et al., 2015; Brix et al., 2015). Correlation between GABA and glutamate 
layers in prefrontal cortices (Brix et al., 2015) might be an indicator of the relationship between 
excitatory and inhibitory neurotransmission. Since the excitatory neurotransmission is degraded 
in neurodevelopmental disorders, activity of the GABAergic cells and GABA levels might be 
altered in order to protect the balance between excitatory and inhibitory neurotransmission 
(Brix et al., 2015; Ramamoorthi and Lin, 2011; Ren et al., 2012).  
In addition, GABA receptors are highly susceptible to rapid neuroplastic changes and various 
mechanisms such as phosphorylation of synaptic proteins (Stelzer et al., 1986). These findings 
are suggestive of dynamic modulation of GABAergic neurotransmission according to the 
dynamics of the synapse or the network. Taken together, these findings may also explain the 
variability of GABA levels reported in previous studies using 1H-MRS, as GABA 
neurotransmission is modulated by several clinical factors prone to rapid changes. On the other 
hand, GABA receptors are often not saturated (Cohen et al., 2000) and therefore the determinant 
of GABAergic signaling is synthesis of GABA from glutamate (Lazarus et al., 2015). 
Therefore, activity level of the enzyme glutamic-acid decarboxylase (GAD) 65 and 67 
isoenzymes, which catalyze the rate limiting step of GABA synthesis, determine the level of 
GABAergic activity. Although postmortem studies have reported decreased expression of 
GAD67 (Lewis et al., 2005), several long term modulations may also alter GABAergic 
signaling as well as short term changes (Sigel and Steinman, 2012) and deficiency of GAD67 
might be compensated upon long term modulations (Lazarus et al., 2015).  
Abnormalities in the left hemispheric auditory cortices are associated with linguistic functions 
and specific symptoms of psychotic spectrum disorders (Mccarley et al., 2002; Jardri et al., 
2011; Atagun et al., 2015; Atagun, 2016) and developmental disorders (Rojas et al., 2016). 
However, GABA levels were higher in right hemisphere in schizophrenia and were positively 
correlated with antipsychotic doses. This finding suggests that antipsychotics could have 
enhanced GABA levels only at right hemisphere and could not enhanced left hemisphere 
GABA levels due to a stronger neuropathology in left hemisphere. In addition, valproate serum 
levels were correlated with GABA levels at right hemisphere in bipolar disorder. This is in line 
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with a previous study [8], which has reported that mood stabilizer anticonvulsants adjunctive 
to antipsychotics have increased GABA levels at parieto-occipital lobe in schizophrenia. On 
the other hand, studies investigating the relationship between antipsychotics and GABA levels 
have been indicated both decrease (Tayoshi et al., 2010; Mao, 2012) and no effect (Öngür et 
al., 2011; Goto et al., 2010) in schizophrenia, as a result of the medication. Further controlled 
studies with specific designs to investigate the effects of medications on GABA levels are 
needed to obtain more consistent and reliable results using 1H-MRS. A current concept suggests 
that antipsychotics may restore the disturbances (disrupted myelination, reverse the loss of 
dendritic spines, enhance synaptic connections) of the excitatory neurotransmission that 
projects to GABAergic cells and stimulate oligodendrocyte maturation (Mao, 2012) and 
increase the efficiency of GABAergic cells (Bernstein et al., 2015). To this end, antipsychotics 
may ameliorate the pathology of the GABAergic cells in schizophrenia and bipolar disorder. 
However, it is not possible to predict the ultimate effects of antipsychotics on GABAergic 
functions currently, as there are several other determinants for GABAergic functions (such as 
excitatory/inhibitory balance, receptor phosphorylation, ion channel physiology), but yet 
GABA level is currently the only measurable in vivo response of the cell.   
Although cortical GABA content as quantified by 1H-MRS has been found to predict the 
functional status of GABA-mediated processes in previous neurophysiology and 
pharmacological studies (Maddock and Buonocore, 2012), normal GABA levels do not imply 
regulated GABAergic function. Determinants of GABA levels and mechanisms of 
compensatory changes in GABAergic activity are future directions for further clarification of 
GABAergic abnormalities in schizophrenia and bipolar disorder. While 1H-MRS utilizing 
edited pulse sequences such as MEGAPRESS is considered a reliable and reproducible method 
for measuring brain GABA (Bogner et al. 2010), 1H-MRS cannot discriminate between intra 
and extracellular GABA levels. Therefore, these results should be viewed cautiously.  
To conclude, higher GABA levels observed in the right auditory cortex of schizophrenia 
patients could be a compensatory mechanism to obtain the balance between excitatory and 
inhibitory impulses in the cerebral cortex. Due to pharmacological and physiopathological 
influences on this balance, in this investigation, we may be capturing a certain phase of GABA 
metabolism that could be modulated in a dynamic process. Dynamic modulation of the 
GABAergic activity might be the underlying reason of the variable results of the 1H-MRS 
studies measuring GABA levels. 
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Despite the advances in science, the pathophysiology of bipolar disorder (BD) is still unknown 
and it is still a debilitating disease. Scientists discussed the diagnostic classification systems of 
psychiatric disorders, criticized their phenotypic definitions, and highlighted the need for more 
precise phenotypic traits like biological markers (or biomarkers).  Electroencephalography 
(EEG), magnetic resonance imaging (MRI) and spectroscopy (MRS) are promising methods in 
identifying the fingerprints of the disease mechanisms and thus biomarkers in psychiatric 
disorders. However, the brain is a sophisticated system in its structure and function and hence 
determining a valid and reliable biomarker is a complex process. In respect to current 
knowledge at the molecular and the circuitry level, it would be over-optimistic to expect a single 
biomarker in BD. However, potential biomarkers might be utilized for both clinical and 
research purposes, such as screening subjects with high risk or manifest symptoms. Biomarkers 
can also be utilized to examine pharmacological processes, such as treatment response or side 
effect monitoring in neurological and psychiatric diseases. In this thesis, EEG and 1 H-MRS 
were the focus of study as potential biomarkers in BD.  
Brain Oscillations in Bipolar Disorder 
Neurons synchronize their discharges in the same oscillatory rhythm to facilitate neuronal 
synchronization, and thereby, to establish networks. Strong links between synchronized 
oscillations and higher cognitive functions promoted research on neural synchronization in 
neuropsychiatric disorders (Uhlhaas and Singer, 2006). Several resting-state or task-based EEG 
studies have been performed in BD. However, the findings have not been consistent, 
particularly because of confounding factors, such as medication. I aimed to assess event-related 
oscillations in medication-free patients with BD in order to circumvent such factors (Chapters 
2 and 3).  
In Chapter 2, event-related theta oscillations were examined in patients with BD. In the Fourier 
transformed EEG, signal by Power Spectrum analysis showed two different resonances with 
two different peaks within the theta frequency range (Figure 1 in Chapter 2). Accordingly, the 
signal was dissected into 4-6 Hz and 6-8 Hz ranges and two theta bands were obtained. In both 
frequency ranges, patients had significantly lower amplitudes in comparison with healthy 
controls at frontal, central and temporal electrodes in the responses of event-related stimuli. In 
evoked oscillations, patients had significantly lower amplitudes at frontal, central, parietal and 
temporal electrode locations. These findings showed synchronization deficits in theta frequency 
range in BD. Theta frequency reflects functional integration of medial temporal and frontal 
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brain structures into coherent neurocognitive networks (Başar, 1999; Klimesch, 1999; von Stein 
and Sarnthein, 2000). The neocortical loops are driven to oscillate at theta frequency by the 
orchestration of the hippocampus. The brain processes novel information in collaboration with 
memory, which depends on the continuous dialogue between the hippocampus and relevant 
parts of the cortex. Hippocampal theta oscillations are one of the rare sustained rhythms within 
this concept. There are correlations between theta oscillations and cognitive performance, in 
particular learning and memory (Klimesch, 1999). Thus, altered theta responses are likely to 
represent neurophysiologic correlates of cognitive deficits, in particular memory disturbances 
(Sakowitz et al., 2000). 
Delta waves are slow in frequency (0.5-4 Hz) but high in amplitude. Spontaneous delta activity 
is typically observed in deep sleep (stage 3 and 4) and disappears in conscious states in the adult 
brain. Functional delta oscillations are also implicated in the synchronization of brain activity 
with autonomic functions, in motivational processes associated with both reward and defensive 
mechanisms with higher emotional involvement, and in cognitive processes related to attention 
and the detection of motivationally salient stimuli in the environment (Knyazev, 2012). In 
addition to homeostatic mechanisms, it is now known that delta oscillations are also related 
with cognitive functions [attention and memory] (Harmony, 2013) and executive functions 
(Nacher et al., 2013). Evoked and event-related delta oscillations (0.5 - 3.5 Hz) in medication-
free patients with BD are presented in Chapter 3. Event-related delta oscillations were 
significantly lower in all brain regions in the BD group in comparison with the healthy control 
group. These findings indicate a synchronization deficit in cognitive tasks in patients with BD. 
Delta oscillations are diminished in other neuropsychiatric disorders including schizophrenia 
(Doege et al., 2010; Ergen et al., 2008) and Alzheimer’s Disease (Yener et al., 2008; Yener et 
al., 2012), which are related with cognitive dysfunction. Therefore, the decrease in event-related 
delta oscillations are proposed to be a common feature of cognitive dysfunction in 
neuropsychiatric disorders (Guntekin and Basar, 2016). One of the most important differences 
between delta and theta oscillations are the networks they use. Major differences between their 
networks are that delta oscillations are associated with the thalamus and the brain stem, whereas 
theta oscillations originate from the hippocampus. Delta oscillations are associated with 
attention-related processes, whereas theta oscillations are associated with learning- and 
memory-related processes.   
The relationship between the cognitive task-based (event-related oscillations) EEG studies and 
neurocognitive performance remains an intriguing question. If the task is able to represent a 
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particular cognitive function (e.g. working memory or attention-related processes) than results 
should be parallel to other tests examining the same cognitive function. However, previous 
studies investigating the relationship between cognitive performance and brain oscillations had 
limitations and results were inconsistent (Reinvang, 1999). Previous research also showed that 
there was no direct association between neurocognitive assessment and event-related potentials 
in schizophrenia or BD (Kim et al., 2019). It might be due to the methodological limitations in 
examining cognitive functions or cognitive tasks used in EEG studies, such as ceiling effects. 
Human brain computation is complex, because there are several interactions between multiple 
parallel loops. A multitude of confounds make it difficult to reveal the causal association 
between behavioral outcomes and a specific brain oscillation. Brain oscillations have multiple 
functions and act as codes or operators for synchronous activity of neuron populations that 
determine large-scale organization of the brain web. In addition to the frequencies of brain 
oscillations, amplitudes, duration, time locking, and phases are other characteristics that 
determine the functions of brain oscillations (Basar et al., 1999). Further studies should be 
designed to assess other characteristics of brain oscillations and their relationship between 
psychiatric and cognitive symptoms in BD.  
Spontaneous brain functions and evoked or event-related potentials are synchronized activities 
of brain networks. Most psychotropic drugs influence neurotransmitter systems or ion channels, 
and consequently, alter neuronal firing patterns. Pharmacological EEG studies have reported 
that almost all medications have specific effects on evoked and event related potentials, as well 
as on resting state activity in EEG. Effects of lithium were investigated with resting state EEG 
studies or evoked potential studies (Atagun, 2016). Task-based studies may also contribute to 
our knowledge, since tasks are related with specific neural mechanisms.  In Chapter 4, effects 
of lithium in auditory event-related beta oscillations were reported. Power spectrum analysis 
showed that the lithium group had significant increase around 20 Hz. The lithium group had 
significantly higher beta oscillations in comparison with the healthy control group and 
medication free patients with BD. Furthermore, serum lithium levels were correlated with 
amplitudes of beta oscillations in patients with BD. It was later reported that visual event related 
beta oscillations are increased in BD on lithium therapy compared with medication free patients 
with BD and healthy controls (Tan et al., 2016). Together with our study, findings of Tan and 
colleagues (Tan et al. 2016) support widespread brain effects of lithium. Even though the 
networks of the visual system are different from the networks of the auditory system, similar 
patterns in beta responses show that lithium is involved with a mechanism that is independent 
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of the sensory system. Correlation between serum lithium levels and amplitudes of event-
related beta oscillations might be an important finding for future studies which might be related 
with pharmacological or biophysical mechanisms such as cortical excitability (Atagun, 2016).  
Elevated background brain activity leads to increased signal-to-noise ratio (SNR) and thus 
enhanced baseline EEG activity in schizophrenia and BD. This alteration is more evident in 
medication free patients and γ-aminobutyric acid (GABA) or glutamatergic dysfunction is 
suggested to be one of  the explanations (Gandal et al., 2012). It is considered that lithium 
decreases SNR values by inhibiting presynaptic alpha-2 receptors (Lenox and Hahn, 2000). 
Moreover, lithium stimulates neuroplasticity, which in turn drives networks to oscillate at beta 
oscillations instead of gamma oscillations. Another reason for enhanced beta oscillations in the 
lithium group might be an excessive activation of the neuron groups in cognitive networks. In 
addition, considering that atypical antipsychotics (Ren et al., 2013) and lithium (Meffre et al., 
2015) stimulate the maturation of oligodendrocytes, along with the synthesis and maturation of 
myelin, it is possible that these drugs provide better GABAergic activity, and thus, potentiate 
fast frequency oscillations. Further studies may evaluate clinical responses to lithium and 
effects of lithium on brain oscillations, as there were associations between serum lithium levels 
and amplitudes of event-related beta oscillations (Atagun et al., 2015a). 
Sensory gating (SG) is defined as the reduction of the irrelevant stimuli from the environment 
by the elimination of unattended stimuli. SG can be examined with the auditory dual-click 
paradigm in EEG. Reduction of the amplitude of the second stimulus is thought to be related to 
the gating function and the dysfunction of SG may lead to cognitive disruption and functioning 
(Freedman et al., 1983). Several studies have shown dysfunction of SG mechanism in BD 
(Cheng et al., 2016). In Chapter 5, a meta-analysis of P50 SG studies was performed in order 
to determine the effects of diagnosis, number of episodes, and medications in BD and 
schizophrenia. Our results showed that SG ratio (S2 amplitudes/S1 amplitudes) and SG 
difference (S1 amplitudes-S2 amplitudes) were significantly altered in schizophrenia and BD 
patients, and their first-degree relatives. There was no significant difference between 
schizophrenia and first-episode psychosis; however, there was significant difference between 
acute episodes and remission in BD. Medication improved P50 SG alterations significantly in 
schizophrenia, whereas trend-level changes were observed in BD. Within BD patients, no 
significant difference was observed between patients with or without psychotic symptoms. 
These results showed that medications improved SG alterations in schizophrenia and this is in 
agreement with an earlier hypothesis (Freedman et al., 1983). Although more evidence is 
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needed for confirmation, medication seems to improve SG in patients with BD. Heterogeneity 
could not be explained by the effects of modifiers such as medication status, diagnostic groups, 
stimulus duration, and stimulus intensity, and the results remained heterogeneous. Although the 
findings might be influenced by the heterogeneity of the sample to a degree, it can be suggested 
that SG is a pertinent measure of illness state in schizophrenia and BD. Medicated and 
medication-free patients were compared in this study and mixed medication groups were 
pooled. In order to explore the specific effects of different psychotropic medications, specific 
designs are needed. Future studies may also assess the longitudinal course of SG alterations in 
mental disorders and their relationship to clinical aspects.    
Neurochemistry of Auditory Cortices in Bipolar Disorder 
The auditory cortices are located on superior temporal lobes (STL), which have been associated 
with auditory hallucinations (Dierks et al., 1999; Shinn et al., 2013) and thought disorders 
(Seese et al., 2011; Shenton et al., 1992) in schizophrenia. Both postmortem studies (McNamara 
et al., 2014; Nudmamud et al., 2003) and MRI studies (Modinos et al., 2013; Vita et al., 2012) 
reported volumetric loss in STL in patients with schizophrenia. Longitudinal studies have 
shown progressive volumetric changes in the STL in schizophrenia (Vita et al., 2012). 
Furthermore, volumetric changes were related with alterations in amplitudes of the P300 
potentials (Salisbury et al., 1998) and mismatch negativity (MMN) reduction (Salisbury et al., 
2007). These findings consistently showed that the STL is a highly relevant brain region for 
schizophrenia as well as auditory hallucinations. The research domain criteria (RDOC) 
approach encourages using symptom dimensions as phenotypes instead of the current 
diagnostic categories (Cuthbert, 2014; Keshavan and Ongur, 2014). Accordingly, auditory 
hallucinations might be a transdiagnostic symptom domain related with a specific mechanism 
and anatomical localization. The STL is a relevant brain region for auditory verbal 
hallucinations even in non-clinical populations without psychiatric diagnosis (Linden et al., 
2011).  
Converging evidence suggests that STL is also a relevant brain region for BD, similar to 
schizophrenia.  Auditory hallucinations, cognitive symptoms such as verbal learning/memory 
deficits, and speech abnormalities such as disorder of associations or accelerated speech 
indicate abnormalities in auditory cortices in BD. Since thoughts are formed by words and their 
semantic representations, they are associated with linguistic functions. Moreover, STLs host 
auditory cortices that are important components of language-related networks. Significant 
cortical thinning in the superior temporal lobes (Hanford et al., 2016), as well as auditory 
 204 
D
IS
C
U
S
S
IO
N
 
9 
processing deficits in functional studies (Chitty et al., 2013) suggest abnormalities in the STL 
in BD.  Postmortem studies of BD patients also revealed metabolic abnormalities within the 
STL, such as reduced levels of fatty acids, linoleic acid, arachidonic acid (McNamara et al., 
2014), and N-acetylaspartate (NAA)  (Nudmamud et al., 2003). Because no study has assessed 
neurochemistry of BD, we studied neurochemistry in superior temporal gyrus (STG) with 1H-
MRS in schizophrenia and BD type I comparatively (Chapter 6). A point-resolved 
spectroscopy sequence (PRESS) was applied around the voxel as implemented to the 3.0 Tesla 
MR system with a thirty-two channel phased-array head coil, and metabolites levels were 
quantified. The basis set used for this study included alanine, aspartate, creatine (Cr), 
phosphocreatine (PCr), GABA, glucose, glutamate (Glu), glutamine (Gln), 
glycerophosphocholine (GPC), phosphocholine (PCh), glutathione (GSH), inositol (Ins), 
lactate, NAA, N-acetylaspartyl glutamate (NAAG), scylloinositol, and taurine, as well as 
macromolecules and lipids. Total NAA (tNAA, NAA and NAAG), Glu, Glx (Glu and Gln), 
total Cr (tCr, Cr and PCr), total choline (tCh, GPC and PCh), and Ins were quantified. There 
were significant differences between schizophrenia, BD, and healthy control groups in the left 
STG but not the right STG. The schizophrenia group had lower Glu levels in comparison with 
the healthy control group and this difference was at trend level (p=0.10). The BD group had 
significantly lower levels of glutamate (p<0.001), NAA (p=0.004), Cr (p=0.008) and Ino 
(p=0.003) in comparison with the healthy control group. Moreover, the BD group had lower Cr 
(p=0.016) and Ins (p=0.001) levels in comparison with the schizophrenia group. Furthermore, 
age at disease onset, duration of disease, and medication status were covariates of the 
metabolites. Covariates affected the results for NAA levels in the left hemisphere STL. In 
addition, metabolite levels were correlated with disease severity estimates and symptoms both 
in schizophrenia and BD. Depression severity correlated with NAA, Cr and Ino in both right 
and left STL in the BD group, whereas left hemisphere glutamate, NAA and Cr correlated with 
negative and positive symptoms in the schizophrenia group.  
Our findings are in line with previous studies showing that glutamatergic metabolites are 
increased in the early phases of psychosis onset in schizophrenia but decreased in chronic, long 
term schizophrenia (Maddock and Buonocore, 2012; Poels et al., 2014). In BD, glutamatergic 
compounds are increased in acute episodes, but there were no significant changes in remission 
(Yuksel and Ongur, 2010). In this first study investigating the STL in BD, we reported for the 
first time that the left STL was a brain region related with a psychosis dimension (auditory 
hallucinations) of BD. Unfortunately, our study (Atagun et al., 2015b) did not have sufficient 
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power to analyze the relationship between the history of psychosis or hallucinations and the 
metabolite levels in the STL in the BD group. However, we compared neurochemistry in type 
I and type II BD with healthy controls in Chapter 7. BD type II patients did not have any 
metabolite differences compared with healthy controls. However, type I patients with BD had 
significantly lower levels of Glu, Glx, mI, Cr, and NAA in the left hemisphere STL compared 
with the type II BD and healthy control groups. In addition, patients with a history of psychosis 
had lower metabolite levels compared with the patients who had no history of psychotic 
episodes in this study (Atagun et al., 2018). These findings show that the STL is a critical region 
for psychosis dimension in BD.  
Although Glu levels were significantly lower in BD and schizophrenia than in healthy controls, 
no significant difference was observed in Glx levels. This finding may indicate that Gln levels 
are not decreased in BD and schizophrenia. Glu to Gln cycle serves for glutamatergic 
neurotransmission. Glial cells reuptake Glu from the synaptic cleft and convert Glu to Gln. Gln 
is transferred to neuron and converted to Glu in the neuron cytoplasm and transferred into the 
vesicle. This turn-over is maintained by glial cells and neurons together and Glu to Gln ratio is 
approximately 40/60. Glial dysfunction may disrupt the Glu-Gln balance and in turn 
glutamatergic neurotransmission in schizophrenia and BD (Maddock and Buonocore, 2012). 
Vital cellular functions might be preserved to some extent; however, glutamatergic 
abnormalities may cause dysfunction in information processing capabilities of neurons. For 
example, MMN abnormalities are related with glutamatergic abnormalities as mentioned above 
(Chitty et al., 2015; Kaur et al., 2019). Decrease of P3a amplitudes were related with Glu/Gln 
ratio (Hall et al., 2015b). Finally, auditory steady state response abnormalities in schizophrenia 
and BD are believed to be a consequence of glutamatergic abnormalities in the auditory cortices 
(Javitt, 2009).   
Cr, mI and NAA were also decreased in BD. NAA is a marker of mitochondrial function of 
oxidative phosphorylation and thus neuronal viability. Decreased levels of NAA may indicate 
neuronal dysfunction (Moffett et al., 2007). As such, Cr and phosphocreatine are phosphorous 
compounds that transfer energy and decreased levels may indicate energy scarcity in the brain 
(Maddock and Buonocore, 2012). Decreased Cr levels in BD and schizophrenia might be 
related to the dysfunction of energy metabolism in the brain (Ongur et al., 2009).  
Finally, in Chapter 8, GABA levels within the STLs and inferior parietal lobe were assessed 
in patients with schizophrenia and BD. Since voxel size of the MEGAPRESS sequence is much 
larger than the PRESS sequence, voxels contained a larger volume including STLs, and inferior 
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parietal lobes which contain auditory belt and parabelt regions (Rauschecker and Scott, 2009). 
There was no significant difference in GABA levels between schizophrenia and BD in the left 
superior temporal and inferior parietal region; however, GABA levels were increased in the 
right hemisphere. In addition, GABA levels were correlated with chlorpromazine equivalent 
doses of antipsychotics in all antipsychotic users (in all patients including schizophrenia and 
BD) and serum levels of valproate correlated with GABA levels in BD. GABAergic 
neurotransmission is dynamically modulated by several mechanisms to keep excitatory and 
inhibitory impulses in balance (Stelzer et al., 1988). Excitatory neurotransmission that stimulate 
GABAergic interneurons is improved by antipsychotics by stimulating myelin synthesis and 
maturation of the innervating neurons’ axon (Ren et al., 2013). Antipsychotics are suggested to 
ameliorate dysfunction of the GABAergic interneurons and restore GABAergic functions and 
increase efficiency of GABAergic cells. Patients of our study were all medicated and 
medication may have enhanced GABA levels in our patient groups. Since mood stabilizers and 
antipsychotics influence GABAergic function (Brady et al., 2013), further studies with 1H-MRS 
MEGAPRESS sequence are needed to evaluate GABA levels in patients with BD and 
schizophrenia and its relationship with medication.  
Abnormalities of Auditory Cortices in Bipolar Disorder 
The superior temporal lobes host primary and secondary auditory cortices. Primary auditory 
cortices consist of receptive cells that have been aligned according to a tonotopic map. 
Accordingly, sounds are processed in different fields according to their physical characteristics 
in the primary auditory cortex. Secondary auditory cortices (also called Wernicke’s Area) are 
even more complex association centers of the auditory system. The auditory system provides 
basis for complex linguistic functions in humans. Such state-of-the-art linguistic functions are 
unique to human beings in nature and the involved brain regions are highly sophisticated than 
in other species. Linguistic functions provide a basis for thought in humans and since the 
auditory cortices are components of linguistic functions, they are associated with thought 
disorders (such as delusions) as well as auditory hallucinations (Humpston et al., 2019). 
However, auditory cortices have been frequently examined in schizophrenia but rarely in BD.  
The development of auditory cortices is a long process—the maturation of the auditory network 
prolongs until late adolescence (Moore, 2002). For example, myelin sheaths of the 
thalamocortical projections to auditory cortices begin to mature in the first four years of life. 
Production of mature neurofilaments for the axonal skeleton prolong until the age of ten. 
Consistently, prolonged developmental processes neurophysiological maturation follows the 
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abovementioned developments. Particularly, event-related potentials P1 and N1 are thought to 
be related with the primary auditory cortices (Ponton et al., 2002) and since P1, N1 and P2 
responses appear around the ages of fifteen, it can be stated that the development of the auditory 
networks continue until late adolescence. Because of this slow and delicate developmental 
trajectory, auditory networks are vulnerable to neuropathological processes more than rapidly 
maturing networks, such as motor networks. As such, disruption of the brain development 
during the onset of BD (MacCabe et al., 2013; Pavuluri et al., 2009) may also transpire in the 
auditory cortices, since auditory cortices are particularly vulnerable to developmental lag. 
Taken together, anatomical location and diversity of functional assessment tools make STL an 
interesting brain region for further research in major mental disorders, including BD. Several 
lines of evidence from postmortem studies (McNamara et al., 2014; Nudmamud et al., 2003), 
neuroimaging (Atagun et al., 2019; Atagun et al., 2015b; Chitty et al., 2015; Hanford et al., 
2016; Hirayasu et al., 1998), and EEG studies (Cheng et al., 2016; Chitty et al., 2013; Hamm 
et al., 2013; Kaur et al., 2019; Parker et al., 2019) point out the STL in BD within this context.   
Conclusions, Limitations and Future Directions  
Brain oscillations under task conditions may show relationships between synchronization 
capabilities of the cognitive networks. Patients with BD exhibited reduced amplitudes in delta 
and theta oscillations. Functioning of the early auditory system can be assessed using ERPs, 
which trace sequential activation of the auditory system from brainstem through auditory 
thalamus (medial geniculate nucleus) and primary auditory cortex (A1) to auditory association 
cortices. In addition to auditory networks, cognitive task-related networks are also examined 
for their event-related synchronization capabilities in task-based EEG studies. The changes 
causing synchronization capabilities may also be related with chemical changes. Further studies 
may investigate this relationship. Three studies in BD have already employed both 1H-MRS 
and EEG and reported associations between MMN or P300 alterations and chemical changes. 
However, it is still not clear whether there is a relationship between changes in GABA levels 
and deficits in gamma oscillations; neither are the differential effects of medications on 
neurophysiology and chemistry. BD is characterized by numerous neurotransmitter 
abnormalities and cognitive dysfunction. Therefore, task-based EEG studies may provide 
information about abnormalities of these alterations. Reduced amplitudes are a common feature 
of EEG studies in both schizophrenia and BD (Atagun, 2016). These findings indicate neural 
synchronization deficits in auditory and cognitive cortices; and medications seem to alleviate 
the deficits.  
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Auditory cortices are critical areas in the cortex, since they are associated with the 
pathophysiology of auditory hallucinations. Both patients with schizophrenia and BD had 
alterations in their auditory cortices. Metabolites in the 1H-MRS are decreased in STLs in 
schizophrenia and BD. BD type I and II differed in terms of metabolites. Patients with type I 
BD had more alterations than patients with type II BD.  
There are several limitations to these studies. First of all, various potential confounders 
including medications, metabolic disturbances, obesity, nicotine, alcohol or substance use, and 
medical and psychiatric comorbidities may have affected the results. For example, daily doses 
of medications and serum levels were associated with the measurements either in EEG or 1H-
MRS. Metabolite levels were measured in a limited volume in STLs in 1H-MRS. Longitudinal 
studies might prove more informative than cross-sectional ones. Examining patients in different 
states may also shed light into state-related changes in BD. More multimodal studies that 
combine 1H-MRS and EEG should be performed in order to determine the role of specific 
metabolites in task-based EEG studies. The meta-analysis study had heterogeneity and 
publication-bias limitations. Both clinical and methodological heterogeneity limited the results.  
The EEG is an optimal tool to estimate functional processes because of its high temporal 
resolution. Event-related task-based studies showed auditory processing abnormalities in BD. 
Neurochemical alterations in the auditory cortices might be related with the auditory processing 
deficits in BD. Pharmacological modulations could be monitored by EEG and neuroimaging 
modalities. For example, lithium induced EEG changes are promising biomarkers for BD. 
Classical analysis techniques might be improved by artificial intelligence  methods such as 
machine learning approaches. Clinical utility as biomarkers might be possible with such 
improved analysis techniques. Future studies with longitudinal designs and larger sample sizes 
may identify causal relationships.  
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Summary 
In chapter 1, electroencephalography (EEG) and magnetic resonance imaging (MRI) are 
introduced as promising methods for identifying the fingerprints of pathophysiological 
mechanisms and thus biomarkers in psychiatric disorders. Pathophysiological mechanisms of 
bipolar disorder (BD) were summarized. Potential biomarkers might be candidate 
monitorization tools for both clinical and research purposes, such as screening high risk subjects 
or those with progression of the symptoms. Pharmacological processes (e.g. treatment response 
or side effect monitorization) can also be assessed in neurological and psychiatric diseases. The 
major advantage of the EEG is its high temporal resolution and researchers concentrated on 
cognitive dysfunction and corresponding imaging findings as candidate biomarkers in BD 
(Pavuluri, 2010). Studies were designed to assess the relationship between cognitive symptoms 
and brain structure and cognitive tasks have been utilized for functional assessments.  
Chapter 2 and 3 present the examination of cognitive alterations in BD. In cognitive task-based 
EEG studies, event-related potentials (ERP) are obtained. ERPs are higher in energy compared 
with evoked potentials and this indicates that higher number of neuron groups is involved with 
cognitive function. The oddball paradigm is a very simple working memory task that minimizes 
the risk of confounds. Two types of stimuli (1500 and 1600 Hz) are presented and the subject 
is asked to discriminate the stimuli and count the rare one (target stimulus, 1600 Hz) mentally. 
Attention and mental counting processes enhance the voltage of the target ERPs. In 
neuropsychiatric disorders characterized with neurocognitive impairment, voltage reductions 
are observed (Chapter 2 and 3). Voltage reductions may result from either non-responding 
neural units or reduced synchronization capabilities in the neural circuits involved with 
cognitive demands of the task. Congruent with this, long range fronto-temporal connectivity 
was reduced in BD (Ozerdem et al., 2011).  
In addition to the examination of neural network synchronization capabilities, the EEG can be 
utilized to assess pharmacological processes such as treatment response. Chapter 4 presents the 
lithium induced changes in beta oscillations in BD. Lithium is the gold standard treatment drug 
for BD, whose mechanism of effect is not clearly known. Although lithium is more effective in 
high doses, its therapeutic range is narrow and serum levels are tightly checked in order to avoid 
its side effects. Lithium is an element and has biophysical and pharmacological properties. 
Several EEG studies are published but neither of them were cognitive task based studies. I 
wanted to evaluate the effects of lithium on cognitive networks. We found that lithium 
excessively enhances event-related beta oscillations upon auditory oddball paradigm (Atagun 
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et al. 2015). In a later study, we also found that lithium also enhances event-related beta 
oscillations upon visual oddball paradigm (Tan et al. 2016). Our interpretation was that, the 
effect of lithium on cognitive networks is cortex-wide and rather than a general enhancement 
of cortical excitability, it activates neurons to participate in cognitive activity specifically upon 
target response (Atagun, 2016). Interestingly, the enhanced amplitudes of the beta responses 
were correlated with the serum levels of lithium. More studies are needed to evaluate the effects 
of lithium on brain oscillations in order to determine their relationship between treatment 
response and possible side effects.  
Chapter 5 presents a meta-analysis of P50 sensory gating studies in schizophrenia and BD. 
Sensory gating is a measure of the integrity of the brain’s inhibitory function. It is measured by 
using the amplitude of the evoked potential at 50 ms to the first of two paired clicks, divided 
by the response to the second. Sensory gating is altered in both schizophrenia and BD and their 
first degree relatives (Chapter 5). Moreover, sensory gating is even more altered in the episodes 
of the diseases and medications seem to reverse the alteration. Therefore, P50 sensory gating is 
a potential biomarker for both schizophrenia and BD, since it is coherent with the progress of 
the diseases.  
Chapters 6 and 7 present proton magnetic resonance imaging (1H-MRS) studies in patients with 
BD. The 1H-MRS in vivo measures major metabolites such as glu, NAA, mI, Cr and Cho in the 
brain. Glu is an amino-acid neurotransmitter and is abundant in the brain. Its cycle as a 
neurotransmitter is provided by glial cells and dysfunction of the glia may disrupt this process. 
NAA is a marker of viability in neurons. Cr is related with the energy metabolism, Cho is related 
with membrane turn-over, and mI is a compound involved with the inositol cycle. Several 
studies were performed and it was found that glutamate levels were increased in BD. Other 
studies showed that Cr levels were altered in BD (Ongur et al., 2009). Most of the studies were 
performed in frontal and anterior cingulate cortices (Maddock and Buonocore, 2012). However, 
although BD is characterized by speech abnormalities during episodes, verbal learning/memory 
deficits and auditory hallucinations in psychotic patients, auditory cortices were not assessed in 
BD. We aimed to assess primary and secondary auditory cortices in BD type I and compare it 
with those of schizophrenia (Chapter 6). Patients with BD had reductions in left STL compared 
with schizophrenia and healthy controls. Furthermore, we also compared BD type I and II and 
found that patients with BD type II did not show a reduction in metabolite levels in STL 
compared with BD type I and healthy controls. Only type I BD patients had reductions in 
metabolite levels (Chapter 7). The 1H-MRS is also available to detect GABA with 
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MEGAPRESS sequence in a given volume. GABA levels can be in vivo assessed by 1H-MRS 
in the STL and we did not observe any abnormality in either type I or type II patients with BD 
(Chapter 8).  
Chapter 9 is the discussion section in which the findings are interpreted. One of the most 
important points of the studies is the alterations of the auditory cortices. Alterations of the 
auditory cortices are reflected in all neuroimaging modalities as well as neurophysiological 
examinations. In addition, there are associations between neurophysiological alterations and 
neuroimaging findings. For example, MMN alterations and STL volumes were found to be 
correlated (Salisbury et al., 2007; Salisbury et al., 1998). These results suggest that auditory 
cortices are critical brain regions for patients with BD. According to the RDOC approach, more 
studies should evaluate the auditory cortices in BD since they are related with specific 
symptoms in BD. Brain stimulation therapies may add auditory cortices into their programs for 
the treatment of related symptoms in patients with BD.  
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Valorization 
Major psychiatric disorders affect millions of people and they can be severely debilitating. The 
etiopathology of major psychiatric disorders has not been clearly identified and thus treatment 
options are yet to be improved. These limitations are because of the complexity of the brain and 
the heterogeneous nature of psychiatric disorders. Many paradigms and technologies have been 
adopted and a great amount of research has contributed to the literature. During the last century, 
psychiatry has evolved towards a multidisciplinary field that collaborates with several fields of 
basic and applied sciences. Perhaps one of the most invaluable contributing fields is cognitive 
neuroscience. Several paradigms developed by cognitive neuroscientists have shed light on 
different brain functions and significantly contributed to psychiatric research.  
One of the earliest modalities is electroencephalography (EEG). After Hans Berger made his 
first experiments in 1929, EEG has been used in psychiatry and neurology for research and 
clinical purposes. EEG is a cheap and non-invasive method that offers a comprehensive 
examination of integrative brain function. Electrical activity of the neurons including 
membrane potentials, rhythmic patterns of action potentials, and postsynaptic discharges 
produce oscillatory activity at the level of neuron ensembles. Synchronized activity of the large 
number of neurons gives rise to brain-wide oscillatory activity, which can be recorded by the 
EEG. Synchronous firing patterns are controlled by feedback loops and interaction between 
neuron populations may give rise to oscillations at different frequencies. Each frequency could 
be related with different brain functions.  
In the recent years, the National Institute of Mental Health (NIMH) of the USA promoted a 
research method in psychiatric disorders, called research domain criteria (RDOC). According 
to this approach, transdiagnostic behavioral and cognitive domains are suggested as target 
phenotypes instead of categorical psychiatric diagnoses. The auditory system is related with the 
formation of thought and auditory hallucinations and thus convenient for this research model. 
Examination of the auditory system has revealed several consistent findings in schizophrenia 
and bipolar disorders. Accordingly, my thesis work has focused on cognitive mechanisms of 
auditory networks and linguistic functions, as well as the chemical integrity of the auditory 
cortices. The innovative aspects of my thesis work are the promising value of associations 
between disease mechanisms and the dysfunction of the related brain networks. I have 
demonstrated that cognitive processing of auditory information is disturbed in schizophrenia 
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and bipolar disorder. Alterations of the auditory and language networks are associated with the 
symptoms of schizophrenia and bipolar disorder. Moreover, I have demonstrated that chemical 
examination of the auditory cortices with magnetic resonance spectroscopy revealed similar 
alterations in schizophrenia and type I bipolar disorder but not in type II bipolar disorder. These 
results suggest that there may be shared biological mechanisms between bipolar disorder and 
schizophrenia, as well as pathophysiological processes that are different between subtypes of 
bipolar disorder. In this regard, my findings provide support for uniform and distinct 
pathophysiological mechanisms and add a unique perspective to the Kraepelinian dichotomy 
of mood and psychotic disorders. Furthermore, these alterations differ in the subtypes of bipolar 
disorder and schizophrenia, and therefore, they could serve as potential biomarkers in the 
future. These findings may pave the way for better etiopathology-driven diagnostic 
classification systems. Moreover, alterations of the auditory networks may show us directions 
in tailoring personalized treatments. For example, transcranial magnetic stimulation (TMS) is 
able to alter brain activity by electrical impulses in a given location. Auditory cortices are close 
to the brain surface and can easily be modulated by TMS. Clinicians are using TMS to modify 
brain activity in auditory cortices in patients with treatment resistant auditory hallucinations. 
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